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The global problem of type 2 diabetes
Type 2 diabetes mellitus is a metabolic disease characterized by chronic insulin resis-
tance and declining pancreatic beta-cell function, with consequent impaired fasting 
or postprandial glycemia.1 Type 2 diabetes gives rise to several health complications2 
such as damage to blood vessels in e.g. the heart, eyes, kidneys, nerves leading to 
other diseases/disability and premature death. For example, type 2 diabetes is a 
major risk factor for cardiovascular events, conferring about two-fold higher risk of 
vascular disease independent of other conventional risk factors.3 The World Health 
Organization (WHO) has estimated that in the past decades diabetes prevalence 
around the world has doubled, rising from 4.7% in 1980 to 8.5% in 2014, the vast 
majority (90-95%) of cases being type 2 diabetes.4 With this rise in prevalence and 
its health complications, diabetes has become the seventh leading cause of death 
in 2016 and the fourth main noncommunicable disease, accounting for 4% of the 
deaths worldwide.5 Its prevalence is expected to keep increasing.
Type 2 diabetes is not only a burden for individual patients because of the adverse 
effects on their health and quality of life, but also a major public health concern 
given the economic burden that diabetes means to nations worldwide. The global 
cost of type 2 diabetes, including both direct treatment costs and indirect costs due 
to type 2 diabetes-associated morbidity and premature death, was estimated to be 
1.8% of global gross domestic product (GDP) for 2015.6 Therefore, it is imperative to 
invest in improving strategies to prevent or delay the onset of type 2 diabetes, as 
well as for implementing early detection methods. 
sex differences in type 2 diabetes and cardiometabolic health
Although cardiometabolic disease events remain a leading cause of death worldwide 
for both sexes,7 several epidemiological studies have reported differences in inter-
mediate cardiovascular risk factors and risk of type 2 diabetes between men and 
women. Moreover, the global trend in the last decades shows that the age-standard-
ized diabetes prevalence has risen in both sexes, but that this increment is stronger 
in men than in women. Between 1980 and 2014 the prevalence of diabetes increased 
from 4.3% to 9.0% in men while from 5.0% to 7.9% in women.8 Recent reports sum-
marizing the available evidence concluded that, overall, adult men are at a higher 
risk of developing type 2 diabetes and cardiovascular disease as compared to adult 
women.9,10 This was the case across the majority,11 but not all,12 of the ethnicities 
investigated. However, evidence of disparities in type 2 diabetes between younger 
men and women remain controversial.13 Although cardiometabolic risk factors 
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and diseases are unequally distributed between sexes, the potential mechanisms 
underlying these differences are not completely understood.9 Sex hormones may 
play a role, because the advantage that women seem to have over men progressively 
disappears with ageing, especially after menopause.14 Nevertheless, to shed light on 
potential biological mechanisms explaining the observed sex differences sill further 
research is needed.
Epigenetics: a potential novel mechanism involved in type 2 
diabetes onset
Type 2 diabetes is a multifactorial product of the complex interplay of environmental 
and genetic factors. History of parental diabetes may confer up to 6-fold higher risk 
for diabetes as compared with those with no family history.15 It was hypothesized 
that type 2 diabetes-associated genetic variants identified in large population stud-
ies16,17 may account for the heritability of the disease. However, studies evaluating 
the predicting value of a genetic component added to the classic risk factors to 
predict type 2 diabetes risk showed a slight improvement in the prediction as com-
pared to models including the classic factors alone.18-21 For example, a study building 
a prediction model to assess type 2 diabetes risk in adults reported C statistics (a 
measure indicating to what extent the model can discriminate the risk of type 2 
diabetes) up to 0.900 when using only classic risk factors, such as age, family history 
of diabetes, body mass index, smoking, blood pressure and plasma high-density 
lipoprotein cholesterol, triglycerides and glucose; while a C statistics of 0.901 was 
observed when adding a genotype score to the model.21 Furthermore, this suggests 
that there is a proportion of type 2 diabetes risk and its heritability that is not fully 
explained by these classic and genetic markers. In search for novel markers that 
may explain the remaining variation, epigenetics has risen as potential mechanism.
Epigenetics is the study of the heritable changes in the function of genes that do 
not comprise variations in the DNA sequence of nucleotides, but refer to covalent 
modifications of histones and DNA,22 altering chromatin structure and consequently 
DNA transcription. Some epigenetic mechanisms are changes in DNA methylation 
and modifications of histone tails (acetylation, methylation, phosphorylation and 
ubiquitination).23 This type of gene expression regulation is needed during develop-
mental stages where it controls tissue differentiation and cellular responsiveness. 
This is how cells in the body, containing the same DNA sequence give origin to spe-
cialized organs and tissues with different functions. Some of these epigenetic marks 
are heritable from cell to cell and transgenerationally from parent to offspring to 
grand-offspring,24 but epigenetic patterns are also most sensitive to suffer modifica-









determine future phenotype and affect health.25 These influences can be dietary, 
physical, chemical, stochasticity and random chance. Moreover, the epigenome can 
still be affected by unfavorable lifetime environmental exposures. Some risk factors 
previously associated with type 2 diabetes and cardiometabolic health such as smok-
ing, sedentarism, drugs, obesity, ageing, unhealthy diet and several other lifestyle 
and biological factors have also been associated with epigenetic changes which in 
turn may cause disease,26,27 including diabetes.28
Among the epigenetic changes, DNA methylation is one of the most studied and 
has been more frequently associated with gene silencing. DNA methylation refers 
to a reversible modification of the DNA, where a methyl (-CH3) group is attached 
to a cytosine at the 5′-position, that is located 5′ to a guanosine. This dinucleotide 
is commonly named CpG island, wherein p refers to the phosphodiester linkage 
between the cytosine and guanosine nucleotides.29 The transfer of the methyl group 
is performed by a family of enzymes called DNA methyltransferases (DNMTs).30 
Modifications in DNA methylation patterns may be in the biological pathway of 
the disease pathophysiology through dysregulation of gene expression that may in 
turn contribute to e.g. insulin resistance and type 2 diabetes onset. Indeed, several 
studies have compared DNA methylation patterns between type 2 diabetes patients 
and healthy subjects, as well as risk of future type 2 diabetes, and have observed nu-
merous differentially methylated CpG sites in diabetes.27,31-39 However the evidence 
is still controversial, with an existing lack of replication across studies.27 If methyla-
tion patterns indeed differ in early stages of disease development, DNA methylation 
marks can be promising candidates to be implemented as biomarkers in clinical 
practice22 for early diagnose of diseases. For example, insulin resistance starts ap-
pearing years before the clinical manifestation and diagnose of type 2 diabetes, 
while consequent organ damage is already occurring. Evidence suggests that early 
insulin therapy can help correct the underlying pathogenetic abnormalities in type 
2 diabetes and improve long-term glycemic control.40 Hence, efforts are being made 
in order to use DNA methylation signatures as biomarkers to identify individuals at 
risk of type 2 diabetes and to monitor the progression of this disease.41-44
Taking into consideration the abundant evidence identifying DNA methylation 
patterns of type 2 diabetes, it is of great interest to explore to what extent known 
and novel environmental factors exert their diabetogenic effect by promoting DNA 
methylation changes, which in turn may lead to the onset of this disease. Further-
more, the missing heritability and the proportion of the disease risk that is not fully 
explained by the currently used measures in medical practice are leading scientists 
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to study lesser-understood environmental exposures affecting cardiometabolic 
health and their potential effect on the epigenome. However, this is an incipient 
field and further efforts are needed.
Environmental risk factors in type 2 diabetes pathophysiology
Well-known classic environmental risk factors for type 2 diabetes are older age, obe-
sity, family history of diabetes, smoking, increased levels of plasma triglycerides and 
glucose, low levels of plasma high-density lipoprotein cholesterol and high blood 
pressure. In the search for novel factors and markers, several studies have recently 
explored the role of lesser-known factors in type 2 diabetes onset. Oxidative stress 
and inflammatory states,45 as well as some medications such as anti-hypertensives, 
antidepressants and statins,46-48 have been hypothesized to promote the develop-
ment of type 2 diabetes.
Several studies suggest that oxidative stress plays a role in the pathogenesis of 
chronic inflammation and related diseases like type 2 diabetes and its complica-
tions.45,49,50 Oxidative stress occurs during the state of redox equilibrium disrup-
tion, an imbalance between the production of reactive oxygen species (ROS) and 
antioxidant capacity, and the body’s response to eliminate them leads to chronic 
inflammation.51 Experimental studies have suggested that oxidative stress decreases 
insulin secretion in beta cells and impairs glucose uptake in adipose and muscular 
tissues.49,52,53 Obesity, a state of excessive accumulation of adipose tissue, may induce 
systemic oxidative stress leading to impaired production of adipokines in the adipo-
cytes, such as leptin and adiponectin.54 Adiponectin, downregulated in obese states, 
has shown to exert an anti-inflammatory effect;55 as well as improvement of insulin 
sensitivity;56 while leptin, increased in obese subjects, is involved in the regulation 
of the energy-balance by controlling food intake and energy expenditure,56 and has 
been positively correlated with markers of inflammation such as C-reactive protein.57 
Several studies have reported pro-inflammatory cytokines in association with type 
2 diabetes,58-62 which is called a state of chronic inflammation.50 Furthermore, a 
recent study investigating the relationship between classic and novel inflammatory 
markers with type 2 diabetes found that C-reactive protein (CRP), Extracellular 
Newly identified Receptor for Advanced Glycation End-products binding protein 
(EN-RAGE), interleukin 13 (IL13), interleukin 17 (IL17), interleukin 18 (IL18), inter-
leukin 1 Receptor Antagonist (IL1ra), Complement Factor (CFH), Complement 3 
and Tumor Necrosis Factor Receptor 2 (TNFRII) were associated with incident type 
2 diabetes in Caucasian population.63 The available evidence has given rise to the 









and metabolic profiles,64,65 albeit the underlying pathophysiological mechanisms are 
not fully understood.50,66
Additional to the classic risk factors, the potential role of oxidative stress and the 
novel inflammatory biomarkers identified, recent evidence has shown that some 
medications may contribute to the early onset of type 2 diabetes, being among them 
statins,46,67 antidepressants47 and beta-blockers.48 Statins class of drugs are have a 
lipid lowering effect, and are well known to effectively reduce the risk of cardiovas-
cular events and CVD-related mortality.68 This drug targets the enzyme HMG-CoA 
reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase), inhibiting the de novo 
synthesis of cholesterol. Nevertheless, recent meta-analyses46,67,69 of epidemiological 
and also experimental70,71 studies have provided evidence of a diabetogenic effect of 
statins, presumably through insulin secretion, sensitivity, and beta-cell dysfunction. 
However, evidence on the mechanistic pathways underlying these associations is 
lacking. Interestingly, statins have been studied in relation to epigenetic changes,72 
nevertheless a possible link with DNA methylation and type 2 diabetes has not been 
explored.
Protective strategies against type 2 diabetes development: diet
Most of the underlying risk factors responsible for the enormous rise in diabetes 
prevalence are modifiable risk factors such as lifestyle. Among factors that can be 
improved to help prevent type 2 diabetes, healthy dietary patterns have shown to 
play a protective role against type 2 diabetes onset. Diets rich in fruits, vegetables, 
wholegrains, legumes, nuts and seeds; while lower in red or processed meat, refined 
grains and sugared beverages; and moderate in alcohol intake have been related 
to decreased risk of type 2 diabetes and improvement of glycemic control.73 Part 
of this effect of a healthy diet may be explained by its high content in polyphenols 
and other antioxidant compounds, who can inhibit ROS formation or interact 
with ROS to prevent tissue damaged, thus modulating the inflammatory response 
involved in chronic inflammatory diseases such as type 2 diabetes.51. Furthermore, 
the total antioxidant capacity of a diet,74 as well as dietary polyphenols alone,75,76 
have demonstrated to have anti-diabetic effects. Foods that are particularly high in 
antioxidants and polyphenols are mainly plant-based foods, and include vegetables, 
fruits, cocoa, tea, extra-virgin olive oil, red wine and coffee. When it comes to bever-
ages, a study assessing the total antioxidant capacity of a Mediterranean diet showed 
that coffee, followed by red wine, was the beverage with the highest antioxidant 
capacity.77 The rich antioxidant capacity of coffee may be due to the high content of 
several bioactive compounds and micronutrients such as chlorogenic acids, caffeine, 
cafestol, kahweol, melanoidins, polyphenols and trigonelline, although the exact 
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composition depends mainly on the genus and roasting process.78 While findings 
from a meta-analysis on clinical trials provided inconsistent results on the associa-
tion between coffee or caffeine intake and serum levels of inflammation markers 
(C-reactive protein, adiponectin, interleukins), a recent study reported positive 
associations between coffee consumption of ≥ 4 cups/day and favorable profiles of 
blood markers related to metabolic and inflammatory pathways such as C-peptide, 
insulin-like growth factor binding protein 3 (IGFBP-3), estrone, total estradiol, free 
estradiol, leptin, C-reactive protein (CRP), interleukin-6 (IL6), tumor necrosis factor 
receptor 2 (TNFR-2), sex hormone-binding globulin (SHBG), total testosterone, total 
adiponectin, and high-molecular-weight (HMW) adiponectin.79 Interestingly, exist-
ing evidence from a meta-analysis and umbrella review concluded that coffee is 
associated with decreased risk of developing T2D.80,81 Whether the apparent protec-
tive effect that coffee consumption exerts on type 2 diabetes risk is mediated by a 
potential modulation of the inflammatory response needs further investigation.
sTUDy DEsiGn anD POPULaTiOns
The work of this thesis includes reviews and original studies. The exponential 
increase in the number of published studies demands the use of a more practical 
approach to gather the current knowledge. In a systematic review, a well-defined 
search procedure and strict statistical protocols are followed to extract data from 
selected existing literature in order to summarize the current evidence.82 Therefore, 
systematic reviews are evidence-based approaches to provide an unbiased overview 
on the topic of interest. In chapter 2 of this thesis, systematic and narrative reviews 
were performed to summarize the current evidence on DNA methylation, type 2 
diabetes and related cardiometabolic traits.
The original studies presented in this thesis were embedded in prospective cohort 
studies. In the prospective cohort design, a representative sample of a population 
is followed in time until the occurrence of endpoints, such as type 2 diabetes. This 
design allows to characterize the exposure, i.e., risk or protective factor, before the 
occurrence of the event of interest or disease onset, as well as the identification of 
biomarkers with potential predictive value, that appear before the diagnosis of the 
disease and that may change over time.83 Hence, a prospective cohort design is useful 
in the study of human complex diseases, wherein environmental factors or genes-
environment interactions play a role.83 Further advantages of the prospective cohort 
designs are the avoidance of recall bias and participants’ selection bias. Among the 









large sample size and regular follow-up checks in order to produce sufficient incident 
cases. Such characteristics make this kind of study costly.83 The prospective cohort 
studies in which the original studies included in this thesis were embedded in, were 
mainly the Rotterdam Study (RS)84 and the UK Biobank (UKBB).85,86 Other prospective 
cohorts contributing to this work were the Kooperative Gesundheitsforschung in 
der Region Augsburg-F4 (KORA-F4),87 The London Life Sciences Prospective Popula-
tion Study (LOLIPOP),88 the Epidemiologische Studie zu Chancen der Verhütung, 
Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren 
Bevölkerung (ESTHER),89 and the Study of Health Pomerania-Trend (SHIP-Trend).90 
Chapters 3 and 4 of this thesis used data from the Rotterdam Study.84 RS is a 
population-based prospective cohort study of middle-aged and elder participants liv-
ing in the well-defined Ommoord district in the city of Rotterdam, the Netherlands. 
The aim of this study is to investigate the risk factors and occurrence of chronic 
diseases such as cardiovascular, endocrine, oncological, respiratory, hepatic, neuro-
logical, ophthalmic, psychiatric and dermatological diseases. The Rotterdam Study 
comprises three sub-cohorts. The first one (RS-I) started in 1990 and recruited 7,983 
subjects aged 55 years or above. The second sub-cohort (RS-II) was initiated in 2000 
and enrolled 3,011 individuals who had turned 45 years old since 1989. The third 
sub-cohort (RS-III) commenced in 2006 and comprised 3,932 participants aged 45 
years and above. Currently, the Rotterdam Study is composed of a total of 14,926 
subjects. Follow up visits were performed every four or five years. The visits to the 
research center included physical and functional measures, completion of question-
naires and blood samples were taken to assess concentrations of lipids, glycemic 
traits, and other biomarkers as well as for genetics and epigenetic measurements. 
DNA methylation levels in blood were determined in a random sample of 1,454 
subjects from the third visit of the second cohort (RS-II-3) and in a non-overlapping 
sample of the first and second visit of the third cohort (RS-III-1 and RS-III-2). Data on 
dietary intake was measured at baseline visits of all three cohorts using validated 
semi-quantitative FFQs and in home interviews by a trained interviewer. Data on 
medication were obtained from digital pharmacy and physician’s records.  
Specifically, chapter 3.2 used additional data from KORA-F4,87 a follow-up study to 
KORA-S4 cohort, established in 1996 in Augsburg, Germany; LOLIPOP,88 a prospec-
tive cohort of South-Asians residing in London, United Kingdom, aged 35 to 75 years; 
ESTHER, 89 a population-based study recruited in Saarland, Germany, with partici-




Chapters 4 and 5 used data from the UK Biobank85,86 The UKBB is a prospective 
population-based cohort study in the United Kingdom that recruited 502,549 
individuals aged 37 to 73 years. This study was established to investigate genetic 
and non-genetic determinants of many diseases and health-related outcomes in the 
middle-aged and elderly. Enrollment and data assessment was carried out between 
April 2006 and December 2010, at 22 research centers across England, Scotland and 
Wales. This design allowed socioeconomic and ethnic heterogeneity, as well as an 
urban–rural mix among the participants. During the visits to the research centers 
participants had physical and functional measures, had to complete questionnaires, 
and their biological samples were collected to determine biomarkers and other 
laboratory assays, as well as for genetic assessment.
aiM OF This ThEsis anD OUTLinE
In this thesis, I sought to investigate potential underlying mechanisms explaining 
associations of protective and adverse determinants of type 2 diabetes. 
Chapter 2 focuses on epigenetics and type 2 diabetes and other cardiometabolic 
determinants. Specifically, in chapter 2.1 we reviewed the clinical use of epigenetic 
marks as biomarkers for diagnosis and prognosis of type 2 diabetes; and in chapter 
2.2 we reviewed epigenetic sex differences in cardiometabolic traits.
Chapter 3 aimed to dissect the association between a novel risk factor for type 2 
diabetes, statin therapy, and the incidence of the disease. Particularly, in chapter 3.1 
we explored the association between statin treatment and type 2 diabetes, including 
the study of the different types of statins. In chapter 3.2 we sought to identify 
DNA methylation signatures associated with statin therapy that may mediate the 
diabetogenic effect of statins use.
Chapter 4 devoted to explore the potential role of in inflammatory markers as 
mediators in the observed beneficial effect of coffee consumption on type 2 diabetes 
onset.
in chapter 5 I studied the effect modification role of type 2 diabetes and sex differ-
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aBsTRaCT
Type 2 diabetes and its accompanying complications constitute a major health 
burden worldwide, which can be partly attributed to the interplay between genetics 
and environments. Extensive research over the last decades has shown that our 
genome is not the only determinant of disease risk. Epigenetic marks induced by 
lifestyle and environmental factors are associated with altered gene expression pat-
terns in important tissues, leading to altered susceptibility to disease later in life. 
Hence, the identification of epigenetic biomarkers unfolds the possibility for a novel 
personalized disease prevention strategy and at the same time holds the potential to 
be a promising prognostic tool for diabetes. So far, evidence on the predictive value 
of epigenetics in diabetes management is very limited. Unlike in cancer pathology, 
where examples of important epigenetic tools are now widely used in clinical prac-
tice as predictive/diagnostic biomarkers, for complex pathophysiological diseases 
such as diabetes, this still remains a challenge. These topics are discussed exten-
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1. inTRODUCTiOn
Diabetes has become a major public health problem with type 2 diabetes (T2D) 
being the predominant condition that accounts for at least 90% of the cases 1. Ac-
cording to the World Health Organization (WHO) reports in 2012, the estimated 
number of people living with T2D by 2030 would have been 366 million 2. However, 
these numbers are expected to be higher since until 2017, 425 million people were 
reported having diabetes 3 overcoming all predictions 4. 
T2D is characterized by insulin deficiency and insulin resistance 5, and its major 
complications comprise macrovascular, microvascular and neurologic changes 
which can lead to organ damage including heart, kidneys, eyes, feet and nerves 5. 
According to the American Diabetes Association (ADA), diabetes diagnosis is defined 
as: fasting plasma glucose ≥ 126 mg/dL (≥ 7.0 mmol/L) where fasting is defined as 
no caloric intake for at least 8 hours or 2-h plasma glucose ≥ 200 mg/dL (≥ 11.1 
mmol/L) during a 75-g oral glucose tolerance test (OGTT, the test should be per-
formed as described by the WHO, using a glucose load containing the equivalent 
of 75 g anhydrous glucose dissolved in water) or A1C ≥ 6.5% (≥ 48 mmol/mol) or 
in a patient with classic symptoms of hyperglycaemia or hyperglycaemic crisis, a 
random plasma glucose ≥ 200 mg/dL (≥ 11.1 mmol/L) 6. These definitions go in line 
with the current WHO diagnostic criteria, except for the glycosylated haemoglobin 
(HbA1c) test, which remains controversial7. 
Studies investigating the aetiology of T2D have been primarily focused into the 
genetic determinants of the disease. Recent evidence shows epigenetics could be a 
major player in the pathophysiology of the disease, through which environmental 
and lifestyle factors could affect T2D pathogenesis (Figure 1) 8. Lifestyle and other 
environmental factors could lead to changes in DNA methylation and histone modi-
fications, which on the other hand, might affect the development of pancreatic β 
cells and the function of insulin secretion, contributing to the decline of insulin 
sensitivity resulting in the occurrence of T2D 8. Animal and human studies investi-
gating the genome-wide maps of epigenetic markers using islet tissue have provided 
a reliable resource for understanding the importance of the epigenetic mechanisms 
in T2D susceptibility 9.
In clinical practice, biomarkers are used routinely to identify individuals at risk and 
are of great importance in disease diagnosis. For T2D, fasting blood glucose, HbA1c 
and 2-hours oral glucose are commonly used, but they come with some drawbacks. 
Blood glucose levels do not reflect the impaired b-cell function or insulin resistance 10; 
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the optimal value for HbA1c for diagnosis of prediabetes state still remain contro-
versial 11 12, whereas the 2-hours oral glucose tolerance test is a time consuming 
procedure. It is not known whether the deterioration in glucose tolerance and 
beta-cell function is linear or whether there is an accelerated loss of function at 
some point prior to the onset of diabetes 7. Therefore, the early identification of 
high-risk individuals demands novel biomarkers that adequately account for the 
inter-individual variance in the different pathological mechanisms underlying 
impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), each of which 
have distinct progression patterns towards diabetes 13. Moreover, the different kind 
of complications from diabetes might leave different methylation signatures which 
could result in type-specific and predictive signatures with potential use as future 
prognostic biomarkers for T2D. Further, considering the rapidly increase in inci-
dence and prevalence of T2D, it has become relevant to extend current knowledge 
and discover new biomarkers that could be identified and/or monitored during the 
diagnosis and progression of the disease. 
In this chapter, the topics of epigenetic alterations, particularly DNA methylation 
and histone modifications and the importance of epigenetic biomarkers for risk 
prediction, diagnosis and prognosis of T2D will be discussed.
 
 
Figure 1. A conceptual model linking epigenomics to T2D and T2D complications. Epigenomics 
represents a critical link between genomic coding and phenotype expression that is influenced by both 
underlying genetic and environmental factors. Epigenetic biomarkers which can be 0influenced by T2D 
risk factors and remodeled epigenetic patterns may contribute to the development of T2D and its 
complications. 
 
Figure 1. A conceptual model linking epigenomics to T2D and T2D complications. 
Epigenomics represents a critical link between genomic coding and phenotype expression that is in-
fluenced by both underlying genetic and environmental factors. Epigenetic biomarkers which can be 
influenced by T2D risk factors and remodeled epigenetic patterns may contribute to the development 
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2. EPiGEnETiC aLTERaTiOns inVOLVED in GLUCOsE 
hOMEOsTasis anD insULin METaBOLisM 
The association between glucose homeostasis related traits and DNA methylation 
has been assessed through different approaches, such as global DNA methylation 
assessment, DNA methylation in candidate genes, and Epigenome-Wide Association 
Studies (EWAS).
Global DNA methylation refers to the overall level of 5-methylcitosine in the ge-
nome, expressed as percentage of total cytosine. Repetitive and transposable ele-
ments, such as LINE-1 and Alu, represent a large portion of the human genome and 
contain much of the CpG methylation found in normal human postnatal somatic 
tissues 14. Given the existing correlation of methylation at such elements with the 
total genomic methylation content, they are considered surrogate markers for 
global genome methylation 14. 
In a candidate gene methylation approach, the association is evaluated only for 
specific genes of interest that have been selected based on their possible role in the 
phenotype of interest. Therefore, the methylation level is assessed only in specific 
regions of the DNA.
EWAS, scan genome-wide epigenetic variants, such as DNA methylation, which 
might be associated with the phenotype of interest. EWAS are mainly performed 
using microarrays, which profile the methylation level of thousands of CpG islands 
in the genome, surveying multiple samples. 
Information about the function of the genes mentioned in this chapter that have 
been studied in relation with T2D and glycaemic traits can be found in Table 1.
2.1. Glucose homeostasis
Epigenetic alterations can have great influence on islet cells and glucose homeostasis 
that can alter their pathophysiological processes and consequently result in T2D 15. 
2.1.1. DNA methylation
Different studies have investigated the association between global DNA methylation 
and glucose levels, reporting inconsistent results 16-18. Increased levels of plasma 
glucose were associated with higher methylation levels in LINE-1 when assessed 
in adipose tissue, blood or skeletal muscle 16 17 19. However, one study showed no 
association or an inverse association between LINE -1 methylation or other markers 
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of global DNA methylation and glucose levels assessed in B and NK lymphocytes 
human cells 18. This stresses the relevance of using cell type-specific assays when 
investigating epigenetic signatures in clinical tissue samples especially those char-
acterized by a high heterogeneity in cell types frequency and phenotype, such as 
blood.
Candidate gene studies have revealed lower methylation levels of GIPR gene and 
PPARGC1A gene in blood and skeletal muscle 20 21. Both genes are believed to contrib-
ute to improve insulin sensitivity, mitochondrial biogenesis and browning of white 
adipose tissue. In another study, the authors reported that high glucose levels affect 
human pancreatic islet gene expression and several of these genes also exhibit 
epigenetic changes 22. This might contribute to the impaired insulin secretion seen 
in T2D. Moreover, one study reported that increased levels of plasma glucose might 
be associated with higher methylation levels of LY86 gene in blood, which has been 
suggested to play a role in inflammation, obesity and insulin resistance 23. Volkmar 
et al. have investigated DNA methylation in human pancreatic islets by exposing the 
pancreatic cells from nondiabetic donors to high glucose levels 9. The study reported 
a non-significant association between DNA methylation and the 16 CpG sites tested, 
concluding that the methylated changes in the islets from T2D patients would not 
likely be a cause of hyperglycaemia 9.
Furthermore, studies conducted using placenta tissue and cord blood have yielded 
interesting results between methylation levels and fasting glucose. Lower DNA 
methylation levels of ADIPOQ, LPL, IGF1R and IGFBP3 on the fetal side of the pla-
centa were associated with higher maternal 2-h post oral glucose tolerance test 
levels during pregnancy, although the association did not remain significant with 
2 h post-oral glucose tolerance test levels 24. Also, the maternal gestational glucose 
levels were positively associated with placental DNA methylation, and negatively 
associated with cord blood DNA methylation of the PPARGC1A promoter in a CpG 
site-specific manner. The researchers concluded that epigenetic alteration of the 
PPAGRC1A promoter may be one of the potential mechanisms underlying the meta-
bolic programming in offspring exposed to intrauterine hyperglycaemia 25. Another 
study investigating whether epigenetic dysregulations of the insulin-like growth 
factor system in placenta were exposed to maternal impaired glucose tolerance, 
confirmed their hypothesis 26. Also, in this study, maternal glucose 2 h post oral 
glucose tolerance test and fasting glucose at the second trimester of pregnancy were 
negatively correlated with GF1R-L4 (7 CpGs) and IGFBP3-L1 DNA methylation levels 26. 
Both GF1R-L4 and IGFBP3-L1 are important genes in foetal metabolic programming 
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Limited evidence exists on EWAS and glucose metabolism. Also, the existing evidence 
so far is inconclusive and inconsistent with studies reporting no association 27 and 
another reporting a positive association between epigenome-wide DNA methylation 
levels and fasting glucose 28. Using whole blood samples from a population-based 
prospective study, one study recently reported 6 CpG sites related to fasting glucose 
and 2-hour glucose, independent of age, sex, smoking, and estimated white blood 
cell proportions 26. Moreover this study showed that effect strengths were reduced 
on average by around 30% after adjustment for BMI, suggesting an influence of BMI 
on the investigated phenotypes 26. The findings provide evidence for the first time 
that DNA methylation may be associated with glucose metabolism, a relationship 
which can be measured in DNA isolated from whole blood.
2.1.2. Histone modifications
Histone modifications may also play a pivotal role in glucose metabolism, but this 
is an understudied research topic 29. Studies have shown that TXNIP gene might 
be important in glucose metabolism, especially in diabetes-related phenotypes 30 31. 
TXNIP is a key component of pancreatic β-cell biology, nutrient sensing, energy me-
tabolism, and regulation of cellular redox 30 31. Moreover, TXNIP expression is highly 
induced by glucose through activation of the carbohydrate response element-binding 
protein, which binds the TXNIP promoter, making it an attractive target for diabetes 
therapy. Previous studies have identified several critical transcription factors, en-
zymes important in histone activation and acetylation, like the ChREBP and p300, 
as the specific chromatin modification mediating this glucose-induced transcription 
of beta cell TXNIP 31. Recently, another study published similar results confirming 
the findings 32. They found that the glucose-induced TXNIP gene expression is greatly 
reduced by p300 silencing, and Ep300 cells are protected from high glucose-induced 
cell death and have elevated insulin secretion 32. In the current study, elevated levels 
of EP300 and TXNIP gene expression in human diabetic islets were correlated with 
reduced glucose-stimulated TXNIP genes expression 32. These data provide evidence 
that histone acetylation could be a key regulator of glucose-induced increase in 
TXNIP gene expression and thereby glucotoxicity-induced apoptosis.
2.2. insulin metabolism
A common feature of T2D that affects the liver and the peripheral tissues is insulin 
resistance (IR). The most relevant tissues that develop insulin resistance are liver 
cells, skeletal muscle, and adipose tissue 33. Impaired response to insulin fails to 
clear the blood stream from glucose, and additionally, stimulates the secretion of 
adipokines from the adipose tissue which may further negatively affect the whole 
body glucose homeostasis 33. 
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2.2.1. DNA Methylation
Several studies have investigated the association between global DNA methylation 
and insulin metabolism, focusing on fasting plasma insulin levels, insulin secretion 
19, and insulin resistance as measured by homeostatic model assessment 34 35. The 
studies on insulin secretion and insulin resistance did not report significant associa-
tions between insulin metabolism and global DNA methylation. However, one study 
reported an interaction of global DNA methylation with circulating folate concen-
trations in relation to insulin resistance 34. The authors found that a lower degree 
of methylation and lower plasma folate concentrations were associated with higher 
insulin resistance 34. Folate metabolism is linked to phenotypic changes through 
DNA methylation by the knowledge that folate, a coenzyme of one-carbon metabo-
lism, is directly involved in methyl group transfer for DNA methylation, making 
them important epigenetic players. Another study assessed global DNA methylation 
as a percentage of 20-deoxycytidine plus 5-methyl-deoxy-cytidine (5mdC) in genomic 
DNA and reported a positive association between insulin levels and global DNA 
methylation assessed in lymphocyte B cells but no association in natural killer cells 
36. Zhao et al. assessed global DNA methylation in Alu elements in peripheral blood 
leukocytes, which was quantified by bisulphite pyrosequencing 35. The study showed 
a positive association with insulin resistance and reported that a 10% increase in 
mean Alu methylation was associated with an increase of 4.55 units in homeostatic 
model assessment 35.
Many candidate gene studies have examined methylation sites in or near known 
candidate genes in relation to plasma insulin, insulin expression and insulin resis-
tance 15. Most of them reported a positive correlation between plasma insulin and 
methylation at PPARGC1A in the liver and at HTR2A and LY86 in blood cells. Lower 
levels of methylation at PPARGC1A were identified in skeletal muscle and lower 
levels of methylation were identified at the insulin promoter gene associated with 
increased levels of plasma insulin or mRNA insulin expression 15. Moreover, inverse 
associations were found between insulin resistance and the degree of methylation 
of TFAM and GIPR3 genes in blood cells and PPARGC1A gene in skeletal muscle 15. 
Furthermore, studies in pregnant women, reported a negative association of meth-
ylation levels of the maternal side of placenta of ADIPOQ gene with insulin resistance 
37. While another study reported a positive correlation between the methylation of 
IGFBP3 with fasting insulin levels and insulin resistance 26.
Further, a few EWAS have been performed in regard to insulin metabolism 38 39. 
Hidalgo et al. reported a significant association between the methylation of a CpG 
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ment-IR, suggesting that methylation of the CpG site within ABCG1 merits further 
evaluation as a novel disease risk marker 39.
The majority of the above mentioned genes are reported to have important func-
tions in metabolic traits and have been associated to insulin metabolism through 
different biological mechanisms. The HTR2C gene is involved in energy expenditure 
and polymorphisms in this gene coding for many receptors are thought to influ-
ence insulin homeostasis 40. While, PPARGC1A upregulates transcription of genes 
involved in mitochondrial oxidative metabolism and biogenesis as well as skeletal 
muscle glucose transport. Because mitochondrial defects have been associated with 
peripheral insulin resistance in healthy subjects it has been suggested that reduced 
PPARGC1A expression in skeletal muscle may be a primary feature of insulin resis-
tance 41. Furthermore, PPARGC1A is involved in biological functions with implica-
tions in insulin action including protection against oxidative stress, formation of 
muscle fiber types as well as regulation of microvascular flow 41 42. Moreover, there 
is evidence linking the LY86, TFAM and GIPR3 genes to insulin resistance, mainly 
their respective encoded proteins that play crucial roles in the pathophysiological 
regulation of inflammation and insulin resistance 42.
2.2.2. Histone modifications
The evidence pertaining the possible role of histone modifications in insulin 
metabolism is also very limited. One study investigated the effects of insulin on 
alterations in post-translational modifications of histone H3 in L6 myoblasts under 
a hyperglycaemic condition 43. The authors demonstrated that insulin induced 
intracellular generated oxidative stress is involved in modulating multiple histone 
modifications under hyperglycaemic conditions 43. Their results also revealed that 
phosphorylation of histone H3 at Ser 10 was independent of known histone kinases 
and suggest the role of serine/threonine phosphatase in modulating insulin signal-
ling, suggesting a possible role of phosphatase and its inhibitor in diabetes 43.
3. EPiGEnETiC aLTERaTiOns in DiaBETEs
T2D is a complex disease, product of the interaction of genetic and environmental 
factors 44 (Figure 1). Epigenetic mechanisms could underlie the connection between 
environmental exposures and pathology of T2D 45. For this reason, in recent years, 
it has been of great interest to study DNA methylation and histone modifications in 
relation to T2D.
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3.1. Dna methylation
When comparing diabetic versus non-diabetic individuals, no difference in global 
DNA methylation has been reported in overall peripheral blood 46 47, lymphocytes or 
monocytes populations assessed separately 18, pancreatic islets 9, omental visceral 
adipose tissue and subcutaneous adipose tissue 17. Also studies that used skeletal 
muscle and subcutaneous adipose tissue from monozygotic twins discordant for T2D 
did not report any differences in global DNA methylation 16. However, significant dif-
ferences in the degree of global DNA methylation have also been reported. Luttmer 
et al. reported hypomethylation in blood samples from T2D patients 48, whereas 
Simar et al. reported an increased degree of global DNA methylation specifically in 
B-cells and natural killer cells from T2D donors 18.
In a candidate gene approach, DNA methylation at several selected genes has been 
investigated in different tissues, comparing diabetic and non-diabetic donors.
The genes that have been reported to have higher methylation levels in T2D patients 
are: IGFBP7 49, IGFBP1 50, TLR2 51, SLC30A8 52, GCK 53, PRKCZ 54, CTGF 46 and leptin gene 
in peripheral blood; PPARGC1A 55, PDX-1 56, insulin promoter gene 57 and GLP1R in 
pancreatic islets 56 and APN in adipose tissue 58. 
On the other hand, in diabetic donors, lower levels of methylation have been found 
at genes: GIPR 59, CAMK1D, CRY2, CALM2 60, MCP1 61, TLR4, FFAR3 51, PP2Ac 62 and CTGF 46 
in the in peripheral blood samples; UBASH3A in B-cells 18 and PDK4 in skeletal muscle 
tissue 63. Additionally, differential methylation between type 2 diabetic patients and 
matched controls has been found at TCF7L2 64.
Further, no clear difference was observed for genes IRS-1 in the peripheral blood 65; 
GADPH, TFAM and TRIM3 in B-cells 18; GLP1R in pancreatic islets 66 and PPARGC1A in 
the skeletal muscle 67.
When comparing monozygotic twins discordant for T2D, the genes that were hyper-
methylated in the diabetic subjects are: HNF4A, KLF11, DUSP9, HHEX and PPARGC1A 
in muscle tissue and CIDEC, HNF4A, ADCY5, CDKN2B, IDE, KCNQ1, MTNR1B and TSPAN8 
in subcutaneous adipose tissue. Whereas the hypomethylated genes found in the 
diabetic twins are CDKN2A, KCNQ1 and SLC30A8 in muscle tissue and CAV1, CDKN2A, 
DUSP9, IRS1 and WFS1 in subcutaneous adipose tissue. However, after adjustment 
for multiple testing only two methylation sites, at CDKN2A and HNF4A genes, in 
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EWAS have raised and evolved as the technology for epigenetics research gradu-
ally develops. Progressively, scientists have had more access to methylation arrays 
with a higher number of methylation probes and new sequencing techniques that 
have allowed researches to perform genome-wide studies in shorter times. Thus, 
genome-wide DNA methylation profiling to find associations with T2D has allowed 
identifying new genes differentially methylated that might provide new insights 
in the pathogenesis of the disease and the search for biomarkers. To date, EWAS in 
association with T2D have been performed in peripheral blood, pancreatic islets, 
skeletal muscle and subcutaneous adipose tissue. 
For the study of methylation in pancreatic islets, a Human Methylation 27 BeadChip 
array was used. It was observed that 276 CpGs affiliated to promotors of 254 genes 
were displaying differentially methylated sites in tissue from T2D donors compared 
with non-diabetic controls 9. Further, a Human Methylation 450 K BeadChip array 
was utilized to carry out the same approach. As a result, 1649 CpGs, annotated to 
853 genes, were reported to have sites of differential methylation in diabetic islets 68. 
In skeletal muscle tissue, methylation levels were compared between monozygotic 
twins discordant for T2D using a Human Methylation 27 Bead Chip array. The test 
identified one CpG, annotated at IL8, to be differentially methylated 16. A similar 
analysis was performed in subcutaneous adipose tissue, revealing that in the diabetic 
donor, CpGs annotated to ZNF668, HSPA2, C8orf31, CD320, SFT2D3, TWIST1 and MYO5A 
genes had methylation levels significantly different from the non-diabetic twins 16. 
DNA methylation studies in blood samples reports dissimilar results, depending on 
the methylation assessment and multiple testing correction methods. When Human 
Methylation 450 K Bead Chip array was used, one study reported 51 significant CpGs 
associated to T2D (correction for multiple tests of FDR < 5%) 69, while other authors 
observed 5 CpGs associated to incident T2D (correction for multiple testing of P < 5 
x 10-7) 30. A different study used Methylated DNA immunoprecipitation sequencing 
(MeDIP-seq). It identified as the strongest signal, a differential methylated region at 
the promoter of MALT1 (FDR < 5%). A study using the affimetrix SNP6 microarray 
with posterior in-deep sequencing of the tip-ranking regions showed that 13 out 
of 93 CpG sites exhibited differences between T2D patients and controls 70. The 
researchers found that, among those sites, a methylation site located in the first 
intron of FTO was significantly hypomethylated in blood samples from diabetic 
subjects 70.
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3.2. histone modifications
Histone changes in acetylation or methylation patterns might induce modifications 
in chromatin structure and, as a consequence, it may promote dysregulated gene 
transcription and disease progression 71 72. 
A limited number of studies have explored the association of histone modifications 
with T2D. Histone methyltransferase Set7 is an enzyme involved in histones methyl-
ation. Using peripheral blood mononuclear cells from diabetic patients, it was found 
a Set7-dependent monomethylation of lysine 4 of histone 3 (H3K4m1) on NK-kβ p65 
promoter, along with an upregulation of the enzyme 73. Another study observed 
an increased level of histone H3 lysine 9 dimethylation (H3K9me2) around IL-1A 
promoter and PTEN coding regions in circulating monocytes from T2D patients rela-
tive to non-T2D controls 74. A different study investigating histone acetylation found 
that histone 3 (H3) acetylation at TNF-α promoter and COX-2 promoter was increased 
in peripheral blood monocytes from type 2 diabetics, compared to controls 75.
4. EPiGEnETiC MEChanisMs as BiOMaRKERs FOR RisK 
PREDiCTiOn 
When T2D is not well managed, it can lead to health complications in different 
organs of the body, increasing the risk of disability and premature death 76. Direct 
and indirect costs of T2D impose a large burden that impacts the economy of the 
country’s 77. These adverse consequences make the development of prevention strat-
egies highly relevant, like the early identification of individuals at risk of developing 
T2D. 
Recently, next to the traditional prevention methods, a novel approach to assess 
individuals risk is developed, by using statistical models that are able to predict 
future onset of the disease, based on epigenetic markers. The performance of a 
prediction model is evaluated by means of the area under the receiver operating 
characteristic (ROC) curve (AUC), being an AUC value of 1.0 a perfect discrimination 
of the outcome to be predicted. So far, the models using conventional components, 
such as anthropometric measurements, family history of diabetes, lifestyle factors 
and biomarkers like glucose, insulin and lipid levels, are able to predict T2D with 
an AUC that ranges from 0.7 to 0.9 78. However, a large number of predictor factors 
and measurements of different nature are required, and models do not perform 
similarly in different populations. As Genome-Wide Association Studies (GWAS) 
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insulin resistance, have been included as predictors in prediction models. Unfortu-
nately, the associated genetic variants have not improved the performance of the 
overall models 79 80, which might not be surprising since studies until now, agree 
that genetic variants explain up to 10% of the heritable risk 81.
Based on findings from previous reports in the field of epigenetics, a limited number 
of studies have been conducted to explore the suitability of the reported epigenetic 
markers to predict the onset of T2D and, whether the findings in blood samples can 
be used as surrogate markers for epigenetic modifications in target tissues for this 
disease 82 83.
4.1. Dna methylation
Investigating global DNA methylation, a study examined the predictive value for 
LINE-1 as a risk marker for T2D and other metabolic disorders. Worsening of meta-
bolic status or T2D onset after 1 year of follow-up was assessed. A model based on 
classic risk factors (age, sex, body mass index and physical activity) showed an AUC 
of 0.64682. The addition of LINE-1 methylation measures to the previous model, sig-
nificantly improved the predictive performance to an AUC of 0.650 82. The study was 
performed among European Spanish women 40 to 65 years old. No other evidence 
has been reporting the added value of global DNA methylation as a predictive tool 
in diabetes.
Methylation sites in the DNA, previously reported to be associated with T2D and 
glucose homeostasis in candidate gene studies or EWAS, have been taken into 
consideration in the search for biomarkers. One longitudinal study found that the 
methylation marker cg06500161, annotated to gene ABCG1, was associated with a 
9% increased risk for future T2D, whereas methylation at cg02650017 annotated to 
PHOSPHO1, was associated with a 15% decreased risk for future T2D 83. Nevertheless, 
no further investigation of the predictive value of these CpGs was performed.
The role of DNA methylation in predicting onset of T2D is still in its infancy of inves-
tigations. An ongoing longitudinal effort is combining clinical investigation, omics 
profiling (metabolomics, lipidomics, transcriptomics and epigenomics) with exer-
cise and dietary interventions to provide novel diagnostic and predictive biomarkers 
to effectively detect the progression towards diabetes in high risk individuals, and 
also to predict responsiveness to lifestyle interventions known to be effective in the 
prevention of diabetes 84. The study included 1455 participants from the DEXLIFE 
consortium and 400 participants in the intervention group. In the future, this com-
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prehensive approach may provide some more insights on the contribution of DNA 
methylation sites as predictive markers.
4.2. histone Modifications
Although a few studies have been conducted to examine the association between 
histone modifications and T2D 73-75, none of these markers have been proposed 
as possible novel biomarkers to identify subjects at high risk for T2D. The lack of 
consistent evidence and replicated studies may explain the absence of a reliable 
candidate marker serving for clinical purposes. 
5. EPiGEnETiC ChanGEs assOCiaTED WiTh DiaBETiC 
COMPLiCaTiOns
Diabetes is associated with significantly accelerated rates of several debilitating 
microvascular complications such as nephropathy, retinopathy, and macrovascu-
lar complications such as cardiovascular events. While several studies have been 
investigating genetic factors related to diabetes and associated complications, 
little is known about epigenetic changes that occur without alterations in the DNA 
sequence.
5.1. Epigenetic modifications in cardiovascular disease
Prospective studies have shown that diabetic patients have a two- to four fold risk to 
develop coronary artery disease, establishing that T2D is an independent risk factor 
for cardiovascular disease (CVD) 85. About 70% of T2D patients at an age ≥65 years 
die from CVD, while T2D cases with no history of coronary artery disease have an 
equal cardiovascular risk as patients with previous myocardial infarction 86. CVD 
and T2D share several common pathophysiological features like the classical car-
diovascular risk factors, such as dyslipidaemia, hypertension and obesity. However, 
all of the known pathways do not explain the complex pathophysiology behind 
cardiovascular complications of diabetes. Up to date, the underlying mechanisms 
are often addressed within a specific pathological context, whereas an integrated ap-
proach should be preferred in order to capture all potential interlinks between T2D 
and CVD. New research investigations have linked the participation of epigenetic 
mechanisms in the process of inflammation, oxidative stress, and endothelial dys-
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5.1.1. DNA methylation
Using human aortic endothelial cells exposed to high glucose and aortas of diabetic 
mice, one study found that the mitochondrial adaptor p66Shc was epigenetically 
upregulated by promoter CpG demethylation and H3 acetylation 87. Moreover, the 
overexpression continued even after returning to normoglycemia and could only 
be inhibited after pharmacologic intervention, providing molecular insights for the 
progression of diabetic vascular complications despite glycaemic control, which 
might help to define novel therapeutic targets 87.
Although emerging data has linked some aspects of hypertrophy, heart failure, 
and arrhythmias in cardiomyocytes to DNA methylation and PTMs of histones, less 
evidence has been reported in hearts of diabetic patients 88. Monkemann et al. re-
ported that oxidative stress damages cardiomyocytes via p53-dependent apoptosis in 
diabetic cardiomyopathy 89. Interestingly, in animal studies, the methylation of the 
p21(WAF1/CIP1) gene that encodes several protein kinases at p53 showed the later to 
be an early step in the development of hyperglycemia-induced cardiomyopathy in 
diabetic rats 89. 
Other epigenetic marks are linked to intermediate risk factors common to CVD 
and T2D and that could contribute in discovering diagnostic and prognostic factors. 
One study, investigating the association between IGF2 methylation and lipid profile, 
showed that higher triglyceride/HDL-cholesterol ratio was associated with hyper-
methylation of IGF2 gene, indicating that this gene might be an important marker 
of metabolic risk 90. The IGF2 gene provides instructions for making a protein called 
insulin-like growth factor 2, which plays an essential role in cell growth and insulin 
mechanisms. Another study that combined genome-wide transcriptome and CpG 
methylation profiling by array, reported many differentially methylated predicted 
sites in adipose tissue from insulin-resistant patients compared to controls, which 
included genes involved in insulin signalling and in the interaction with integrins 91. 
Current therapies for diabetes are aimed to optimize glycaemic control and reduce 
the associated cardiovascular risk. Some preliminary studies have shown that DNA 
methylation plays an important role in the reversibility and treatment of diabetic 
complications such as CVD, including vascular inflammation 92. Resveratrol is a 
polyphenol with antioxidative and anti-inflammatory properties. Numerous studies 
have shown that resveratrol might have cardiovascular protective effects and also 
might contribute in improving insulin sensitivity, reducing plasma glucose levels 
and reducing inflammation 92. Lou et al. aimed to investigate the effects of resveratrol 
(trans-3, 5, 40-trihydroxystilbene) on the expression of pro-inflammatory cytokines 
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such as IL-1β, IL-6, TNF-α and IFN-γ in diabetic rat aortas and the potential epigenetic 
mechanisms involved 92. It showed that the expression levels of pro-inflammatory 
cytokines were significantly lower in the resveratrol-treated diabetic group. More-
over, the untreated group showed reduced levels of DNA methylation at the specific 
cytosine phosphate guanosine sites of IL-1β, IL-6, TNF-α and IFN-γ and these levels 
were reversed by resveratrol 92. Furthermore, incretins such as glucagon-like peptide 
1 receptor (GLP1R) agonist are shown to have cardiovascular protection beyond gly-
caemic control in diabetes subjects93. Recent data show that methylation of GLP1R 
is associated with glycaemic control but also cardiometabolic risk factors, such as 
obesity 94. Thus, although the studies of epigenetics marks and CVD in diabetes are 
scarce, they provide some insight on epigenetic modifications as possible targets to 
develop novel therapeutic agents at preventing and treating vascular complications. 
5.1.2. Histone modifications
Gaikwad et al. reported deacetylation and dephosphorylation of histone H3 in 
the heart and kidney of diabetic Sprague-Dawley rats leading to changes in gene 
expression in the extracellular matrix and therefore hypertrophy 95. A recent study 
used peripheral blood mononuclear cells to measure histone deacetylases (HDACs) 
activity and expression in relation to glycaemia, inflammation and insulin resis-
tance in patients with T2D. Low-grade chronic inflammation and insulin resistance 
induced HDAC3 activity and expression, and correlated positively with circulating 
levels of TNF-α, IL-6, and other proinflammatory markers, and negatively with Sirt1 
expression 96. Using aortic endothelial cells, another study showed that exposure 
to high glucose correlates with the inverse acetylation of the histone H3K9/K14 and 
modified DNA methylation patterns 97. Several histone lysine modifications have 
also been described following transient high glucose levels that may account for a 
persistent transcriptional induction of the RELA gene, encoding for the p65 subunit 
of NF-kB, even after subsequent incubation of endothelial cells with normal glucose 
concentrations 98. Miao et al. recently compared patients previously included in the 
conventional treatment arm of the Diabetes Control and Complications Trial who 
developed diabetic microangiopathy (cases) to patients who were allocated the in-
tensive treatment and had no progression of microvascular complications (controls) 
99. They reported a significantly greater number of promoter regions with enrich-
ment in H3K9Ac (hyperacetylation) in monocytes, but not in lymphocytes, in cases 
versus controls 99. These findings further support the existence of an epigenetic 
component in the metabolic memory—the concept that early glycaemic control is a 
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5.2. Epigenetic modifications in diabetic nephropathy
Diabetic nephropathy (DN) is a major chronic complication of diabetes and the most 
common cause of end-stage kidney disease 100. Approximately 50% of patients who 
have end-stage renal disease needing painful and costly dialysis are diabetic 100. The 
underlying molecular mechanisms leading to DN are not fully elucidated. High glu-
cose levels adversely impact all renal cell types including mesangial cells, tubular 
cells, podocytes and endothelial cells, and augment monocyte and macrophage infil-
tration 101. High glucose conditions also increase the formation of advanced glycation 
end-products and production of growth factors such as transforming growth factor 
β1 (TGF-β1) and angiotensin II in renal cells 101. Although several classic mechanisms 
and pathways leading to DN have been described over the years, new molecular and 
epigenetic mechanisms are emerging 102.
5.2.1. DNA methylation
The role of DNA methylation in DN has elicited much interest 102 mainly because 
most genome-wide association studies of DN have yielded few susceptibility loci. 
Studies of DNA methylation profiles in genomic DNA of diabetic patients with or 
without DN revealed differential methylation levels in several genes, including 
UNC13B, which has been suggested to mediate apoptosis in glomerular cells as a 
result of hyperglycaemia, and hence the association could be relevant to the ini-
tiation and pathogenesis of DN 103. In DN, prolonged exposure to hyperglycemia 
induces production of cytokines, chemokines, and growth factors including TGFβ1 
and connective tissue growth factors, which leads to abnormal glomerular pathol-
ogy. Brennan et al. measured DNA methylation in 192 candidate genes previously 
identified to be differentially expressed in in vitro models of DN and in renal biopsies 
from individuals with DN. The study found that 301 CpGs in 38 out of 192 genes 
were differentially methylated 104. The gene ontology analysis of the differentially 
methylated genes revealed that the predominant biological function of the affected 
genes was organism development 104. Additional studies using various DNA methyla-
tion assays and DNA collected from peripheral blood samples or saliva identified 
specific DNA methylation profiles for diabetic patients with and without nephropa-
thy 105 106. These studies proposed using DNA methylation profiles as biomarkers to 
help predict disease status and progression; however, they did not report associated 
gene expression data.
5.2.2. Histone modifications
Growing evidence suggests that histone post-translational modifications can have 
key roles in the pathogenesis of diabetes. TGF-β1-induced expression of plasminogen 
activator inhibitor-1 (PAI-1) and p21 in renal mesangial cells plays a major role in 
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glomerulosclerosis and hypertrophy, key events in the pathogenesis of diabetic 
nephropathy. However, the involvement of histone acetyl transferases (HATs) and 
HDACs that regulate epigenetic histone lysine acetylation, and their interaction 
with TGF-β1-responsive transcription factors, are not clear. In vitro studies in rat 
mesangial cells, have shown that TGF-β1, which is a central mediator of fibrogenesis 
and high glucose treatment, increased H3K9/14ac enrichment near Smad and SP1 
binding sites (proteins related to the control of gene expression and cell growth) 
at the plasminogen activator inhibitor 1 and p21 gene promoters, together with 
HATs p300 and CREB-binding protein 107. Histone H3K9/14ac was found to have a key 
role in transcription of these genes in response to TGF-β1 107. High glucose treat-
ment also elicited similar histone post-translational modifications at fibrotic and 
cell-cycle gene (p21) promoters, which were blocked by an anti-TGF-β antibody 107. 
Therefore, it is conceivable that histone hyperacetylation and related chromatin 
events involved in TGF-β1-mediated PAI-1 and p21 expression play important roles 
in the pathogenesis of DN and could therefore serve as potential therapeutic tar-
gets for diabetes-induced renal dysfunction. In vivo animal models of DN have also 
demonstrated changes in histone post-translational modifications. NF-κB-dependent 
inflammatory gene expression has been extensively studied due to the involvement 
of these target genes in the pathology of several inflammatory diseases, including 
atherosclerosis, insulin resistance, diabetes and its complications. Studies demon-
strated that H3K4me HMT SET7 could be a NF-κB coactivator at a subset of inducible 
inflammatory genes in monocytes108. SET7/9 may therefore be a novel therapeutic 
target for inflammatory diseases, including diabetes, DN and related metabolic 
disorders. Interestingly, treatment of mice with losartan, an Ang II type 1 receptor 
blocker, ameliorated key indices of diabetic nephropathy, and reversed key changes 
in epigenetic enzymes and H3K9ac enrichment at promoters of genes encoding PAI-1 
and RAGE, but did not reverse all the diabetes-induced epigenetic changes 109. Thus, 
the relative inefficiency of drugs commonly used for diabetic nephropathy, such 
as Ang II type 1 receptor blockers, to prevent progression to renal failure, in many 
patients could be due to the incomplete reversal of diabetic nephropathy-associated 
epigenetic changes 109. Also, several clinical trials (NCT01038089, NCT00937222) 
have been conducted testing resveratrol, (class III histone deacetylases group) which 
is thought to protect against development of diabetic nephropathy via changes in 
phosphorylation of histone H3 and Sir-2. The activity of resveratrol shows great 
potential in the prevention and therapy of diabetes and its complications especially 
to DN, nevertheless the compound is still in its experimental phases. These and 
other studies emphasize the role of epigenetic mechanisms in the regulation of 
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5.3. Epigenetic modifications in diabetic retinopathy
Retinopathy, a sight-threatening disease, remains one of the most feared complica-
tions of diabetes. Although altered levels of glucose are the main initiators, pro-
gression of diabetic retinopathy continues even after the hyperglycaemic insult is 
reversed by good glycaemic control, suggesting a ‘metabolic memory’ phenomenon 
110 111. 
5.3.1. DNA methylation
Recent studies have implicated epigenetic modification in the metabolic memory 
phenomenon associated with the continued progression of diabetic complications. 
T2D activates the enzymes responsible for maintaining DNA methylation status in 
the retina, increasing the activities of DNA methyltransferases (DNMTs) and ten-
eleven translocation enzymes (Tets) which can lead to hypo- or hypo- DNA meth-
ylation of many genes responsible for mitochondrial homeostasis 112-114. A dynamic 
DNA methylation process of the matrix metalloproteinase gene MMP-9 is shown to 
maintain its transcriptional activation, though the transcription factor binding sites 
of the MMP-9 promoter, which are hypermethylated in diabetes. Due to concomitant 
increased binding of Tet at the same site, MMP-9 DNA remains hypomethylated 
resulting in its transcriptional activation 114 and this continues to fuel into the mito-
chondrial damage 110. Abrogation of MMP-9 gene protects against the development of 
retinopathy and it is considered to play an important role in the apoptosis of retinal 
capillary cells.
5.3.2. Histone modifications
Histone acetylation and methylation (HDAs, HATs, SETs and LSD1) play also a crucial 
role in epigenetic modifications that occur during diabetic retinopathy. However, 
experimental studies of diabetic retinopathy have provided contradictory results 
for histone acetylation, with some showing increased global acetylation of retinal 
histones with activation of HAT and inhibition of HDACs 115, and others reporting 
significant increase in retinal histone acetylation 116 117. The reasons for such dis-
crepancies are still unknown. Although histone modifications and DNA methylation 
generally regulate gene transcription independently, DNA methylation and histone 
modifications are also shown to work in concordance; e.g., cooperation of DNA 
methylation with histone methyltransferase SETDB1/ESET results in trimethylation 
of H3K9 (known for its function in condensing the chromatin) 110. DNMTs and histone 
modifying enzymes, SUV39h1 and EZH2 lysine histone methyltransferase, can work 
in coordination, and the agents that interact with histone methyl transferases, in 
addition to regulating histone methylation, also regulate DNA methylation 118.
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Some of the studies have shown that even after the reverse of the hyperglycemic 
insult, H3K4 and H4K20 at Sod2 methylation levels continue to be altered. Also, the 
enzymes responsible for histone methylation (SUV420h2) and demethylation (LSD1) 
remain dysfunctional 116. Upregulation of MMP-9, which encodes another enzyme 
implicated in diabetic retinopathy, was associated with reduced promoter H3K9me2 
and increased H3K9ac levels, along with increased recruitment of NF-κB in retinal 
endothelial cells from diabetic rats 119. Furthermore, mass spectrometry studies 
demonstrated that hyperglycaemia causes acetylation of retinal histones, which 
was associated with increases in proinflammatory proteins 120. The HAT p300 was 
implicated in endothelial fibronectin expression related to diabetic retinopathy, and 
in gene expression relevant to diabetic cardiac hypertrophy 120. 
5.4. Epigenetic modifications in diabetic neuropathy
Diabetic neuropathy is a common but irreversible complication that develops in 
up to 50% of patients with diabetes and results in sensory loss, pain, and risk of 
amputation 121. The molecular mechanisms involved in the development of diabetic 
neuropathy is a complex process that includes activation of the polyol pathway, 
exaggerated oxidative stress, over activity of protein kinase C and increased for-
mation of advanced glycation end-products in the presence of hyperglycaemia. 
Diabetic neuropathy entails decreased nerve conduction velocity, which indicates 
a prominent role for Schwann cells because they ensheath peripheral nerves and 
provide support for nerve conduction and axon regeneration 122. Moreover, high 
glucose induces oxidative damage in Schwann cells, considered a major factor in 
diabetic complications 122. With respect to diabetic neuropathy, several biological 
mechanisms have been studied, although the role of epigenetics has only recently 
been suggested 122.
5.4.1. DNA methylation
Previous studies have suggested that diabetic neuropathy involves dysregulation of 
the transcription factor peroxisome proliferator-activated receptor (PPRG or PPARγ) 
123. Although drugs that activate PPARγ improve glycaemic control in T2D, its role 
in metabolic memory has not been extensively examined. Because high glucose 
produces changes in gene expression that persist after cell division 124, a plausible 
mechanism for these stable changes is DNA methylation. Using quantitative PCR 
arrays for glucose and fatty acid metabolism, one study found that chronic high 
glucose induced a persistent increase in genes that promote glycolysis, while inhib-
iting those that oppose glycolysis and alternate metabolic pathways such as fatty 
acid metabolism, the pentose phosphate pathway, and trichloroacetic acid cycle 122. 
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tently increased reactive oxygen species, cellular NADH, and altered DNA methyla-
tion 122. Their results suggest that Schwann cells might exhibit features of metabolic 
memory that may be regulated at the transcriptional level therefore, targeting PPAR 
may prevent metabolic memory and the development of diabetic complications 
such as diabetic neuropathy.
5.4.2. Histone modifications
With respect to diabetic neuropathy and histone modifications, little evidence is 
available. Nevertheless, factors like dyslipidaemia, oxidative stress and inflammation 
have been reported to be particularly important for the development of neuropathy 
125. Therefore, one could speculate that some of the reported mechanisms linking 
diabetes with dyslipidaemia, oxidative stress and inflammation through histone 
modifications, could play a role also in diabetic neuropathy. Nevertheless, future 
studies are needed to shed light about the role that epigenetic mechanisms such as 
histone modifications play in diabetic neuropathy.
6. EPiGEnETiC BasED BiOMaRKERs FOR DiaGnOsis 
anD PROGnOsis OF T2D
Extensive research over the last decades, has shown that our genome is not the 
only determinant of disease risk, and that epigenetic marks induced by lifestyle 
and environmental factors are associated with altered gene expression patterns in 
important tissues, leading to altered susceptibility to disease in later life 8. Thus, it 
should be possible to detect these altered epigenetic marks and use them as predic-
tors of future metabolic capacity, early detection of disease and better prognosis 
(Figure 2). A premature diagnosis of disease is crucial as it might greatly improve 
clinical outcomes for patients. For example, population screening for cancers 
and the surveillance of high-risk patients allows an early diagnosis of cancer and 
therefore reduces morbidity by using less invasive treatment, resulting in fewer 
complications and side effects. However, constant screening for a broad range of 
diseases across whole populations is not routine and realistic and it poses a high 
economic burden to governments 77. Hence, the detection of epigenetic alterations 
has become a promising tool in many health areas for the diagnosis and prognosis 
of disease and for the prediction of drug response. 
6.1 Epigenetic based biomarkers for diagnosis of T2D
Although great progress has been made in the description of epigenetic modifica-
tions in normal and diseased tissues, the studies so far have been mainly focused 
50 Chapter 2.
Epigenetics of type 2 diabetes
on cancer research. In prostate cancer, DNA hypermethylation at the glutathione 
S-transferase pi 1 (GSTP1) enzyme gene has been suggested as the most relevant 
candidate biomarker. It has been detected in 69% of proliferative inflammatory 
atrophy lesions, that are considered precursor lesions for the development of 
prostate cancer and/or high-grade prostatic intraepithelial neoplasia, underlining 
its importance for diagnosis 126. This epigenetic mark was consistently validated in 
many studies, showing a sensitivity of 82% and a specificity of 95% 127, compared to 
serum prostate-specific antigen (PSA, 20%), which is the only biomarker currently 
used for the detection and monitoring of this cancer. However, GSTP1 can also be 
hypermethylated in some other types of cancers. Therefore, combinations with 
additional biomarker genes and PSA testing have been recommended in order to 
increase specificity. Nevertheless, later studies that combined DNA hypermethyl-
ation of GSTP1, APC, RASSF1, PTGS2, MDR1 and TIG1 resulted in both sensitivity and 
specificity up to 100% 128 129. Furthermore, for the detection of glioblastoma, the 
hypermethylation at the promoter of the gene O-6-Methylguanine-DNA Methyltrans-
ferase (MGMT) has been established as a promising biomarker, since it was possible 
to detect glioblastomas with a very high sensitivity and specificity (95% and 60% 
respectively) in serum samples 130. Also, researchers were able to predict a lack of 
cancer progression and overall survival of the patient 130. A step further, in colorectal 
cancer (CRC), the Food and Drugs Administration (FDA) has already approved the use 
of epigenetic markers like SEPT9 (ColoVantage) and vimentin (ColoSure)131 in clinical 
practice, after showing a high sensitivity and a specificity for CRC diagnosis 132 133.
As the field has grown, efforts are made also in discovering candidate biomarkers 
in the diagnosis and prognosis of other types of diseases such as type 2 diabetes, 
but this research field is still in its early phases. Twin studies might be a powerful 
approach as, despite the identical genetic background, discordant twins for T2D 
have differences in DNA methylation 134 135. 
Recently a new classification of diabetes types has been proposed. Using a data-driven 
cluster analysis approach, newly diagnosed diabetic patients were stratified into five 
subgroups with differing disease progression and risk of diabetic complications 136. 
The study identified five replicable clusters of patients with diabetes, who had sig-
nificantly different patient characteristics and risk of diabetic complications. Cluster 
1 included severe autoimmune diabetes patients; cluster 2 included patients with 
severe insulin-deficient diabetes; cluster 3 included severe insulin-resistant diabetes 
patients; cluster 4 was labelled as mild obesity-related diabetes and cluster 5 was 
labelled as mild age-related diabetes. They found that individuals in cluster 3 had 
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5, but had been prescribed similar diabetes treatment. While, individuals in cluster 
2 had the highest risk of retinopathy compared to the other clusters. Moreover, 
genetic associations in the clusters differed from those seen in traditional T2D 136. 
Considering the high heterogeneity of T2D, epigenetics might be a promising path 
that could help to better disentangle the differences in diabetic phenotypes, which 
would provide more information on treatment target, as well in prevention strate-
gies individualized by diabetes type, thus evolving towards personalized medicine. 
In type 1 diabetes mellitus, recent findings propose the circulating β cell-derived 
unmethylated insulin (INS) DNA as a potential diagnostic tool for the early detection 
of type 1 diabetes (T1D) 137. This is based in previous evidence showing that the 
autoimmune destruction conducted by immune cells in T1D leads to the release 
of unmethylated INS DNA from pancreatic β cells, into the circulation. Thus it is 
possible the detection of the circulating DNA in blood samples, and the consequent 
assessment of the unique methylation pattern present in the promotor of the INS 
gene in β cells from patients with early T1D, or in patients with islet transplantation 
therapy 138.
6.2 Epigenetic based biomarkers for prognosis of T2D
In addition to its diagnostic potential, DNA methylation could be informative for 
patient prognosis in terms of disease progression/recurrence, complications, treat-
ment and survival. High resolution data usually used for cancer, subtypes-specific 
profiles can also be used for the identification of powerful single epigenetic bio-
marker genes and gene combinations at various stages of disease. This advanced 
screening strategy can be beneficial for many types of clinical applications. 
Initially, the potential prognostic profile of DNA methylation has been reported in 
childhood acute lymphoblastic leukaemia 139. DNA methylation profiling classified 
these patients in lymphoblastic leukaemia subtypes and stratified them with high 
hyperdiploidy and translocation t(12;21) into two subgroups with different prob-
abilities of relapse. DNA methylation profiling therefore resulted in subtype-specific 
and predictive signatures with potential use as future prognostic biomarkers for 
this disease 139. In breast cancer, DNA methylation profiling identified a previously 
unrecognized subtype associated with T lymphocyte infiltration. Importantly, profil-
ing immune genes determined a prognostic value of the profile. In particular, the 
hypermethylation at the promoter of lymphocyte transmembrane adaptor 1 (LAX1) 
and CD3D significantly correlated with survival in certain breast cancer subtypes 
140. Another study discovered and validated the epigenetic signature of NEFH and 
HS3ST2 as an independent prognostic factor for type II ovarian cancer 141. Moreover, 
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they showed that 3-0 sulfation of HS was important to oncogenic signalling, such as 
IL-6 and EGF signalling, which could render useless current targeted therapies for 
ovarian cancer without further patient stratification 141. 
However, when it comes to the role of epigenetics used as a prognostic marker for 
T2D the data are very limited. Recent published studies have suggested that the 
differentially methylated circulating DNA might be a promising novel biomarker 
which reflects beta cell death and could predict the progression of diabetes 142. The 
novel beta cell death marker unmethylated insulin (INS) DNA has been studied in 
TPIAT (total pancreatectomy with islet autotransplantation) patients before and 
immediately after islet infusion, and also 90 days post-TPIAT concurrent with meta-
bolic functional assessments 143. Universal early elevations in the beta cell death 
marker INS DNA after TPAIT were observed, with pronounced elevations in the islet 
supernatant pre-infusion, likely reflecting beta cell death induced by islet isolation. 
In addition, persistent post-transplant elevation of INS DNA predicted greater hy-
perglycaemia at 90 days 143. Although, more studies are needed to identify the best 
methylation target sites in the INS gene, differentially methylated circulating DNA 
may be a good method to evaluate progression, diagnosis and prognosis of islet 
related diseases and in diabetes patients for whom insulin production is impaired.
Aging is also an important risk factor for metabolic disorders, including obesity, im-
paired glucose tolerance, and T2D 144. Almost one third of the elderly in the United 
States of America have diabetes and three quarters have diabetes or prediabetes 
145. Recent attempts have been done in identifying biomarkers of aging, which are 
thought of as individual-level measures of aging that capture inter-individual dif-
ferences in the timing of disease onset, functional decline and death over the life 
course. In this context, DNA methylation has gained a lot of interest as a potential 
biomarker that could predict mortality 146. Successfully, a DNA methylation based 
biomarker of aging (PhenoAge) was developed, which is highly predictive of nearly 
every morbidity and mortality outcome tested, especially cardiovascular disease and 
coronary heart disease. In addition, the study observed that higher DNA methyla-
tion PhenoAge was associated with increases in the activation of proinflammatory 
pathways, such as NF-κB, increased interferon signalling and decreases in damage 
recognition and repair pathways 146. Given this, one could hypothesize that DNA 
methylation PhenoAge might have an influence also on T2D. Future studies could 
test this hypothesis in diabetes patients which would provide some insights on 
whether methylation age of specific methylation sites would identify T2D patients 
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7. COnCLUsiOns anD FUTURE REsEaRCh DiRECTiOns
Epigenetics promises an auspicious future in its role as clinical instrument to comple-
ment the current practice. Current evidence in the field suggests that study of the 
role of epigenetic changes in the onset and progression of the diseases is a promising 
opportunity for the development of prediction, diagnostic and disease progression 
monitoring tools, as well as novel therapeutic targets (Figure 2). Overall, changes 
in global DNA methylation, CpG islands methylation, and histone acetylation and 
methylation have been found in relevant genes for aorta, heart, kidney, retina, 
nerves and glia cells function in samples from diabetic human and rodent donors 
or after hyperglycaemic stimuli of the same type of tissues, albeit some of them ex-
hibit contrary results. However, since epigenetic changes have shown to be dynamic 
and vary in response of environmental stimulations, epigenetic mechanisms are 
important to study also because it is believed that they may play a significant role 
in the reversibility and treatment of diabetic complications, contributing even as 
a protective mechanism against them, though which drugs and other therapeutic 
tools may exert their effect. Furthermore, not solely for risk prediction, epigenetic 
changes also arise as a promising tool in the diagnosis, stratification of the patients, 
prognosis and monitoring of therapy response. Various research methodologies and 
DNA methylation assessment methods have been used to disentangle the epigenetic 
network; however, the technological advances in DNA methylation arrays have per-
mitted EWAS approach to analyse a higher number of CpGs, a larger samples size 
and a more standardized method to assess DNA methylation. Nevertheless, identify-
ing optimal methods of detecting possible epigenetic biomarkers and implementing 
appropriate reference standards are rapidly evolving. The use of common plans in 
the study designs, methylation assessment methods and statistical models for data 
analysis with similar strategies for confounding control, would allow comparability 
and independent validation of the findings, thus better quality evidence to identify 
biomarkers for T2D precision medicine, reliable for both clinicians and the patients.
54 Chapter 2.
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Figure 2. Characteristic epigenetic patterns for T2D and glycemic traits can be investigated in key tissues 
for glucose homeostasis and energy balance in the body. After the identification of an epigenetic 
signature, it can be used as a biomarker for the detection of subjects at high risk of developing T2D, 
before the onset of the disease. Thus, the patient can receive health-care advice and is still on time to 
implement strategies in order to prevent the progression toward T2D. A biomarker can also be of use 
after the onset of the disease, to make a more accurate diagnose, to choose the best treatment 
strategy, and to monitor the progression of T2D and its complications in order to augment patient´s 
survival and reduce comorbidities. 
Figure 2. Characteristic epigenetic patterns for T2D and glycemic traits can be investigated in 
key tissues for glucose homeostasis and energy balance in the body. After the identification of an 
epigenetic signature, it can be used as a biomarker for the detection of subjects at high risk of 
developing T2D, before the onset of th  disease. Thus, the patient can receive healthcare advice 
nd is still on tim  to imple ent strategi s in order t  prev n  the prog ession towards T2D. A 
biomarker can also be of use after t  ons t of the dis ase, to make a more accurate diag ose, to 
choose the best treatment strategy and to monitor the progression of T2D and its complications 
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aBsTRaCT 
Sex is a major determinant of cardiometabolic risk. DNA methylation (DNAm), an 
important epigenetic mechanism that differs between sexes, has been associated 
with cardiometabolic diseases. Therefore, we aimed to systematically review studies 
in adults investigating sex-specific associations of DNAm with intermediate cardio-
metabolic traits and incident cardiovascular disease including stroke, myocardial 
infarction (MI) and coronary heart disease (CHD). Five bibliographic databases were 
searched from inception to 15 July 2019. We selected 35 articles (based on 30 unique 
studies) from 17,023 references identified; including a total of 14,020 participants 
from European, North American and Asian ancestries. Four studies reported sex 
differences between global DNAm and blood lipid levels and stroke risk. In 25 
genome wide and candidate gene approach studies, DNAm at 31 gene sites were 
associated with sex differences in cardiometabolic diseases. The identified genes 
were PLA2G7, BCL11A, KDM6A, LIPC, ABCG1, PLTP, CETP, ADD1, CNN1B, HOOK2, GFBP-
7, PTPN1,  GCK,  PTX3, ABCG1, GALNT2, CDKN2B, APOE,  CTH, GNASAS, INS, PON1, TCN2, 
CBS, AMT, KDMA6A, FTO, MAP3K13, CCDC8, MMP-2 and ER-α. Prioritized pathway con-
nectivity analysis associated these genes with biological pathways such as vitamin 
B12 metabolism, statin pathway, plasma lipoprotein, plasma lipoprotein assembly, 
remodeling and clearance and cholesterol metabolism. Our findings suggest that 
DNAm might be a promising molecular strategy for understanding sex differences 
in the pathophysiology of cardiometabolic diseases and that future studies should 
investigate the effects of sex on epigenetic mechanisms in cardiometabolic risk. In 
addition, we emphasize the gap between the translational potential and the clinical 
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inTRODUCTiOn 
Cardiometabolic diseases include cardiovascular diseases (CVD), type 2 diabetes 
(T2D) and their associated risk factors including components of the metabolic 
syndrome and obesity[1]. Aging is associated with development of unfavorable 
cardiometabolic profile which in large contributes to increased incidence of major 
cardiovascular events and mortality[2]. Intermediate cardiometabolic risk factors 
are unequally distributed among sexes, and sex differences are also described in 
cardiometabolic diseases prevalence, clinical characteristics and prognosis[3, 4],[5]. 
Generally, before menopause women have better cardiometabolic risk profiles than 
same aged men; however, this sex advantage gradually disappears with advancing 
age, particularly after menopause[6]. Mechanisms underlying sex differences in 
CVD have been extensively studied in the past two decades and signaling pathways 
including epigenetic modifications of the genome emerged as possible pathways 
leading to sexual dimorphism in cardiometabolic diseases [7]. 
Epigenetic modifications comprise dynamic changes in the genome engaged in 
the modification of important cellular processes such as gene expression, chromo-
somal stability and genomic imprinting [8, 9]. DNA methylation (DNAm) is the best 
understood and most extensively studied epigenetic mechanism in regard to CVD 
risk [8, 9]. DNAm refers to the transfer of a methyl group into the C5 position of 
the cytosine to form 5-methylcytosine (5mC) and increases or decreases in genomic 
5mC are referred as DNA hyper- and hypomethylation respectively [8, 9]. The global 
DNAm assessed at long-interspersed nuclear element (LINE-1) has been inversely 
associated with intermediate CVD risk factors and higher risk of metabolic status 
worsening [10]. Conversely, a higher degree of global DNA methylation measured at 
Alu repeats or by the LUMA method was associated with the presence of CVD [10]. 
Also, gene specific hyper- or DNA hypomethilation was associated with changes in 
gene expression and was shown to affect cardiometabolic risk including atheroscle-
rosis, inflammation, blood pressure, serum lipid and glucose levels, subsequently 
leading to increased risk of developing T2D, stroke and myocardial infarction [11]. 
Also, sex-specific differences in DNAm have been found in brain, human pancreatic 
islets and blood [12, 13]. Men in general seem to have lower levels of methylation in 
their genome as compared to women [14, 15], indicating that similarly to sex chro-
mosomes, methylation at the autosomes might be subject to sex differences. Despite 
this, only a relatively small number of studies in the ample field of cardiometabolic 
epigenetics stratify according to sex or focus in sex differences. Although a few stud-
ies [11, 16, 17] have summarized the existing literature on this complex topic, they 
did not focus on epigenetically induced sex differences in CVD, intermediate CVD 
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risk factors or T2D, with the exception of a recent review that focused only on major 
CVD events[16]. 
Therefore, we aimed to systematically review the available evidence in human 
studies exploring the association between sex-specific DNAm and cardiometabolic 
diseases.
METhODs 
Data sources and searches
This review was conducted using a predefined protocol (which was not registered at 
online platforms) and following a recently published guideline on how to perform 
systematic reviews[18] and in accordance with PRISMA guidelines[19]. A literature 
search was done using 5 electronic databases (Medline ALL via Ovid (1946-current), 
EMBASE (1974-current) via embase.com, Web of Science Core Collection (1900-cur-
rent), Cochrane CENTRAL registry of trials (issue 7 2019) via Wiley and Google Schol-
ar) until 15 July 2019 (date last searched) with the help of an experienced medical 
information specialist (WMB). All references were imported in an EndNote library 
and deduplicated with the algorithm developed by Bramer et al[20]. Additionally, 
we searched the reference lists of the included studies and relevant reviews. Two 
independent reviewers screened the titles and abstracts of all studies identified ini-
tially, according to the selection criteria. Full texts were retrieved from studies that 
satisfied all selection criteria. All disagreements were resolved through consensus or 
consultation with two other independent reviewers.
study selection
Observational (cross-sectional, case-control, prospective) studies conducted in 
adults and investigating the associations of global or gene-specific DNAm with 
cardiometabolic outcomes were selected. Studies were included if they investigated 
sex-stratified associations between DNAm and intermediate cardio-metabolic traits 
(blood lipids, glucose, blood pressure, inflammatory markers, atherosclerosis, T2D) 
and CVD (MI, CHD, stroke). Also, we included studies that reported a significant 
interaction term with sex but did not stratify by sex in their analysis. Furthermore, 
studies conducted only in men/women were not included in the current review. 
Data Extraction
A predesigned electronic data abstraction form was used to extract relevant infor-









A Systematic review of sexually dimorphic DNA-methylation in cardiometabolic health
included in the study, participants’ age, cardio-metabolic outcome, tissue type, 
DNAm technique used and general and sex-specific findings. Two authors indepen-
dently extracted the data and a consensus was reached in case of any inconsistency 
with involvement of an additional author.
assessing the Risk of Bias 
Two independent investigators used the Newcastle-Ottawa Scale[21] to assess the 
risk of bias of the included observational studies. The Newcastle-Ottawa Scale uses 
a star system (maximum of nine stars) to evaluate three domains: selection of par-
ticipants; comparability of study groups; and the ascertainment of outcomes and 
exposures of interest. Studies that received a score of nine stars were judged to be 
of low risk of bias; a score of seven or eight stars was medium risk and those that 
scored six or less were considered at high risk of bias.
Pathway connectivity analysis
To identify biological pathways of the differentially methylated genes previously 
linked to CVD, we used the CPDB (ConsensusPathDB-human) tool from the Max 
Plank Institute for Molecular Genetics[22]. This tool integrates interaction networks 
in humans (in this study) and includes information on binary and complex protein-
protein, genetic, metabolic, signaling, gene regulatory and drug-target interactions, 
as well as biochemical pathways[22]. Data that explains interactions was derived 
from 32 public resources.
REsULTs
search Results and study Characteristics
The search strategy identified 17,023 potentially relevant studies; after titles and 
abstracts were screened 16, 814 references were excluded (Figure 1). For the remain-
ing 209 references, full-text articles were reviewed, 174 of which were excluded for 
various reasons outlined in Figure 1. A total of 35 articles based on 30 unique studies 
were included in this systematic review including a total of 14,020 non-overlapping 
participants, of whom approximately 53% were women. The studies included popu-
lation with European (n=13), North American (n=3) and Asian (n=14) ancestries with 
age ranging from 32 to 75 years. Due to differences in the epigenetics marks and 
outcomes investigated, as well as different study designs of the included studies, we 
were not able to quantitatively pool the estimates from various studies. Therefore, 
we report in this review a detailed descriptive summary of the available published 
literature. The characteristics of the included studies are described in Table 1. The 
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median Newcastle-Ottawa quality score for the included studies was 7 of 9 possible 
points. The Table 1 depicts the methodologic quality of all included studies.
The Role of sex-specific Dnam in intermediate Cardio-metabolic 
Traits
Blood Lipids
Global DNA methylation is a frequent used marker for epigenetic screening since it 
captures the DNA methylation also at unknown genetic locations while the results 
of average DNA methylation correlate with the methylation of some trait-relevant 
genes[23, 24]. Ten articles[14, 25-33] investigated sex-specific associations between 
DNAm and blood lipid concentrations applying global (n=2), epi-genome wide (n=1) 
and candidate gene (n=7) approaches. In total 2,443 non-overlapping participants 
(1,174 women and 1,269 men) from USA, Canada, Finland, UK and China were 
included in these studies. 
Two cross-sectional studies[14, 25] investigating global DNAm and blood lipid levels 
reported sex differences. In the study conducted by Cash et al, LINE-1 methylation 
was significantly higher in men than in women, and among the entire sample, lower 
levels of LINE-1 methylation was associated with higher levels of fasting low-density 
lipoprotein-cholesterol (LDL) and lower levels of fasting high-density lipoprotein-
cholesterol (HDL)[14]. However, when stratifying by sex, the inverse association 
between global LINE-1 methylation, LDL and HDL remained significant only in 
men[14]. Malipatil et al, in their study reported that an increase of 10% in LINE-1 
methylation was associated with decreased cholesterol/HDL ratio by 0.4 mmol/L 
in the overall sample of men and women. However, when stratifying by sex, the 
inverse association remained significant only in women[25]. In an EWAS performed 
by Garcia-Calzon et al, female samples displayed on average higher methylation in 
the X-chromosome, whereas males presented higher methylation in the autosomes. 
Further, women showed higher HDL levels, which were associated with higher 
KDM6A expression and epigenetic differences in human liver[31]. The results were 
not replicated. Further, the authors integrated DNA regulatory regions and other 
epigenetic factors for CpGs in the autosomal and X-chromosome based on sex (q < 
0.05) for only four liver donors. Particularly, 42% of the autosomal CpG sites (13,817 
CpGs) and 27% of the X-chromosome sites (2601 CpGs) differentially methylated 
by sex overlapped with histone marks related to active chromatin and enhancer 
regions (H3K4me1), whereas 14% of the autosomal sites (4760 CpGs) and 11% of 
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In three candidate gene-studies PTPN1[32], PLA2G7[26] and BCL11A[27] DNAm was 
positively associated with serum lipids in women, but not in men. Another study 
reported that methylation at ABCG1 was negatively associated with triglycerides in 
women only[28], whereas methylation at LIPC was negatively associated with triglyc-
erides only in men[27]. This latter study also reported sex-specific associations for 
total cholesterol: whereas ABCG1 was associated with triglycerides only in women, 
methylation at this CpG site was inversely associated with total cholesterol only in 
men[28]. For some CpG sites there were specific associations with HDL for males; 
methylation at PLTP[28], CETP[29], and LIPC[28] were negatively associated with HDL 
in men, but not in women. Moreover, a male-specific association was found between 
GCK CpG4 methylation at GCK and total cholesterol concentration[33]. However, a 
single study performed among 739 African Americans in the Genetic Epidemiology 
Network of Arteriopathy (GENOA) did not find overall or sex-specific significant as-
sociations between DNA methylation and lipid levels[30].
Blood pressure 
Seven articles[25, 34-39] based on five unique studies reported associations between 
sex-specific DNAm and essential hypertension (EH), while one study investigated the 
cross-sectional association between DNAm and blood pressure[25]. Among these, 
five studies investigated candidate gene methylation[34-36, 38], while another study 
investigated epi-genome wide methylation[40] in regard to hypertension. Studies 
included 3,561 non-overlapping participants (2,029 women and 1,373 men) from 
China and UK. 
In the study conducted by Malipatil et al, in the overall sample of men and women, a 
10% increase in LINE-1 methylation was associated with a 2.5 mmHg lower baseline 
diastolic blood pressure. The stratified analysis by sex did not show any significant 
influence of sex on this association[25]. One candidate gene study reported higher 
methylation levels of the two CpG sites at SCNN18 in women compared with men 
as controls (CpG1: t=-2.283, P=0.025; CpG2: t=-2.568, P=0.012) and incident EH cases 
(CpG1: t=-2.694, P=0.009; CpG2: t=-2.583, P=0.011)[35]. However, for these two CpG 
sites no significant difference was observed between males and females in the preva-
lent cases group (CpG1: t=0.409, P=0.068; CpG2: t=0.621, P=0.536)[35]. These results 
indicated a significant association between EH and SCNN1B methylation, which was 
affected by age, sex and antihypertensive therapy. Similarly, in one other study, 
higher ADD1 DNAm levels were observed in females as compared to males (CpG1: 
P = 0.016; CpG2-5: P = 0.021)[34]. Further, the study showed that lower ADD1 CpG1 
methylation levels were significantly associated with EH in females (cases versus 
controls (%, SD): 10.00±1.41 versus 11.36±3.63, adjusted P =0.042) but not in males 
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(adjusted P = 0.133). In contrast, lower levels of ADD1 CpG2-5 methylation were as-
sociated with an increased risk of EH in males (cases versus controls: 22.48% versus 
31.86%, adjusted P = 0.008) but not in females[34]. The prediction potential of EH for 
ADD1 CpG1 and CpG2-5 methylation levels was assessed by the ROC curves. CpG2-
5 methylation was reported as a significant predictor of EH in males (area under 
curve (AUC) = 0.855, P = 0.001), while CpG1 methylation showed a trend toward 
being an EH indicator in females (AUC= 0.699, P =0.054)[34]. In the same population, 
AGTR1 CpG1 methylation was a significant predictor of EH in both sexes[36] and 
hypomethylation of CpG3 site at IL-6 promotor was significantly associated with EH 
risk in both, men and women. Further, sex-specific DNAm levels were observed only 
at CpG1 and CpG2 sites of IL-6 promoter (males were hypomethylated as compared 
to females)[38]. Another study by Han et al, investigated the interactions between 
alcohol consumption and DNA methylation of the ADD1 gene promoter and its as-
sociation with EH, involving 2040 cases and controls[36]. The researchers concluded 
that CpG1 methylation was associated with EH in females while CpG2-5 methylation 
was significantly associated with EH in males, suggesting that these interactions 
in the ADD1 gene promoter might play a role in modifying EH susceptibility[36]. 
Finally, Bao et al. reported that hypomethylation of the IFNG promotor region was 
associated with a higher risk of EH. However, the authors did not observe any sex 
differences overall, except that in the control group DNAm levels were found to be 
higher in males when compared to females[39]. 
inflammation and atherosclerosis
Three articles[41-43], investigated the associations between epi-genome wide DNAm 
(n=2), candidate gene methylation and inflammatory markers. Also, we did not 
identify any study investigating the sex-specific role of DNAm in atherosclerosis. 
Studies in inflammatory markers included 2,771 non-overlapping participants (713 
women and 317 men and one study did not report the number of men and women 
separately[41]) from Germany, China and USA. None of the epi-genome wide studies 
reported sex specific associations between global DNAm and inflammatory mark-
ers[41, 42]. Nevertheless, Guo et al, reported men-specific association between lower 
PTX3 promoter methylation levels and higher neutrophil to lymphocyte ratio. Also, 
the level of PTX3 promoter methylation in the coronary artery disease group (mean, 
SD: 62.69% ± 20.57%) was significantly lower than that of the group free of coronary 
artery disease (mean, SD: 72.45% ±11.84%), suggesting a role of this gene in develop-
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Glycemic Traits and T2D
Eight articles[12, 27, 32, 33, 44-47] reported sex-specific associations between DNAm 
and glycemic traits and T2D. Five studies were candidate gene studies and three 
were epi-genome wide studies. Among them, six studies focused on DNAm and 
T2D, one investigated the association between DNAm and metabolic syndrome and 
another investigated insulin metabolism. Studies included 2,239 non-overlapping 
participants (353 women and 554 men, with one study not specifying the number of 
men and women[46]) from Israel, Spain, Sweden, China and USA. 
In a case-control study including 1,169 individuals, individual methylation levels at 
the FTO gene showed that CpG sites in the first intron were slightly (3.35%) hypometh-
ylated in T2D cases relative to controls[46]. The odds of developing T2D increased by 
6.1% for every 1% decrease in DNAm. Men were hypomethylated relatively to women 
and the effect of DNAm was stronger in males compared to females (P =0.034 for sex 
interaction, AUC = 0.675 among men and 0.609 among women)[46]. Also, in another 
case-control study association between PTPN1 promoter methylation and the risk of 
T2D was observed in the overall population and in females[32] .
In the study by Burghardt et al., a significant increase in CDH22 gene methylation in 
subjects with metabolic syndrome was identified in the overall sample[44]. However, 
when investigating males and females separately; differential methylation levels 
were observed within the MAP3K13 gene in females and the CCDC8 gene in males 
with metabolic syndrome. In the validation sample a significant difference in meth-
ylation was again observed for the CDH22 and MAP3K13 genes, but not for CCDC8 
gene[44]. Another study investigated the impact of sex on the genome-wide DNAm 
pattern in human pancreatic islets from 53 males and 34 females, and relate the 
methylome to changes in expression and insulin secretion[12]. The study identified 
both chromosome-wide and site-specific sex differences in DNA methylation at the 
X chromosome of human pancreatic islets. However, the autosomal chromosomes 
showed differences in DNA methylation only on the level of individual CpG sites 
between sexes. Importantly, they found higher insulin secretion in pancreatic islets 
from females compared with males, as well as sex differences in gene expression[12]. 
Additionally, the authors did not find any difference in β-cell number between 
females and males. This could suggest that the DNA methylation differences seen 
between males and females might not be due to altered β-cell composition in the 
islets[12]. 
In a case-control study conducted by Rodriguez-Rodero et al. [45], hypermethylation 
at CpG sites annotated to the HOOK2 gene was associated with the presence of 
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T2D. Interestingly, when these results were analyzed by sex, female T2D samples 
were found hypermethylated at the cg04657146-region and the cg11738485-region 
of the HOOK2 gene, whilst male samples were found hypomethylated in this latter 
region only[45]. Tang et al. reported a significant association only in males when 
investigating the overall BCL11A methylation in T2D patients[27]. While in another 
study among the same population, significantly elevated methylation levels of GCK 
CpG4 were observed in T2D patients than in the healthy controls. Also, this associa-
tion was characteristic to males only[33]. Further, serum IGFBP-7 protein levels were 
similar among newly diagnosed and treated T2D patients and were not correlated 
with IGFBP7 DNAm overall, but solely in males[47].
The Role of sex-specific Dnam in CVD
Coronary Heart Disease
Eight articles[48-55] investigated the associations between DNAm and CHD and MI. 
All studies applied a candidate-gene approach and included a total of 2,353 partici-
pants (1,010 women and 1,343 men) from China, Italy and the Netherlands. 
One study reported that a higher DNAm at the imprinted loci of INS and GNASAS 
was associated with the incidence of MI in women (INS: +2.5%, P = 0.002; GNASAS: 
+4.2%, P = 0.001)[48]. Hypermethylation at one locus and at both loci was associated 
with odds ratios (ORs) of 2.8 and 8.6, respectively (Ptrend = 3.0 × 10−4) while no as-
sociation was observed among men. Similarly, one study revealed a female-specific 
significant association between methylation at PLA2G7 promoter and risk of CHD[49]. 
Another study reported a female specific association of CDKN2B methylation with 
CHD [women with CHD (mean, SD: 7.21±2.40%) compared with women without 
CHD. In contrast, four studies reported men-specific associations between DNAm 
of various genes and CHD[43, 50, 51]. Peng et al, reported significant associations 
of the methylated promoter of the ABCG1 and GALNT2 genes with an increased 
risk of CHD overall and among men only[50]. Also, CHD patients had significantly 
lower levels of APOE methylation than non-CHD controls. In addition, rs7412-T and 
rs7259620-A were protective factors for CHD in males (rs7412-T: OR=0.527, allele 
P=0.004; rs7259620-A: OR=0.743, allele P=0.029)[54]. Giannakopoulou et al. reported 
a sex specific increased methylation in the CTH promoter gene in 34 patients who 
had coronary artery bypass surgery (CABG) (19.1%) compared to 16 control subjects 
(10.3%). Increased methylation levels were observed in male CABG patients compared 
to male control subjects while in females this was not observed[51]. Furthermore, 
Xu at al., showed that CHD cases had a significantly lower methylation level of the 
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difference of GCK methylation level between males and females and no significant 
interaction between gender and disease[52]. However, a significant difference of the 
CpG2 methylation level with CHD was observed in males only[52]. On the other 
hand, one study evaluated the association between the DNA methylation profiles 
of genes involved in One-Carbon Metabolism (OCM) and the homocysteine (Hcy) 
pathway, with the myocardial infraction risk due to the low B-vitamins intake[53], 
based in the rationale that B-vitamins and folates pathway may modulate DNA 
methylation[53]. The results from this study showed an inverse association between 
B-vitamins intake and the hypermethylation in three genes (TCN2 promoter, CBS 
50UTR, AMT gene-body) in male cases, as well as two genes (PON1 gene-body, CBS 
50UTR) in female cases[53]. 
Stroke
Four articles[15, 56-58] reported sex-specific associations between DNAm and stroke. 
Among these, three articles[56-58] used data from the same population for their 
analyses. Two studies applied global and two others candidate gene approaches. 
These studies applied a cross-sectional design, used blood samples and included a 
total of 1,045 non-overlapping participants (459 women and 586 men) from diverse 
ethnic backgrounds, such as Chinese-Taiwanese[56-58] and Spanish[15]. 
Two of the studies used a candidate gene approach and performed pyrosequencing 
to assess methylation of the targeted regions in the gene promoter[57, 58], while 
the two other studies investigated the global DNAm of the LINE-1 elements using 
pyrosequencing[56] or luminometric methylation assay (LUMA)[15]. Further, two 
studies found a significant decrease in LINE-1 methylation in men compared to 
women in cases of stroke[15, 56]. One of them also reported that cases of ischemic 
stroke presented a lower methylation level compared to controls. In addition, this 
hypomethylation of LINE-1 in men was associated with an increased stroke risk by 
1.2-fold after adjusting for risk factors, while no significant association was observed 
in women[56]. On the other hand, among the two studies investigating the estrogen 
receptor alpha ERα[57] and the matrix metalloproteinase-2 (MMP-2)[58] respectively, 
the methylation levels were lower in individuals with stroke compared to controls, 
in all the CpG sites analyzed in both studies. Further, when exploring the sex-
specific associations, the two studies obtained contrary results. One study found a 
significant difference in methylation levels in all the investigated CpGs annotated to 
the gene ERα only between female cases and controls[57]. Whereas the other study 
reported a significant difference between the methylation levels in one out of eight 
CpGs annotated to MMP-2 only between male cases and controls[58]. None of these 
studies investigated the difference between male and female cases. 
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Genes, pathways and cardiovascular disease
Studies included in this systematic review report that methylated CpG sites an-
notated to KDM6A, PLA2G7, CETP, ABCG1, LIPC, BCL11A, ADD1, CNN1B, HOOK2, PLTP, 
GALNT2, PON1, TCN2, CBS, AMT, CTH, INS, GNAS-AS1, MMP2, CCDC8, MAP3K13, FTO, ESR1, 
CDKN2B, APOE, IGFBP7, PTPN1, GCK and PTX3 were differently methylated for men and 
women. An overview of these genes, function and their sex specific methylations is 
provided in Table 1. In addition, Figure 2 shows the prioritized pathway connectiv-
ity between cardio-metabolic genes that were found to be differentially methylated 
in men and women. The most significant pathways, that in Figure 2 are shown 
with darker red nodes with more representative enrichment include the Vitamin 
B12 Metabolism, Statin Pathway, Plasma lipoprotein, Plasma lipoprotein assembly, 
remodeling and clearance and Cholesterol metabolism. Hence, the most important 
genes connecting these pathways that merit further consideration were: ABCG1, 
APOE, PLTP, LIPC, CETP, CTH and INS. Overall, the majority of the genes reported in 
this review were previously known to be associated with CVD risk factors or CVD 
outcomes. 
DisCUssiOn
In this review, we systematically summarized the current evidence on sex differ-
ences in DNA methylation in relation to cardiometabolic diseases. We included 30 
unique studies that had either stratified their analyses by sex and/or specified that 
their results did not differ among sexes by testing for statistical sex-interaction. 
Overall, our findings indicate that global DNAm might influence cardiometabolic 
risk in a sex-specific manner, and that DNAm at 31 gene sites could be differentially 
associated with various cardiometabolic traits in men and women. 
Global Dna methylation 
We identified four studies suggesting that altered LINE-1 DNAm may play a role 
in CVD risk in a sex-specific manner: (i) DNAm measured in LINE-1 repeats was 
inversely associated with different serum lipids in men and women[14, 25], (ii) 
decreased LINE-1 was associated with higher stroke risk in the overall sample and 
in men[56] and (iii) DNAm measured using genomic 5-methyl cytosine content and 
LUMA indicated hypomethylation in male as compared to female stroke cases[15]. 
In the current review, global DNA hypomethylation was associated with poorer 
outcomes. In particular, global DNA hypomethylation was associated with higher 
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women[14] and increased stroke risk in Chinese men but not in women53. These 
findings are in line with observations in healthy Caucasian men where subjects with 
decreased LINE-1 methylation were more likely to develop ischemic heart disease 
and stroke (women were not included in this study)[59]. Global DNA hypomethyl-
ation has been previously reported in stroke patients as compared with healthy[59] 
and in a large study with participants from European ancestry, decreased global 
DNAm was observed in male as compared to female stroke cases56. In experimental 
studies, global DNA hypomethylation has been shown to precede the formation of 
atherosclerosis in Apoe-/- mice, and has been associated with hyperhomocysteinemia 
and aortic lipid deposition in mutant mice deficient in methylenetetrahydrofolate 
reductase[60]. While in humans global loss of DNAm has been previously associ-
ated with atherosclerosis in both, atherosclerotic lesions[61] and peripheral blood 
leukocytes[62] but also with blood lipids, inflammation and blood pressure[10] 
implying that LINE-1 hypomethylation could be associated with an unfavorable 
cardiovascular risk profile. Global DNAm is considered a robust measurement of the 
overall genomic methylation which is reported to be one of the earliest molecular 
changes in the transition of a cell from a normal to a diseased state[63]. Blood DNA 
hypomethylation might be easily measured and could be used to identify people 
at risk of cardiovascular events. Our findings emphasize the need of sex-specific 
approaches when further exploring the possible role of global DNAm as a biomarker 
and potential intervention target in cardiometabolic diseases.
Epigenome wide-association studies and candidate gene 
approach
We identified only six studies[12, 31, 41, 42, 44, 46] that investigated differentially 
methylated regions in the genome with cardiometabolic diseases in a hypothesis-free 
approach. Among these, three EWAS[12, 31, 44] reported sex-specific associations, 
and KDMA6A, FTO, MAP3K13 and CCDC8 were some of the important genes that were 
found to be methylated in a sex-specific manner with blood lipids and glycaemia 
traits. Among 25 candidate gene studies, 22 studies reported sex-specific associations 
between DNAm and cardiometabolic diseases at the following genes PLA2G7, BCL11A, 
KDM6A, LIPC, ABCG1, PLTP, CETP, ADD1, CNN1B, HOOK2, GFBP-7,PTPN1,  GCK,  PTX3, 
ABCG1, GALNT2, CDKN2B, APOE, CTH, GNASAS, INS, PON1, TCN2, CBS, AMT, MMP-2 and 
ER-α. Based on the prioritized pathway connectivity analysis, although, limited, the 
evidence suggests an involvement of biological pathways related to vitamin B12 
metabolism, statin pathway, plasma lipoprotein, plasma lipoprotein assembly, 
remodeling and clearance and cholesterol metabolism, with sex differences in car-
diometabolic diseases (Figure 2). Some of the most relevant genes from the pathway 
analysis were ABCG1, APOE, PLTP, LIPC, CETP, CTH and INS. Overall, these genes have 
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been associated to cardiometabolic outcomes, however little evidence links them to 
epigenetics and cardiometabolic diseases and even less to sex differences in cardio-
metabolic diseases.
ABCG1 gene is a transmembrane cholesterol transporter that effluxes cellular choles-
terol from macrophages by delivering cholesterol to mature high-density lipoprotein 
particles. Beyond a role in cellular lipid homeostasis, ABCG1 equally participates to 
glucose and lipid metabolism by controlling the secretion and activity of insulin and 
lipoprotein lipase. Moreover, there is a growing body of evidence suggesting that 
modulation of ABCG1 expression might contribute to the development of diabetes 
and obesity[64], which are major risk factors of CVD. The ABCG1, GALNT2 and HMGCR 
genes have been previously associated with pathogenesis and progression of CHD 
through manipulating the various lipid pathways[65, 66]. In the current review, 
hypermethylation of these three genes was associated with higher levels of total 
cholesterol and LDL , and increased CHD risk in men[50], while it was linked to 
higher levels of TG in women but not with risk of CHD7. The expression of ABCG1 
gene reduces cholesterol accumulation in macrophages by promoting the transfer of 
intracellular cholesterol into HDL pathway[67]. In contrast to this, hypermethylation 
at PLA2G7 was associated with levels of total cholesterol, triglycerides and ApoB in 
females but not in males, and also only female CHD cases were hypermethylated as 
compared to controls5. PLA2G7 is the coding gene for Lp-PLA2 whose abnormal activ-
ity can cause high risk of CHD and may serve as a diagnostic marker for CHD[68]. 
Therefore, the sex disparities in the ABCG1 and PLA2G7 methylation may have an 
effect in the molecular mechanisms underlying the sex-specific pathophysiology of 
CHD and may provide epigenetic clues to explain the inconsistency in the epide-
miological studies. However, both studies were done in Han Chinese population, 
and sample size was rather small (only 85 CHD patients and 54 participants without 
CHD[50] and 36 CHD cases and 36 controls). Hence, further replication studies with 
larger sample size and in different ethnic populations are required to confirm these 
findings.
The APOE gene encodes apolipoprotein ε (ApoE), a protein that associates with 
lipids to form lipoproteins that package and traffic cholesterol and lipids through 
the bloodstream and has been linked with numerous physiological conditions, 
including healthy aging[69], cardiovascular disease[70], diabetes[71] and cognitive 
function[72]. One study using samples of 563 blood-bank donors, found that 1% of 
the inter-individual variation in plasma ApoE levels was attributable to variation of 
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effect of age on mean levels of ApoE[74]. In men, the levels of ApoE levelled off after 
the age of 45 years, whereas they continued to increase in women[74].
PLTP (phospholipid transfer protein) is essential for the transfer of excess surface 
lipids from TG-rich lipoproteins to HDL particles. PLTP-mediated phospholipid 
transport among HDL particles is also known to be associated with HDL particle size 
and lipid composition. Sex disparities for HDL levels associated with PLTP have been 
previously reported[75]. In the PAGE study, the major allele of rs7679 was associated 
with higher HDL levels in women only. The locus with the most consistent evidence 
for sex disparities across the studies is LPL, or lipoprotein lipase. Different SNPs in 
this gene exhibited sex disparities for HDL levels in two prior studies, with a larger 
effect in males[76, 77]. In two other studies, LPL exhibited sex differences for TG 
levels, also with a stronger effect in males[75, 78]. LPL is the rate-limiting enzyme 
for hydrolysis of triglycerides in lipoproteins and polymorphisms and mutations 
in LPL have been associated with lipid metabolism disorders. Hormone levels have 
been shown to affect regulation of LPL, including thyroid hormone, estrogen, and 
testosterone[79], which could possibly and partially explain the observed associa-
tion in cardiometabolic diseases. 
Although these pathways and the respective reported genes need further investiga-
tion, confirmation and translational research, the current evidence suggests they 
could be biologically relevant and could hold the key for future drug discovery, 
diagnosis and treatment of cardiometabolic diseases overall and in a sex specific 
manner. Determining the relationships between genes is essential for molecular 
biology and medicine. These relationships often cluster together into functional 
and disease pathways, and the characterization of these pathways is necessary to 
improve disease classification, patient stratification and, ideally, personalized treat-
ment[80].
Epigenetic mechanisms in biological processes of sex differences
Sex differences in pathophysiology of cardiometabolic diseases could be attributed 
to several gender and sex-specific factors[81]. Lifestyle factors (smoking, diet, stress) 
can determine gender differences by modifying cardiometabolic risk directly, and 
they can also modify the epigenetic marks in a sex-specific manner leading to sex 
differences in cardiometabolic diseases[81](Figure 2). Sex differences may also be 
driven by biological dissimilarities rather than different environmental exposures 
among men and women[81]. In particular, the major mechanisms by which sex 
might influence cardiometabolic diseases epigenetics may include: (i) the genomic 
and non-genomic effects of steroid hormones and their receptors on DNAm en-
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zymes, histone modifiers and miRNAs, (ii) genomic imprinting, leading to DNAm of 
either maternal or paternal alleles and (iii) increased expression of X-chromosomal 
escape genes in women targeting epigenetic modifications and the expression of 
non-pseudo-autosomal Y-chromosomal epigenetic modifiers in men[16] .
Sex hormones have been extensively studied in the past decade in regard to 
cardiometabolic diseases due to the better cardiometabolic profiles in women as 
compared to their male counterparts. In the current review, we found some impli-
cations for the interactions between sex hormones and methylation in modifying 
sex differences cardiometabolic diseases. Three[15, 57, 58] of the studies included 
in the current review, investigating epigenetic changes and stroke and reporting 
differences between men and women, highlight the importance of sex hormones 
and their receptors. Using a global DNA methylation approach, Soriano-Tarraga et 
al[15], found that global hypomethylation was independently associated with stroke 
subtypes only in females. Moreover, there was an association between lower ERα 
methylation levels and large-artery and cardio-embolic stroke subtypes in women, 
while in men this association was not observed. It might be that women suffering 
from a major ischemic stroke may cause a more significant change in ERα meth-
ylation levels to reduce the brain injury[57]. In line with this, differential DNAm 
profiles mediated sex differences in the endogenous neuroprotective response to 
middle cerebral artery occlusion (MCAO) in mice were reported. In female mice, 
MACO induced selective demethylation of the ERα gene promoter, leading to the 
increase in ERα expression[82]. Also, sex differences were observed in MMP-2 meth-
ylation, with expression of MMP-2 being closely related to sex hormones[58]. Males 
with small-vessel ischemic stroke had lower methylation levels at all MMP-2 CpG 
sites, while no association was observed in women[58]. Further exploration of the 
underlying mechanisms is needed. Sex- and stroke-subtype-specific effects must be 
taken into consideration when investigating potential strategies to alter the activity 
of MMP-2 in patients with ischemic stroke. Steroid hormones can induce, among 
others, modification of histones. Androgen or estrogen receptors act by binding 
to hormone response elements in the DNA and attract various cofactors that have 
inherent histone acetyltransferase or methyl transferase activity. This is particu-
larly known for the CREB binding protein and E1A binding protein p300[83]. The 
histone-modifying enzymes alter the epigenetic state of gene promoters to which 
the nuclear receptors bind, thereby changing gene expression. 
It is known that DNAm contributes to X-chromosome inactivation in females[84], 
and findings by Garcia-Calzon et al, demonstrated that DNA methylation in the X-
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They reported higher average degree of X-chromosome methylation in females 
than in males with 37% of the significant sites on the X-chromosome having higher 
methylation in males[31]. Around 95% of the CpG sites in the X-chromosome that 
had differential DNAm in human liver between sexes also had different methylation 
levels between males and females in pancreatic islets and brain independently of 
the clinical characteristics of the population[12, 85]. Further, they identified four 
genes on the X-chromosome with large differences in DNA methylation between 
males and females and being more expressed in liver from females than males: XIST, 
ARSE, RPS4X, and KDM6A[31]. Also, higher ARSE and RPS4X mRNA expression has been 
found in pancreatic islets, and higher XIST and RPS4X mRNA expression was also 
found in brain from females compared with males15,[85]. These differences in gene 
expression in several tissues may explain some metabolic differences between males 
and females. Interestingly, these four genes are known to escape X-chromosome 
inactivation[86-88]. In this study serum HDL levels were positively associated with 
KDM6A mRNA expression in human liver in addition to higher serum HDL levels 
and higher KDM6A expression in females. Also, silencing KDM6A in hepatocytes re-
sulted in lower HDL levels and lower expression of key genes encoding proteins that 
regulate HDL levels, supporting the direct contribution of KDM6A in the differences 
found in HDL levels between males and females[31]. 
Potential clinical implications and recommendations for future 
research 
Although the clinical use of epigenetic marks in the field of cardiometabolic dis-
eases is still in its infancy this is not the case with cancer research. Molecular risk 
stratification using (epi)genetic marks have been focused on identifying molecular 
features associated with clinical outcome and have applied them to patients’ risk 
stratification and treatment guidance[89, 90]. Such results indicated that a gene 
expression score that incorporates prognostic genetic and epigenetic information 
could be used as a model for treatment response but also for risk stratification and 
early disease detection. In particular, sex-specific epigenetic marks against or as a 
supplement to existing risk scores (such as the Framingham Risk Score[91]) may be 
an added value when predicting the risk of cardiometabolic diseases. This is also 
supported by our findings suggesting that for cardiometabolic traits epigenetic 
markers may not be equally good predictors in men and women, emphasizing the 
role of sex in epigenetic patterns of cardiometabolic diseases. Further, as sex is one 
of the strongest predictors of treatment response, the epigenetic signatures may 
be used as markers to indicate the successfulness of pharmacological or dietary/
lifestyle interventions in cardiometabolic diseases among sexes. Given the lack 
of sex-stratification in studies focusing on epigenetic mechanisms and the fact 
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that the majority of the studies were focused to epigenetic changes in autosome 
chromosomes in regard of cardiometabolic diseases, our review underscores the 
emerging need for future studies to investigate the influence of sex on epigenetic 
mechanisms in cardiometabolic diseases. In complex phenotypes such as cardio-
metabolic diseases, the collection of high-quality blood samples and metabolically 
active tissues could provide the basis for the creation of large data sets that should 
accurately incorporate the many sources of variability (age, sex/gender, race/ethnic-
ity). In particular, future prospective observational studies should aim to explore 
the role of sex when studying the associations between epigenetic marks and 
mechanistic pathways of cardiometabolic diseases by stratifying their analyses by 
sex and comparing male and female participants. Second, studying the associations 
between DNAm and intermediate CVD risk factors is valuable, however, from the 
clinical perspective, the value of DNAm as a biomarker of the risk factor is as good as 
the intermediate risk factor itself. Therefore, as we did not identify studies focusing 
on outcomes such as stroke or myocardial infarction, it might be of great value 
for future research to investigate the role of sex on the epigenetic determinants of 
stroke and myocardial infarction. Third, potential biological mechanisms underly-
ing sex-specific associations should be further explored in an experimental setting. 
It is now known that sex differences in morphology and in response to stress exist 
also in cellular levels[92-94]. Therefore, when translating the observational findings 
into experimental settings a clear distinction between male and female animal 
models or cell cultures is of high importance in order to obtain non-biased results 
on the sex-specific pathophysiology of cardiometabolic diseases.
strengths and limitations
In this systematic review on sexually dimorphic DNAm, we critically appraised the 
literature following an a priori designed protocol with clearly defined inclusion 
and exclusion criteria using a comprehensive literature search in five databases. 
While previous systematic reviews on the topic are limited only to major CVD 
outcomes[16], our study took in consideration a broad range of cardiometabolic 
risk factors and diseases. However, the limitations of the findings from this study 
merit careful consideration. The included studies in this review were limited in 
sample size and the majority of studies included were cross-sectional assessments, 
making it difficult to conclude whether DNAm patterns are a cause or consequence 
of cardiometabolic changes. In addition, the results of some of the studies need 
cautious interpretation when it comes to the biological or functional relevance of 
their findings. Even though a study may report a significant difference in DNAm 
the biological relevance of small differences could be likely minimal and unknown. 
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need to be interpreted with caution given the heterogeneity of metabolic syndrome 
and that the subjects may or may not have dyslipidemia, elevated BP, and hypergly-
cemia. Therefore, interpreting associations between changes in DNAm and subjects 
classified as having metabolic syndrome is Moreover, although individual studies 
attempted to adjust for established CVD risk factors, adjustment levels were incon-
sistent across the studies. Also, DNAm patterns reported in blood samples may not 
mirror the methylation patterns in the relevant targeted tissues. Further, we did not 
perform the search for non-coding microRNAs and histone modifications because 
the scope of our search was DNA methylation. Given the importance of microRNAs 
and histone modifications as epigenetic mechanisms, future systematic reviews and 
meta- analyses on microRNAs, histone modifications and sex differences in different 
types of cardiovascular tissues would be an added value on the topic. Moreover, we 
hand searched relevant reviews and references of studies included in the current 
review in order to minimize the possibility of missing important studies. Also, we 
cannot exclude the possibility of publication bias from underreporting negative find-
ings. Lastly, a meaningful quantitative pooling of the existing data was unfeasible 
due to the heterogeneity in the input parameters, assumptions and study design. 
COnCLUsiOns
Although a growing body of evidence suggests biological, genetic and epigenetic 
sex differences in cardiometabolic diseases, only a small number of studies in the 
field stratify or present their results by sex. Nevertheless, the cumulative evidence 
from the studies that reported sex-based results, suggest that epigenetic changes in 
specific individual genes might be differently associated with cardiometabolic traits 
in males and females, encouraging further and larger-scale investigation. Robust, 
replicable results from carefully designed studies have the potential to uncover the 
molecular biological processes involved in disease onset and progression. In addi-
tion, future studies should help characterize gene regulatory effects of non-coding 
genetic variations, and, hopefully, give indications into disease-relevant biological 
pathways which could be addressed by preventive or therapeutic interventions. 
Clearly, a considerable amount of functional work is required in the future to ex-
pand our field of view beyond the classic biological mechanisms involved in sex 
differences of cardiometabolic diseases, and that could be important to design new 
drugs that target sex-specific mechanisms and permit more precise and efficient 
care.
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aBsTRaCT
There are several epidemiological studies on the association between statins and in-
cident diabetes, but most of them lack details. In this study, we aimed to investigate 
the association of statin use with glycaemic traits and incident type 2 diabetes. Using 
the prospective population-based Rotterdam Study, we included 9,535 individuals 
free from diabetes at baseline (>45 years) during the study period between 1997 
and 2012. Linear regression analysis was applied to examine the cross-sectional as-
sociations between statin use and glycaemic traits including fasting blood serum of 
glucose and insulin concentrations, and insulin resistance. In a longitudinal follow-
up study, we applied a Cox regression analysis to determine adjusted hazard ratios 
(HR) for incident type 2 diabetes in new users of statins. The mean age at baseline 
was 64.3±10.1 year and 41.7% were men. In the fully adjusted model, compared to 
never users of statins, baseline use of statins was associated with higher concentra-
tions of serum fasting insulin (β, 0.07; 95% CI: 0.02-0.13) and insulin resistance (β, 
0.09; 95% CI: 0.03-0.14). Ever use of statins was associated with a 38% higher risk of 
incident type 2 diabetes (HR, 1.38; 95% CI: 1.09-1.74). This risk was more prominent 
in subjects with impaired glucose homeostasis and in overweight/obese individuals. 
Individuals using statins may be at higher risk for hyperglycaemia, insulin resis-
tance and eventually type 2 diabetes. Rigorous preventive strategies such as glucose 
control and weight reduction in patients when initiating statin therapy might help 
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inTRODUCTiOn
Although it is well known that statins significantly reduce the risk of cardiovascular 
disease (CVD) and CVD related mortality [1, 2], statin therapy may lead to increased 
risk of type 2 diabetes [3, 4]. A recent meta-analysis of 29 randomized clinical trials 
(RCTs) reported a 12% significantly increased risk of developing type 2 diabetes in 
the treated arm of statin therapy [5]. However, use under everyday circumstances 
differs from use in a clinical trial setting with its homogeneous population and short 
follow-up [6]. Experimental studies suggest that statins may have a diabetogenic 
effect through beta-cell dysfunction and glucose and insulin secretion/sensitivity [7, 
8]; however, the data linking statins with glucose and insulin resistance to show the 
underlying mechanisms is limited. The literature so far on statin use and the risk of 
developing type 2 diabetes has been limited by several drawbacks: i) underestimated 
cases of incident type 2 diabetes due to the inclusion of questionnaire-based data, 
ii) short follow-up time not adequately taking into account the long-term effects of 
statins, and iii) lack of a direct comparison between different statin types, dosages 
and duration of use with respect to diabetes-related outcomes [3, 9, 10]. 
We hypothesized that statins have influence on serum blood glucose and insulin 
concentrations and insulin resistance, and lead to hyperglycaemia and hyperinsu-
linemia as early markers of type 2 diabetes. In this study, exploring different aspects 
of statin therapy including type, dosages and durations of use, our objective was 
to assess the population-based association of statins with concentrations of serum 
fasting glucose and insulin, insulin resistance, and incident type 2 diabetes. 
METhODs
Study setting.
The Rotterdam Study is a prospective population-based cohort study in Ommoord, a 
district of Rotterdam, the Netherlands. The design of the Rotterdam Study has been 
described in more detail elsewhere [11]. Briefly, in 1989 all residents aged 45 years 
or older within the well-defined study area were invited to participate, of whom 
78% (7,983 out of 10,275) agreed. In 2000, an additional 3,011 participants were 
enrolled (RS-II), consisting of all persons living in the study district who had become 
55 years of age. A second extension of the cohort was initiated in 2006, in which 
3,932 participants aged 45 years or older were included (RSIII). The Rotterdam Study 
has been approved by the medical ethics committee according to the Population 
Screening Act: Rotterdam Study, executed by the Ministry of Health, Welfare and 
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Sports of the Netherlands. All participants in the present analysis provided written 
informed consent to participate and to obtain information from their physicians.
Study Design.
We performed two analyses. First, a cross-sectional analysis to test the association 
between statins and glycaemic traits and second, a longitudinal follow-up study to 
test the association of statins with incident type 2 diabetes.
Population for analysis.
The present study used data from the third visit of the first cohort, RSI-3 (March 
1997- December 1999) and the baseline examinations of the second cohort, RSII-1 
(February 2000-December 2001) and third cohort, RSIII-1 (February 2006-December 
2008) (Supplementary Figure s1). To study the association between statins and 
the outcomes of interest, we excluded prevalent type 2 diabetes cases at baseline 
(n=1,565), and included only participants with available data on statin use and base-
line glycaemic values (n=9,535). To study the association of statins with incident 
type 2 diabetes, patients who used statins at baseline and prevalent cases of cardio-
vascular diseases (n=691) were also excluded from the analysis. The end of follow-up 
for incidence of type 2 diabetes was January 1st 2012 (supplementary figure 1).
Exposure measurement.
All community pharmacies in the Rotterdam Study area store all information on 
drug dispensing on one common computer network. Information on statin treat-
ment was obtained from the dispensing data using the Anatomical Therapeutical 
Chemical code (ATC code) (supplementary table s1). On the baseline date, an in-
dividual was considered as current statin user if this date fell within a prescription 
episode. During follow-up, each participant was classified into one of the following 
mutually exclusive categories on the event date of type 2 diabetes (in non-cases at 
the same day of follow-up): ‘current use’, ‘past use’, and ‘never use’. If the outcome 
measurement occurred within a prescription episode of statins, a person was classi-
fied as a current user and stratified by statin duration into three mutually exclusive 
groups: <30 days; 31-365 days; and >365 days. If the participant had previously used 
statins but was no longer a current user on the event date, this was defined as past 
use. If the participant had not used statin during the study period, this was defined 
as ‘never use’ whereas any use (‘current’ or ‘past use’) during the study period was 
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OUTCOMEs’ MEasUREMEnT
Fasting serum glucose concentrations, insulin and insulin 
resistance.
Serum glucose (mmol/l) and insulin (pmol/l) concentrations were measured at the 
research centre after an overnight fast. For collecting serum specimens from the 
whole blood, fasting blood samples were centrifuged at 4 °C at 3500 rpm, then 
serums were immediately frozen at – 140 °C and stored at −80°C in the clinical 
chemistry laboratory at Erasmus Medical Centre in Rotterdam. Glucose concentra-
tion was measured using glucose hexokinase method within 1 week after sampling 
[12] and insulin concentration by metric assay (Biosource Diagnostics, Camarillo, 
CA). Homeostasis model assessment-insulin resistance (HOMA-IR) index as a sur-
rogate marker for the degree of insulin resistance was calculated by the following 
formula: (fasting serum insulin (mU/l) × fasting serum glucose (mmol/l))/22.5 [13].
Type 2 diabetes diagnosis.
From the date of baseline centre visit and during follow-up, first incident type 2 
diabetes cases were identified through active follow-up and according to general 
practitioners’ records, hospital discharge letters, and glucose measurements. Type 
2 diabetes was defined as a fasting serum glucose concentration of ≥7.0 mmol/l or 
a non-fasting serum glucose concentration of ≥11.1 mmol/l (in case fasting serum 
samples were not available), or the use of blood glucose-lowering medications [14]. 
Covariates assessment.
At baseline and during follow-up, information was obtained on individuals’ charac-
teristics, health status, clinical data including medical and medication history, and 
behavioural/lifestyle factors. Physical activity levels assessed using the Longitudinal 
Aging Study Amsterdam Physical Activity Questionnaire expressed in MET-h/week 
[15] and defined as number of hours per week that participants spent in each ac-
tivity in the past year. Body mass index (BMI) was calculated as body weight (in 
kilogram) divided by the square of body height (in metres) included as a continuous 
variable. Baseline and postbaseline values (at the closest time to diabetes diagnosis) 
for BMIs were categorized as overweight/obesity defined as BMI ≥25 kg/m2 versus 
normal (BMI<25 kg/m2). Hypertension was defined as an average value (of two 
measurements) of ≥140 mmHg for systolic- and ≥90 mmHg for diastolic blood pres-
sure after two measurements and/or a current prescription for an antihypertensive 
agent. Serum total cholesterol (TC) (mmol/l), high density lipoproteins-cholesterol 
(HDL-C) (mmol/l), and triglycerides (TG) (mmol/l) were all measured on the COBAS 
8000 Modular Analyzer (Roche Diagnostics GmbH). We calculated low density 
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lipoproteins-cholesterol (LDL-C) levels (mmol/l) indirectly from the measurements 
of TC, HDL-C and TG using the Friedewald equation (TC minus HDL-C minus TG/5) [16]. A 
family history of diabetes was defined as having a parent, sibling, or both with type 
2 diabetes; the information on family history of diabetes was collected during home 
visits at RSI and RSII. All biochemical variables were assessed in serum samples 
taken after an overnight fasting. 
statistical analyses.
For comparison of baseline characteristics between statin users and never users in 
the first analysis, we used chi-square statistics for dichotomous variables and inde-
pendent sample t-tests for normally distributed continuous variables. To achieve a 
symmetric distribution, non-normally distributed data on BMI, TG, fasting serum in-
sulin concentrations and the HOMA-IR index were natural log transformed. Univari-
able and multivariable linear regression analyses were used to study the association 
between statins and glycaemic traits including serum fasting glucose and insulin 
concentrations and HOMA-IR. Correlation coefficients to identify the magnitude of 
the linear association between serum fasting glucose and insulin concentrations 
and the HOMA-IR index were studied with the Pearson test. 
To study the association between statin use as a time-varying exposure during the 
follow-up and incident type 2 diabetes, we used multiple Cox regression analyses [17]. 
The association was estimated by calculating hazard ratio (HR) and 95% confidence 
intervals (CI). All analyses show the effect estimates for ever, past or current versus 
never statin users as the reference group. Among ever statin users, in subgroup 
analyses, we analysed the risk of different outcomes in relation to statin type, dose, 
and duration of use. 
Because statins are often started in patients with type 2 diabetes, we performed 
two subgroup analyses to avoid confounding by indication. First, we subtracted one 
year from the event date in type 2 diabetes cases (in non-cases one year from the 
same date of follow-up) and studied the association with statin use until that date 
(cumulative statin use). Second, for those participants for whom we had an incident 
date of impaired fasting glucose (defined as a serum fasting glucose concentration 
between 6.1 and 6.9  mmol/l), we studied the association between statin use and 
incident impaired fasting glucose during follow-up. 
All regression analyses were adjusted for potential baseline confounding factors 
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III), smoking status, alcohol consumption, physical activity, and education level, and 
model 2 additionally adjusted for BMI and hypertension. 
sensitivity analyses for the association between statin and 
incident type 2 diabetes.
In a sensitivity analysis, we examined the association between statins and risk of 
incident type 2 diabetes only in a subset of patients (n=6,787) with normal baseline 
fasting glucose concentrations <6.1 mmol/l by excluding cases of impaired fasting 
glucose cases (n=2,748). To exclude the likelihood of residual confounding, the as-
sociation was further adjusted by postbaseline values of BMI. To explore if biological 
risk factors could partly explain this association, the model 2 was further adjusted 
for (i) TC, or (ii) HDL-C, LDL-C and TG. In another sensitivity analysis, the model 
2 was further adjusted for family history of diabetes, and use of proton pump in-
hibitors (PPIs) at baseline [18]. To test whether the association between statins and 
incident type 2 diabetes would be explained by the potential intermediate factors, 
serum glucose and insulin concentrations were added to the model 2. Using strati-
fied analyses, we also checked the potential effect modification from age at baseline 
(≤65 years versus >65 years), gender and BMI at baseline (overweight/obese (BMI>25) 
versus normal BMI individuals). We further tested an interaction between statin 
ever use and serum fasting glucose concentrations using a Cox regression model 
containing statin ever use, glucose concentrations and the product term of statin 
ever multiplied by glucose concentrations adjusted for potential confounders in the 
model 1. 
A p-value of 0.05 was used to assess the significance of main effect associations. All 




A total of 9,535 diabetes-free individuals at baseline were included after exclusion 
of patients with prevalent type 2 diabetes (Table 1). The median follow-up for the 
entire study population was 4 years (a follow-up of up to 15 years.) The mean age at 
baseline was 64.3±10.1 years and the majority of patients included in this study were 
females (58.3%). 64.5% of individuals at baseline were overweight/obese. Median se-
rum fasting glucose, insulin concentrations and HOMA-IR index (interquartile range 
(IQR)) were 5.4 (5.0-5.8), 67.0 (46.0-97.0), and 2.3 (1.5-3.4), respectively. 
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Characteristics of the baseline statin users and never users are shown in Table 
1. Compared to never users, statin users had significantly higher BMIs, TGs, fast-
ing serum glucose and insulin concentrations and insulin resistance and higher 
prevalence rates of hypertension. Statin users had significantly lower TC, HDL-C and 
LDL-C as compared to never users. Serum glucose concentrations were weakly but 
significantly (p-value<0.001) correlated with both (ln) insulin concentrations (r=0.14) 
and (ln) HOMA-IR (r=0.25).








Age, years, mean ±SD 64.3±10.1 64.9±8.2 64.3±10.2 0.04
Gender (male), n (%) 3977 (41.7) 481 (49.7) 3496 (40.8) <0.001
BMI, kg/m2, mean ±SD 27.0±4.1 27.5±3.9 26.9±4.1 <0.001
Family history of diabetes, n (%) 524 (8.7) 53 (5.5) 471 (5.5) 0.98
Hypertension, n (%) 3472 (36.5) 651 (67.3) 2821 (32.9) <0.001
Total cholesterol, mmol/l, median 
(IQR)
5.7 (5.1-6.4) 5.1 (4.4-5.7) 5.8 (5.2-6.5) <0.001
HDL-C, mmol/l, median (IQR) 1.4 (1.1-1.7) 1.3 (1.1-1.5) 1.4 (1.2-1.7) <0.001
LDL-C, mmol/l, median (IQR) 4.0 (3.4-4.6) 3.4 (2.8-3.9) 4.1 (3.5-4.7) <0.001
Triglycerides, mmol/l, median (IQR) 1.3 (1.0-1.8) 1.5 (1.1-2.1) 1.3 (0.97-1.7) <0.001
Physical activity, MET-h/week, mean 
±SD
75.6±49.6 75.4±47.2 75.7±49.8 0.44
Education status (High), n (%) 1717 (18.0) 153 (15.8) 1564 (18.3) 0.05
Smoking status (ever), n (%) 2040 (21.4) 222 (22.9) 1818 (21.2) 0.28
Alcohol consumption (ever), n (%) 5443 (57.1) 539 (55.7) 4904 (57.2) 0.32
Glucose, mmol/l, median, IQR 5.4 (5.0-5.8) 5.5 (5.1-5.9) 5.4 (5.0-5.8) 0.02
Insulin, pmol/l, median, IQR 67.0 (46.0-97.0) 78.0 (54.0-115.0) 66.0 (46.0-96.0) <0.001
HOMA-IR index, median, IQR 2.3 (1.5-3.4) 2.7 (1.8-4.1) 2.3 (1.5-3.4) <0.001
Type of statins 
Simvastatin (C10AA01) 529 (57.0) - - -
Atorvastatin (C10AA05) 237 (25.5) - - -
Pravastatin (C10AA03) 96 (10.3) - - -
Fluvastatin (C10AA04) 66 (7.1) - - -
average statin dose, mg
Simvastatin (C10AA01) 36 - - -
Atorvastatin (C10AA05) 42 - - -
Pravastatin (C10AA03) 33 - - -
Fluvastatin (C10AA04) 54 - - -
abbreviations: SD, standard deviation; IQR, interquartile range; HDL-C, high density lipoproteins-cho-
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After excluding patients who used statins at baseline (n=968), the remaining study 
participants were subsequently followed for a period up to 15 years for incident 
type 2 diabetes. There were 716 cases of incident type 2 diabetes. In approximately 
12.4% of the study population, statins were used during follow-up. In the majority 
of current statin users, the duration of use was longer than 365 days (75.5%). The 
most frequently dispensed statins were simvastatin (57.0%), atorvastatin (25.5%), and 
pravastatin (10.3%). 
The association of statin use with glycaemic traits.
As shown in Table 2, in a cross-sectional analysis, baseline statin use was statistically 
significantly associated with increased serum fasting insulin concentrations (β, 0.07; 
95%CI: 0.02-0.13) and HOMA-IR index (β, 0.09; 95%CI: 0.03-0.14). However, the as-
sociation with serum fasting glucose concentrations was no longer significant after 
adding BMI and hypertension to the model 1 (β, 0.08; 95%CI: -0.03-0.18). Subgroup 
multiple linear regression analyses showed no role of statin type and dosage on 
these associations (Table 2).
The association of statin use with incident type 2 diabetes.
In a longitudinal follow-up study, compared with never statin users, ever statin use 
was associated with incident type 2 diabetes (crude HR, 1.64; 95%CI: 1.37-1.97). The 
observed association remained statistically significant even after adjusting for a 
range of potential confounders; model 2: HR, 1.38; 95%CI: 1.09-1.74 (Table 3). Cur-
rent but not past use of statins was associated with a greater risk of type 2 diabetes; 
model 2: HR, 1.52; 95%CI: 1.15-2.00 vs. HR, 1.18; 95%CI: 0.83-1.67. 
Among ever statin users, no statistically significant effect of statin type and dosage 
on risk of incident type 2 diabetes was found. However, we found a significant asso-
ciation of statin duration with incident type 2 diabetes in which longer duration of 
statin use was associated with a statistically significantly increased risk of incident 
type 2 diabetes (Table 3).
sUBGROUP anaLysEs 
The association of cumulative statin use with incident type 2 
diabetes.
In a fully adjusted model, cumulative exposure to statins was associated with a 35% 
higher risk of type 2 diabetes (HR, 1.35; 95% CI: 1.01-1.82). Among statin users, statin 
dose did not modify the association; HR, 1.12; 95% CI: 0.87-1.44. 
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The association of cumulative statins with incident impaired 
fasting glucose.
In a Cox regression analysis, cumulative statin use was associated with a 9% higher 
risk of incident impaired fasting glucose; HR, 1.09; 95% CI: 1.08-1.10 after adjusting 
for multiple confounders (model 2). Among statin users, in a fully adjusted model, 
the association between statin dose and incident impaired fasting glucose was 
Table 2. Multivariate linear regression analysis on the association between statin therapy and 
serum fasting glucose/insulin concentrations and HOMA-IR 
Crude effect Model 1 Model 2






Baseline statin users 0.12 (0.07); -0.02-0.25 0.14 (0.06); 0.04-0.27 0.08 (0.06); -0.03-0.18
Subgroup analyses
Statin type
Simvastatin 0.03 (0.09); -0.14-0.20 -0.01 (0.06); -0.14-0.11 0.01 (0.05); -0.08-0.11
Atorvastatin -0.10 (0.10); -0.29-0.10 0.02 (0.08); -0.13-0.18 -0.06 (0.06); -0.17-0.06
Others* Ref
Statin dose -0.13 (0.07); -0.27-0.01 0.02 (0.06); -0.09-0.14 -0.07 (0.04); -0.16-0.01
(ln) insulin concentration 
Baseline statin users 0.15 (0.02); 0.11-0.20 0.13 (0.03); 0.08-0.19 0.07 (0.03); 0.02-0.13
Subgroup analyses
Statin type
Simvastatin 0.01 (0.04); -0.07-0.09 0.08 (0.05); -0.02-0.18 0.05 (0.05); -0.04-0.15
Atorvastatin 0.11 (0.05); 0.01-0.20 0.05 (0.06); -0.08-0.17 0.05 (0.06); -0.07-0.16
Others* Ref
Statin dose 0.19 (0.03); 0.13-0.25 0.03 (0.05); -0.06-0.12 -0.01 (0.04); -0.09-0.08
(ln) hOMa-iR 
Baseline statin users 0.19 (0.02); 0.14-0.23 0.16 (0.03); 0.10-0.21 0.09 (0.03); 0.03-0.14
Subgroup analyses
Statin type
Simvastatin 0.01 (0.04); -0.07-0.10 0.08 (0.05); -0.03-0.19 0.05 (0.05); -0.04-0.15
Atorvastatin 0.10 (0.05); -0.02-0.19 0.04 (0.07); -0.09-0.17 0.04 (0.06); -0.08-0.16
Others* Ref
Statin dose 0.19 (0.04); 0.12-0.25 0.03 (0.05); -0.07-0.13 -0.02 (0.05); -0.11-0.07
abbreviation: SEM, standard error of the mean; Ln, natural logarithm; CI, confidence interval; HOMA-
IR, homeostasis model assessment-insulin resistance.
Model 1 adjusted for age, gender, cohort (I, II and III), smoking status, alcohol consumption, physical 
activity, and education level, and model 2 included all variables in model 1 addition to body mass index 
and hypertension.
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statistically significant in which higher dosages were related to an increased risk of 
incident impaired fasting glucose; HR, 2.34; 95% CI: 2.32-2.36. 
sensitivity analyses for the association between statin use and 
incident type 2 diabetes
In a series of sensitivity analyses, when we excluded cases with impaired fasting 
glucose at baseline, the positive association did not change (crude HR, 1.58; 95% CI: 
1.23-2.04); however, when we added BMI and hypertension to the model 1, the asso-
ciation was not statistically significant anymore (HR, 1.28; 95% CI: 1.00-1.76). Using 
postbaseline values for BMIs did not change the effect estimates. Further adjustment 
for TC, PPIs, fasting serum glucose and insulin concentrations did not affect the 
association (Table 4). Substituting TC with other blood lipids (HDL-C, LDL-C and TG) 
attenuated the observed associations. Stratification by age resulted in a statistically 
significant association only in individuals >65 years (HR, 1.36; 95% CI: 1.02-1.83) but 
not in those younger than 65 years (HR, 1.25; 95% CI: 0.85-1.84). In gender-stratified 
analyses, the association between statin use and risk of incident type 2 diabetes was 
Table 3. Univariate and multivariate Cox regression analysis on the associations of statin use 
with incident type 2 diabetes 
Crude effect: hR; 
95% Ci
Model 1: hR; 
95% Ci
Model 2: hR; 
95% Ci
Type 2 diabetes (n=8,844)
Ever statin users 1.64; 1.37-1.97 1.49; 1.19-1.86 1.38; 1.09-1.74
Past statin users 1.44; 1.10-1.89 1.20; 0.85-1.68 1.18; 0.83-1.67
Current statin users 1.63; 1.32-2.02 1.61; 1.23-2.10 1.52; 1.15-2.00
Subgroup analyses-among ever statin users
Statin type
Simvastatin 0.98; 0.65-1.50 0.92; 0.55-1.53 0.91; 0.54-1.55
Atorvastatin 1.09; 0.69-1.72 1.50; 0.88-2.56 1.73; 0.99-3.01
Others* Ref
Statin dose 1.04; 0.92-1.17 1.02; 0.85-1.23 1.01; 0.79-1.28
Statin duration
<30 days 1.04; 0.43-2.51 0.31; 0.04-2.21 0.29; 0.04-2.04
31-365 2.02; 1.48-2.74 1.66; 1.11-2.49 1.70; 1.13-2.56
>365 days 1.51; 1.21-1.89 1.51; 1.15-1.98 1.37; 1.04-1.81
Never statin users Ref
abbreviation: HR, hazard ratio; CI, confidence interval 
Model 1 adjusted for age, gender, cohort (I, II and III), smoking status, alcohol consumption, physical 
activity, and education level, and model 2 included all variables in model I addition to body mass index 
and hypertension.
*Others including pravastatin and fluvastatin. 
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only statistically significant in males (HR, 1.52; 95% CI: 1.07-2.16) but not in females 
(HR, 1.28; 95% CI: 0.93-1.74). When we stratified the analysis by baseline BMI, our 
findings showed a statistically significant association only in a subset of overweight/
obese subjects (HR, 1.42; 95% CI: 1.10-1.83) but not in those with normal BMI (HR, 
1.18; 95% CI: 0.69-2.02). The interaction term of statin ever use with serum fasting 
glucose concentrations was highly significant exerting the highest odds of incident 
type 2 diabetes (HR, 3.51; 95% CI: 2.51-4.91). 
DisCUssiOn
To the best of our knowledge, this is the first detailed population-based study to 
show the effect of statin use on incident type 2 diabetes in those free from diabetes 
at baseline. At baseline, statin use was associated with elevated values for several 
glycaemic traits. After excluding these baseline statin users, new ever statin users 
during a follow-up of up to 15 years showed a 38% increased risk of incident type 2 
diabetes independent of statin type and dosage. All observed associations between 
statin use and incident type 2 diabetes remained significant even after adjusting for 
several potential risk factors for diabetes, e.g. age, physical activity and education 
level. However, there was a steep decrease in the effect estimates corresponding to 
the adjusted models.
Impaired glycaemic traits are important hallmarks of incident diabetes in which 
impaired glucose metabolism and decreased insulin sensitivity are the two major 
pathophysiological disturbances required for the conversion to overt type 2 diabetes 
[19]. Currently, limited evidence is available concerning the impact of statin use on 
Table 4. Sensitivity analyses on the associations of statin ever use with incident type 2 diabetes 
Model 2: hR; 95% Ci
Excluding cases with impaired fasting glucose at baseline 1.28; 1.00-1.76
Model 2+TC 1.42; 1.12-1.80
Model 2+HDL-C, LDL-C and TG 1.26; 0.99-1.61
Model 2+F.H.D 1.26; 0.98-1.62
Model 2+ PPIs 1.30; 1.03-1.65
Model 2+ fasting serum glucose and insulin concentrations 1.41; 1.12-1.78
Interaction between statin ever use and serum fasting glucose concentrations 3.51; 2.51-4.91
abbreviations: HR, hazard ratio; CI, confidence interval; TC, total cholesterol; HDL-C, high density 
lipoproteins-cholesterol; TG, triglycerides; F.H.D, family history of diabetes; PPIs; proton pump inhibi-
tors.
Model 2 adjusted for age, gender, cohort (I, II and III), smoking status, alcohol consumption, physical 
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glycaemic traits [20, 21]. Elevated baseline serum glucose and insulin concentrations 
might be explained by a diabetogenic effect of statins. However, conclusions from 
previous studies on this effect is inconsistent [22-24]. Theoretically, some potential 
underlying mechanisms for this effect in diabetes-free individuals consist of i) de-
creased insulin-mediated cellular glucose uptake leading to glucose intolerance, ii) 
decreased isoprenoids synthesis which causes downregulation of glucose transporter 
4 and leads to hyperglycaemia and hyperinsulinemia, and iii) reduced factors such 






Fig 1. Flowchart of study population for the current study 
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secretion/resistance [25-28]. Since the association of statin use and serum fasting 
glucose concentrations was no longer significant after including BMI and hyperten-
sion, our finding suggests that the association between statins and diabetes could be 
through insulin secretion/resistance. 
In our study, the significantly higher risk of incident type 2 diabetes among statin 
users confirms and extends the results of previous studies [6, 24, 29]. Several ob-
servational studies and RCTs have already reported an increased risk of incident 
type 2 diabetes in subjects treated with statins; where the increased risk reported 
by observational studies is much higher (44%) compared with RCTs (9–13%) [6, 24]. 
Discrepant results might be explained by the much longer follow-up time in ob-
servational studies than in RCTs and a relatively less healthy population as trials 
preferably enrol participants without multimorbidity. Longer time could result in 
an increased probability of developing adverse drug events such as diabetes [29]. 
According to the findings of a previous study including over 2 million subjects in 
the UK, the statin-associated diabetes risk (HR=1.22) over a period of 3 years was 
increased with longer statin duration in which the strongest significant association 
was observed when patients were followed-up for 15–20 years (HR=3.63) [30]. The 
magnitude of the association between statins and incident type 2 diabetes is also 
partly dependent on different confounders such as lipid profile and family history 
of diabetes [31]. In the 3 large RCTs, baseline fasting glucose concentrations and fea-
tures of the metabolic syndrome e.g. TG were shown as predictive factors of incident 
type 2 diabetes among statin users [32]. Similarly, we showed that the association 
between statin therapy and incident type 2 diabetes was partly dependent on lipid 
profiles including HDL-C, LDL-C and TG, though, independent of several diabetes 
risk factors such as hypertension. Moreover, our result of the interaction between 
statin use and serum fasting glucose concentrations was highly significant implying 
the greatest statin-associated diabetes risk in presence of baseline impaired glucose 
concentrations. Our finding here is consistent with the results of JUPITER trial where 
the majority of statin users who developed diabetes during 5 years of follow-up had 
already impaired fasting glucose. However, this study was restricted to rosuvastatin 
at a single dosage of 20 mg daily [33]. 
In our study, the majority of patients were on lipid-soluble statins (simvastatin, 
atorvastatin and fluvastatin) while the number of patients on water-soluble statins 
(pravastatin) was low (10.3%). Therefore, due to different actions of specific mol-
ecules of statins on insulin resistance and metabolic risk profiles, further studies 
are required. Our findings concerning a significantly increased risk of incident type 
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analysis [34]. To date, limited evidence suggests that different statin therapy includ-
ing different types, dose and duration might exert distinct effects on statin related 
outcomes and the results reported by previous studies are conflicting [6, 34]. In line 
with our hypothesis of a cumulative effect of statins on impaired glucose and insulin 
resistance, the risk of incident diabetes was significantly higher in intermediate 
(31-365 days)- and long-term (>365 days) users of statins. 
We showed a significantly increased risk of statin-related type 2 diabetes only among 
overweight/obese but not in individuals with a normal BMI. Given the concern that 
BMI values above normal and dyslipidaemia are both associated with the onset of 
type 2 diabetes [35], it is important to focus on more effective prevention in indi-
viduals with a high risk taking this medication. This could also help improving their 
lipid profile and thereby reducing the risk of cardiovascular diseases.
Our study has some strengths and limitations. First, the population-based and pro-
spectively gathered information on disease outcome make selection- and informa-
tion bias unlikely. The long follow-up, the availability of data on statin type, dose 
and duration of use along with the use of a series of adjusted regression models with 
a broad range of potential confounders are among the most important strengths 
in this study. Moreover, we were able to provide a comprehensive overview of the 
associations between statins and glycaemic traits and incident type 2 diabetes. 
However, our study has some potential limitations that should be acknowledged. 
Most importantly, to study the association between statins and incident type 2 
diabetes, we excluded prevalent type 2 diabetes cases at baseline (n=1,565), and 
included only participants with normal fasting glucose levels (<6.1 mmol/l) who 
were not on hypoglycaemic medication. Unfortunately, we did not have data on 
HbA1c at baseline, a marker with the ability of reflecting the long-term glycemic 
history. Also, the association between statins and type 2 diabetes could be caused 
by reverse causation in which high risk individuals e.g. patients with obesity and 
fatty liver were prescribed statins to prevent CVD. However, to decrease the effect 
of reverse causality on our findings, we performed two subgroup analyses including 
the associations of type 2 diabetes with cumulative statin use until one year before 
diabetes and an impaired fasting glucose, where the results still showed significant 
associations. Cumulative statin users during follow-up showed a 9% increased risk 
of incident impaired fasting glucose in which the magnitude of increased risk was 
directly proportional to the statin dosage. Though, we were able to adjust the as-
sociations for many measured confounding variables, the possibility remains that 
some factors e.g. genetic factors which we have not measured still modify the as-
sociations  [36]. Additionally, compared with never statin users, patients treated 
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with statins tend to be sicker and are more prone to enhanced glucose and insulin 
concentrations, and to eventually developing diabetes [37]. We cannot rule out the 
effect of detection bias in our study in which individuals treated with statins are 
more likely to be clinically evaluated. Finally, since our study included a population 
consisting of roughly 95% Caucasian ethnicity and race might be an important factor 
for the association between statin use and susceptibility of diabetes, our findings 
cannot be easily generalized to other populations.
In summary, using multiple subgroup and sensitivity analyses, we found a consis-
tent significant association between statin use and incident type 2 diabetes. Our 
analysis also highlights the greatest effect of statins in presence of hyperglycaemia 
and overweight/obesity. This suggests that it is necessary to take statin diabetogenic-
ity into consideration in clinical practice when statin is indicated, emphasising the 
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aBsTRaCT
We aimed to investigate the role of epigenetics on statins’ diabetogenic effect 
comparing DNA methylation (DNAm) between statin users and non-users, in an 
epigenome-wide association study (EWAS) in blood.
Five cohort studies’ participants (n=8,270) were classified as statin users when they 
were on statin therapy at the time of DNAm assessment with Illumina 450K or EPIC 
array, or non-current users otherwise. Associations between DNAm and various out-
comes like incident type 2 diabetes, plasma glucose, insulin and insulin resistance 
(HOMA-IR) as well as with gene expression were investigated. 
Discovery (n=6,820) and replication phases (n=1,450) associated five DNAm sites 
to statin use: cg17901584 (1.12x10-25; DHCR24), cg10177197 (3.94x10-08; DHCR24), 
cg06500161 (2.67x10-23; ABCG1), cg27243685 (6.01x10-09; ABCG1), cg05119988 
(7.26x10-12; SC4MOL). Two sites were associated with at least one glycemic trait or 
type 2 diabetes. Higher cg06500161 methylation was associated with higher fasting 
glucose, insulin, HOMA-IR and type 2 diabetes (odds ratio 1.34 (0.20, 0.39)). Mediation 
analyses suggested ABCG1 methylation to partially mediate the effect of statins on 
high insulin and HOMA-IR. Gene expression analyses showed that statins exposure 
and ABCG1 methylation were associated with ABCG1 downregulation, suggesting 
epigenetic regulations of ABCG1 expression. Further, outcomes insulin and HOMA-IR 
were significantly associated with ABCG1 expression.
This study sheds light on potential mechanisms linking statins with type 2 diabetes 
risk, providing evidence on DNAm partially mediating statins effects on insulin 
traits. Further efforts shall disentangle the molecular mechanisms through which 
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inTRODUCTiOn
Statins effectively reduce the risk of cardiovascular disease.1 However, clinical trials 
and observational studies show that statins lead to insulin resistance and type 2 
diabetes.2,3 The underlying mechanisms remain unclear. 
Statins are associated with epigenetic changes, including histone acetylation, mi-
croRNA regulation4 and DNA methylation (DNAm), particularly at genes related to 
lipid and insulin metabolism.5 DNAm is linked to type 2 diabetes pathophysiology,6 
thus it may be a potential mechanism contributing to the increased risk of type 
2 diabetes observed in statin therapy. Nevertheless, this hypothesis has not been 
investigated.4 
We conducted an Epigenome-wide Association Study in blood investigating the asso-
ciation between statin use and changes in DNAm at sites in the genome called CpGs. 
Further, we sought to replicate the findings, study the associations of the statin-
related CpGs with gene expression, glycemic traits and type 2 diabetes. Finally, we 
explored he potential role of the statin-related CpGs mediating the association of 
statins with glycemic traits and type 2 diabetes.
METhODs
study design and population
Overall, 8,270 participants from five prospective cohort studies were included. In 
EWAS analyses, the discovery panel included 6,820 Caucasian individuals from: 
Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimi-
erten Therapie chronischer Erkrankungen in der älteren Bevölkerung (ESTHER),7 an 
population-based study recruited in Saarland, Germany, with participants aged 50 to 
75 years; Kooperative Gesundheitsforschung in der Region Augsburg-F4 (KORA-F4),8 
a follow-up study to KORA-S4 cohort, established in 1996 in Augsburg, Germany; 
Study of Health Pomerania-Trend (SHIP-Trend),9 a population-based study of par-
ticipants from northeast Germany; and a population-based cohort of South-Asians 
residing in London, United Kingdom, aged 35 to 75 years: The London Life Sciences 
Prospective Population Study (LOLIPOP).10 Our study included 998 individuals from 
ESTHER; 1,726 from KORA-F4; 247 from SHIP-Trend and 3,848 from LOLIPOP. Hence, 
the discovery panel was composed by 56% South-Asians and 44% Caucasians.
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The replication panel was selected based on ethnical homogeneity and availability 
of data for post-EWAS analyses. It included 1,450 Caucasians from the Rotterdam 
Study (RS; subcohorts RS-III-1 and RS-BIOS),11 a prospective population-based cohort 
study of participants living in Ommoord, Rotterdam, the Netherlands, aged 45 years 
and over. Only RS had information on former statin users (n=74). Additional associa-
tions analyses of DNAm with glycemic traits (n=1,165) and gene expression (n=731) 
included RS data, whereas associations with incident type 2 diabetes used RS, KORA 





Figure 1. Study design. An epigenome-wide association study was conducted to identify DNA methylation 
changes at CpG sites related to current statin use, compared to non-current statin use. Four cohorts were 
used as a discovery panel and finding were replicated in an independent cohort. The replicated CpG sites 
were investigated in their association with glycemic traits and incident type 2 diabetes. The significant 
associations from this analysis were tested in a causal mediation analysis. Association analyses of the 
identified  CpGs, current statin use and glycemic traits with gene expression were performed.
Figure 1. study design. An epigenome-wide association study was conducted to identify DNA 
methylation changes at CpG sites related to current statin use, compared to non-current statin 
use. Four cohorts were used as a discovery panel and finding were replicated in an independent 
cohort. The replicated CpG sites were investigated in their association with glycemic traits and 
incident type 2 diabetes. The significant associations from this analysis were tested in a causal 
mediation analysis. Association analyses of the identified  CpGs, current statin use and glycemic 
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statin use 
Information on medication was obtained from pharmacy records in RS, self-decla-
ration in KORA-F4, LOLIPOP and SHIP-Trend, and general practitioner’s records in 
ESTHER.
Statin-use status was categorized in current users and non-current users. Current 
users were defined if the statins prescription occurred at the time of blood drawing 
for DNAm assessment, or as non-current users otherwise. RS additionally identified 
former statin users as participants who had previously used statins but were no 
longer users on the blood draw date.
Dna methylation data
DNA was extracted from whole peripheral blood (stored in EDTA tubes) by standard-
ized salting out methods. Genome-wide DNAm was measured in bisulfite-converted 
genomic DNA using the Illumina-Infinium Methylation 450K or Illumina-Infinium 
EPIC BeadChip, according to manufacturer’s protocols. Samples showing inadequate 
hybridization, incomplete bisulfite treatment and gender swaps were excluded. 
Details on cohort-specific methods in eTable 1.  CpG methylation proportion was 
reported as a normalized β-value ranging from 0 to 1, where 1 represents 100% 
methylation. To avoid sex bias, CpGs annotated to genes in sex chromosomes were 
excluded. After normalization and quality control, overlapping CpGs across studies 
were meta-analyzed. CpGs missing in one cohort were also included, while CpGs 
missing in two or more cohorts were excluded, leaving 332,357 CpGs for final analy-
sis.
Messenger rna expression data
Messenger RNA data included a subset of the replication panel (n=731, RSIII-1). Total 
RNA was isolated (PAXgene Blood RNA kits—Qiagen) from whole blood (PAXgene 
Tubes—Becton Dickinson). Samples were analysed using the LabChip GX (Caliper) 
according to the manufacturer’s instructions. Samples with an RNA quality score 
>7 were amplified, labelled (Ambion TotalPrep RNA) and hybridized to the Illumina 
HumanHT-12-v4 Expression BeadChips, according to the manufacturer’s protocol. 
Expression data was quantile normalized to the median distribution and log2 
transformed. Probe and sample means were centred to zero. Genes were considered 
significantly expressed when detection P-values calculated by Genome Studio were 
<0.05 in more than 10% of all discovery samples. Thus, 21,238 probes were available 
to study. Quality control used eQTL mapping pipeline (https://github.com/molgenis/
systemsgenetics/tree/master/eqtl-mapping-pipeline).12  Only probes that uniquely 
mapped to the human genome build 37 and represented gene mRNA expression 
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were analyzed.13 Samples were processed at the Genetic Laboratory of Internal 
Medicine, Erasmus Medical Center, Rotterdam. Expression data is available for 881 
samples at Gene Expression Omnibus public repository (accession GSE338828).
Covariates, glycemic traits and type 2 diabetes 
Covariates were selected based on previous literature on DNAm studies, includ-
ing: age, sex, BMI, smoking status, history of coronary heart disease (CHD), 
anti-hypertensive medication, systolic blood pressure (SBP), total cholesterol, HDL, 
triglycerides and LDL. BMI was calculated by dividing weight in kilograms by height 
in meters squared. Smoking history was self-reported and classified as current, 
former and never smokers. SBP was the mean of 2 consecutive measurements at the 
right brachial artery with a random-zero sphygmomanometer with the participant 
in sitting position. Anti-hypertensive medication use was defined as the use of di-
uretics, β-blockers, angiotensin-converting-enzyme inhibitors and calcium channel 
blockers. CHD was defined as the occurrence of myocardial infarction, revasculariza-
tion, coronary artery bypass graft surgery or percutaneous coronary intervention. 
Triglycerides, HDL, and total cholesterol concentrations were measured in blood 
using an automated enzymatic method.
Glycemic traits examined were plasma fasting glucose, insulin, homeostatic model 
assessment-insulin resistance (HOMA-IR) and type 2 diabetes incidence. Type 2 dia-
betes cases were defined as the presence of either serum glucose level ≥7.0 mmol/L 
or glucose-lowering medication use in RS; self-report in KORA; physician diagnosis 
or use of glucose-lowering medication in ESTHER; diabetes medication use, HbA1c 
≥6.5%, serum glucose level (non-fasting) ≥11,1 mmol/l or self-report in SHIP-Trend; 
diabetes history or fasting glucose ≥7.0 mmo/L or HbA1c >6.5% in LOLIPOP. The 
interassay coefficients of variations are: insulin <8%, glucose <1.4% and lipids <2.1%. 
LDL was calculated using the Friedewald formula (total cholesterol − HDL − triglyc-
erides/5).
sTaTisTiCaL anaLysEs
Epigenome wide association study (EWas)
The association between CpGs methylation and current versus non-current statin 
users was investigated in a two-step EWAS approach: discovery and replication. Nor-
malized DNAm β-values at each CpG were the dependent variable and current statins 
use (yes=1, no=0) the predictor. Per individual CpG, participants with methylation 
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regression analysis used the ‘lme4’ package in R v.3.4.2 (https://cran.r-project.org/
web/packages/lme4/index.html) to perform linear mixed-effect models. The random 
part of the model included adjustment for array-number and position-on-array as 
random terms to account for batch effects in the DNAm measurement. The fixed 
part included leukocyte proportions (to account for cell mixture), sex, age, smoking 
status, BMI, SBP, anti-hypertensive medication, prevalent CHD and type 2 diabetes. 
Leukocyte proportions (B-cells, CD4, T-cells, CD8, T-cells, granulocytes, monocytes 
and NK-cells) were estimated in the R ‘minfi’ package, as described by Houseman.14,15 
Statistical significance for discovery was determined by a Bonferroni-corrected 
threshold (1.0×10-7). Heterogeneity (I2) of effect estimates was assessed to account for 
differences between cohorts. Results across the discovery cohorts were combined in 
a meta-analysis by inverse variance weighted method in METAL v.2011-03-25. 
The identified CpGs were replicated in an independent panel using identical 
models. Bonferroni correction for replication was 0.05 divided by the number of 
discovery findings. Results of discovery and replication panels were combined in a 
meta-analysis as aforementioned.
Pearson test was used to assess the correlation among the replicated CpGs in the 
replication panel (RS).
associations between statin-related CpGs and glycemic traits and 
incident type 2 diabetes
Standardized methylation values at the replicated CpGs as predictors of fasting glu-
cose, insulin and HOMA-IR (RS, n=1,165) were tested in a linear mixed-effect models. 
To explore reverse causation, prevalent type 2 diabetes cases and former statin users 
were excluded. Logistic regression was used to assess the association with incident 
type 2 diabetes (RS, KORA, LOLIPOP, n=4,422, including 1,173 cases). Results across 
cohorts were meta-analyzed as aforementioned. The adjusting covariates included 
leukocyte proportions, batch effects, sex, age, smoking status, SBP, anti-hypertensive 
medication, CHD and statin use. Bonferroni-correction was applied (<0.0025). Vari-
ables with right-skewed distributions were transformed to the natural logarithmic 
scale (glucose, insulin, HOMA-IR, HDL).
Causal mediation analysis
To investigate whether DNAm changes are part of the pathway though which statins 
exert their diabetogenic effect, we explored the significant associations in the previ-
ous stage in a non-parametric causal mediation analysis using the R ‘mediation’ 
package,16 as elsewhere.17 The mediation analysis dissects the total effect of the 
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exposure (statins treatment) on the outcome (glycemic traits and incident type 2 
diabetes) into the (i) indirect effect acting via the mediator of interest (DNAm), and 
(ii) direct effect acting directly or via a mediator other than the one under study. The 
mediation package compares the effect estimates of each association between statin 
use and traits, in subjects with different methylation levels. Non-parametric boot-
strap with 20,000 resamples was performed. Data from the RS were used (n=1,180), 
excluding prevalent type 2 diabetes cases and former statin users. The normalized 
CpG methylation β-value was modeled as mediator and the CpG-associated trait as 
outcome. eFigure 1 shows an schematic representation. Sex, age and cohort were 
considered confounders. To investigate potential unmeasured confounding the 
sequential ignorabolity assumption (no confounder assumption) was tested in a 
sensitivity analysis using the correlated residuals method,18 which estimates the 
correlation that quantifies how strong the confounder would have to be to change 
the conclusion. 
Gene expression-association analysis
To investigate possible biological pathways, relations between the identified CpGs 
and transcriptome-wide gene expression were explored (RS, n=731). Statin-related 
CpGs were regressed against methylation batch variables as random terms; similar 
approach was applied for 21,238 transcription probes and the expression batch vari-
ables. Next, linear regressions between the residuals from the CpGs regression (pre-
dictors) and the expression probes residuals (dependent variable) were performed. 
The Bonferroni-correction was 0.05/number of probes times number of CpGs tested.
Additionally, the significant expression probes in the aforementioned analysis were 
tested in association with statin use exposure (n=631), and as predictors of the sig-
nificant glycemic traits in the mediation analyses (n=616). Type 2 diabetes cases and 
former statin users were excluded.
Dose effects
In 303 current statin users from SHIP-Trend and RS with available data on statin 
dose, we examined the association between the replicated CpGs and the defined 
daily dose (DDD, WHO ATC/DDD-classification, https://www.whocc.no/atc_ddd_in-
dex/), using the EWAS model. Next, the association between gene expression and 
statin dose was studied in the RS. 
Confounding and Ethnicity 
To investigate whether the associations of statin use with the replicated CpGs were 
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cholesterol or for individual blood lipids instead (HDL, LDL and triglycerides) in 
both discovery and replication. 
In an effort for ruling out confounding by indication, we restricted the EWAS to 
subjects with LDL ≥70 mg/dL or ≥100 mg/dL, cut-offs used to advice statins use.19,20 
Further, we reran the EWAS excluding prevalent type 2 diabetes and pre-diabetes 
cases.
To account for ethnicity heterogeneity in the discovery panel (South-Asians and 
Caucasians) we reran the EWAS, taking Caucasians (n=4,349) for discovery and 
South-Asians (n=3,849) for replication.
Post-hoc power analysis
To calculate the range of power for replication of the findings we utilized GPower 
3.1 tool21 with 6 predictors representing all discovered CpGs except for cg03467813 
which was not included due to its high heterogeneity (I2=99%). CpGs’ smallest beta 
estimate (0.0039, cg10177197) and probability error 0.008, or the largest estimate 
(0.0219, cg17901584) were used.
REsULTs
association between statin use and Dna methylation
The mean [SD] age in the discovery panel ranged from 51.5 [13.8] years (SHIP-Trend) 
to 62.1 [6.5] (KORA-F4). Of the total discovery panel, 2,969 (43.5%) participants were 
women. eTable 2a-b shows other baseline characteristics.
In the discovery panel, seven CpGs passed Bonferroni threshold for significance 
(P<1.0×10-7), being differentially methylated in current statins users compared to 
non-current users. Of them, current users had lower methylation at four CpGs, an-
notated to genes DHCR24 (cg17901584, located at TSS1500), FAM50B (cg03467813, lo-
cated at gene body), SC4MOL (cg05119988, located at 5´ untranslated region (5’UTR)) 
and AHRR  (cg05575921, located at gene body). Three CpGs annotated to ABCG1 
(cg06500161, cg27243685, located at gene body) and DHCR24 (cg10177197, located at 
gene body) showed higher methylation among current users (Table 1; eFigure 1). All 
associations were independently replicated, except for two CpGs annotated to AHRR 
and FAM50B, which failed to reach statistical significance after Bonferroni-correction 
for replication (P<7.14×10-3). The post-hoc power analysis showed a power ranging 
from 39% to 99% for our replication study. In the replication panel, correlations 
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among CpGs ranged from r=-0.011 between cg06500161 (ABCG1) and cg17901584 
(DHCR24) to r=0.477 for cg06500161 and cg27243685 (both annotated to ABCG1) 
(eTable 3).
The meta-analysis across the discovery and replication panels revealed one new 
CpGs at DHCR24 (cg17475467). The heterogeneity in the associations between statin 
use and the replicated CpGs across cohorts varied from I2=0 for cg10177197 (DHCR24) 
to I2=74.8 for cg17901584 (DHCR24)  (Table 1). Unreplicated CpGs were not further 
investigated.
The sensitivity analysis using RS data with never statin users as reference group 
(former users excluded) revealed similar results, replicating the five CpGs (eTable 4). 
associations of the statin-related CpGs with glycemic traits and 
type 2 diabetes
After a Bonferroni-correction (2.5x10-3) and comprehensive assessment of potential 
confounders, increase in one standard deviation of methylation at cg06500161 
(ABCG1) was associated with incident type 2 diabetes (odds ratio 1.34 (95% CI 1.22, 
1.47)), fasting glucose (1.03x10-3),  insulin (4.63x10-8) and HOMA-IR (1.05x10-8). 
Increase in one standard deviation of methylation at cg27243685 (ABCG1) was as-
sociated with incident type 2 diabetes (1.24 (1.13, 1.38)) and approaching borderline 
statistical significance with augmented insulin (4.62x10-3) , but not statistically sig-
nificantly associated with glucose and HOMA-IR. Increase in one standard deviation 
of methylation at cg17901584 was approaching borderline statistical significance 
with incident type 2 diabetes (6.2x10-3), but was not significantly associated with 
glucose, insulin and HOMA-IR. No significant findings were observed for cg05119988 
(SC4MOL) and cg10177197 (DHCR24) (Table 2).
Causal mediation
Significant results were obtained for the models with outcome fasting insulin 
and HOMA-IR. For both cases the analyses showed that: i) current statin use has a 
significant overall effect of β=0.275 (0.190, 0.360) on insulin, and β=0.291 (0.199, 
0.380) on HOMA-IR; ii) part of that effect goes directly or via mediator(s) other than 
cg06500161, called average direct effect (ADE). We found an ADE of β=0.233 (0.149, 
0.320) on insulin, and β=0.242 (0.151, 0.330) on HOMA-IR; iii) Another part of such 
effect may go via an indirect path (indirect effect) possibly through cg06500161 
methylation, with an average causal mediator effect (ACME) of β=0.043 (0.024, 0.060) 
on insulin and β=0.049 (0.028, 0.070) on HOMA-IR; iv) consequently, of the total 
effect of statins on insulin and HOMA-IR,  15.5% (0.086, 0.260) and 16.8% (0.095, 
134 Chapter 3.



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Epigenetic Link Between Statin Therapy and Type 2 Diabetes
0.270) are suggested to act via cg06500161 methylation, respectively. According to 
these results, cg06500161 methylation does not explain 100% of the effect of statins 
on insulin/HOMA-IR, thus we may call cg06500161 methylation a partial mediator, 
instead of a total mediator.
No significant findings were observed for the mediation model with outcome glucose 
(Table 3). We also investigated the potential mediation of cg27243685 on incident 
type 2 diabetes, with no significant findings. The sensitivity analysis showed that 
residual correlation due to unmeasured confounding of r≥0.2 would be needed to 
violate the sequential ignorability assumption. 
Further mediation models were performed to account for potential confounders. 
Additional to age, sex and cohort, we further adjusted for 1) BMI; 2) BMI and HDL; 
3) smoking status, systolic blood pressure, anti-hypertensive medication and pres-
ence of coronary heart disease. Results did not materially change with these further 
adjustments, although the effect sizes attenuated (eTables 5-7).
Table 3: Causal mediation analysis on the significant associations between the statin-relat-
ed CpGs (cg06500161 and cg27243685) as mediators and glycemic traits and incident type 













log Glucose a 0.006 (0.003, 0.010) 0.009 (-0.007, 0.020) 0.015 (-6.79E-03, 0.030) 0.404 (-1.250, 2.600)
log Insulin a 0.043 (0.024, 0.060) 0.233 (0.149, 0.320) 0.275 (0.190, 0.360) 0.155 (0.086, 0.260)
log HOMA-IR a 0.049 (0.028,  0.070) 0.242 (0.151, 0.330) 0.291 (0.199, 0.380) 0.168 (0.095, 0.270)
Incident type 
2 diabetesb




0.0005 (-0.006, 0.010) 0.127 (0.033, 0.23) 0.128 (0.035, 0.23) 0.004 (-0.053, 0.10)
Models adjusted for sex, age and cohort.
Bold text indicates statistically significant results.
a Sample n=1,180 (RS) complete cases, of which 178 were current statin users. Non-fasting samples 
(n=25), prevalent type 2 diabetes cases (n=181) and former statin users (n=74) were excluded from the 
analysis. 
b Sample n=642 (RS) complete cases, of which 23 were cases of incident type 2 diabetes type 2 diabetes.
Abbreviations: CI, confidence interval; ACME, average causal mediator effect; ADE, average direct ef-
fect; HOMA-IR, homeostatic model assessment insulin resistance.
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Gene expression
To explore potential epigenetic regulations of gene expression by DNAm, the identi-
fied CpGs (predictors) were tested in association with transcriptome-wide gene ex-
pression in the RS. Cg06500161 was inversely associated with two expression probes 
at ABCG1 (ILMN_1794782 and ILMN_2329927), after Bonferroni correction (4.71×10-7). 
An inverse association was observed for cg27243685 and one probe (ILMN_1794782). 
These results indicate a lower expression of ABCG1 with increasing cg06500161 
and cg27243685 methylation. Furthermore, cg17901584 methylation was directly 
associated with ABCG1 expression (ILMN_1794782) and suggestively associated with 
another probe at the same gene (ILMN_2329927). There were no significant findings 
for the other two CpGs after Bonferroni correction (eTable 8). Moreover, exposure 
to statin treatment was associated with lower ABCG1 expression (eTable 9). When 
ABCG1 expression was studied as predictor of insulin traits, we found an inverse 
association between ILMN_1794782 and fasting insulin and HOMA-IR (eTable 10).
Dose effect
Statin dose exposure was significantly associated with the five identified CpGs after 
Bonferroni-correction (P<0.01) (eTable 11). Exposure to increasing statin dose was 
nominally associated with lower levels of ABCG1 expression at ILMN_1794782 and 
suggestively with ILMN_2329927 (eTable 12).
sensitivity analyses
Residual confounding and confounding by indication: i) Additional adjustment of the 
EWAS for serum total-cholesterol or blood lipids HDL, LDL and triglycerides instead 
(eTable 13);  ii) exclusion of prevalent type 2 diabetes and pre-type 2 diabetes cases 
(eTable 14); or iii) restriction of the EWAS to participants with  LDL ≥70 mg/dL or ≥100 
mg/dL (eTable 15)  did not change the associations of the five CpGs. Further, exclusion of 
type 2 diabetes cases from the other analyses did not affect the results (data not shown).
Trans-ethnic replication: the new EWAS taking Caucasians only for discovery and 
South-Asians for replication showed that all five CpGs passed Bonferroni-correction 
threshold (eTable 16). 
DisCUssiOn
The current study sheds light on potential mechanisms linking statin use and  type 2 
risk diabetes, by firstly, identifying and replicating associations between statin thera-
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and cg05119988) independent of blood lipids; and secondly, providing evidence on 
the partial mediaton via ABCG1 methylation in the effect of statins on increased 
levels of insulin and insulin resistance under the sequential ignorability assumption.
Our results on the association between statin use and DNAm agree with a report 
from the Framingham Study who found epigenome-wide significance at only two 
sites (cg17901584 and cg06500161).5 They examined this association in a smaller 
sample (n=1,545 versus 6,820 of our discovery panel), and contrary to our investiga-
tion, they did not proceed with replication nor examined associations with gene 
expression, metabolic markers and type 2 diabetes. Moreover, our work reports 
novel associations and adds to current knowledge that statin dosage might be impli-
cated on the degree of methylation and ABCG1 expression. The latter finding goes in 
line with an experimental study where macrophages treated with various types of 
statins showed lower ABCG1 expression as dose increased.22
Sites cg06500161 and cg27243685 are annotated to ABCG1, cg17901584 and 
cg10177197 to DHCR24, and cg05119988 to of SC4MOL. ABCG1 (ATP-Binding Cassette 
Member-1 Subfamily-G) encodes a protein that mediates the transport of different 
molecules, such as cholesterol efflux to the high-density lipoprotein, oxysterols and 
phospholipid transport in macrophages.23,24 It is also involved in insulin secretion 
and sensitivity.25 ABCG1 expression was reduced in statin users compared to non-
users,26  and in type 2 diabetes patients.27,28 Genes DHCR24 (24-Dehydrocholesterol 
Reductase) and SC4MOL (Sterol-C4-methyl oxidase-like) code enzymes catalyzing 
different steps during cholesterol biosynthesis. DHCR24 mutations are related to 
desmosterolosis29,30 and Alzheimer´s disease.31 SC4MOL deficiency protein produces 
congenital cataracts, microcephaly, growth delay, skin conditions and immune dys-
function.32 An observational study found that DHCR24 and SC4MOL were up-regulated 
among statin users,26 while SC4MOL up-regulation increased type 2 diabetes risk.27,28 
Methylation at four of the identified CpGs (cg06500161, cg27243685, cg17901584 
and cg05119988) were previously associated with glycemic traits, type 2 diabetes 
and blood lipids while cg06500161 (ABCG1) was associated with increased glucose, 
insulin, HbA1c, HDL and triglycerides levels.33-35 Our causal mediation analyses 
provided evidence on cg06500161 methylation to partially mediate the association 
between statin use and higher fasting insulin and HOMA-IR. Although, given the 
crossectional nature of these analyses our results must be interpreted with caution. 
Since the mediator was measured at the same time as the outcome, reverse causa-
tion can not be completely ruled out. However, in an effort to overcome this issue, 
we excluded type 2 diabetes cases. The mediation effect observed may be the result 
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of more complex interactions of combined effects across the epigenome. Moreover, 
the lack of significant findings in mediation by the other CpG at ABCG1 (cg27243685) 
could reflect a power issue. Hence, future studies shall explore how the CpGs within 
the same gene interact and mediate the effects.
Based on our findings and the available evidence, we hypothesize that cg06500161 
hypermethylation may be a consequence of statins use, possibly inducing a decrease 
on ABCG1 transcription in blood. Further research is needed to investigate to what 
extent this down-regulation could in turn compromise downstream signals, result-
ing in impaired insulin metabolism. In this line, imapaired insulin sensitivity and 
secretion as a consequence of statin treatment was recently observed in a longitu-
dinal study.36 Furthermore, a functional study suggested an epigenetic regulation 
of ABCG1 mediated by methylation-dependent transcription factor binding.37 Our 
hypothesized model is displayed in Figure 2. Nevertheless, further investigations 
should test this hypothesis and assess the effect of statins in target tissues, and to 
what extent these findings are generalizable to populations with ethnic backgrounds 






Figure 2. Scheme of the hypothesized mechanism linking statin therapy and risk of type 2 diabetes The solid 
black arrow represents the effect of statins on plasmatic insulin and HOMA-IR levels that goes directly or 
through a pathway different from the mediator analyzed in the current study (methylation at cg06500161). 
The dotted black arrows represent the suggested alternative pathway, where an indirect effect of statins on 
insulin and HOMA-IR is mediated by cg06500161 methylation. The black thin arrows indicate decreased or 
increased level of the parameter; in this figure they are representing decrease in gene expression of ABCG1 
and increase in serum levels of fasting insulin and HOMA-IR. 
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We highlight the large sample size with DNAm data in our study, the use of a rep-
lication panel and the comprehensive assessment of confounding factors. Addition 
of complementary data like gene expression, trans-ethnic replication and use of a 
causal inference method as mediation analysis, also add value to our research. 
One limitation is the lack of data on DNAm and gene expression from specific tissues 
of interest for type 2 diabetes and drug metabolism (pancreas, liver, adipose tissue) 
as both DNAm and gene expression may be tissue specific.38 Instead, we used whole 
peripheral blood, allowing for cell mixture. Consequently, we included adjustments 
for estimated blood leukocytes proportions.  
Most cohorts had limited information on former statin users, thus it is likely that 
they were included in the reference group. However, the replication panel showed 
the same results are valid for the group of current statin users only, although we had 
limited numbers to investigate such associations. Furthermore, it was not possible 
to explore potential effects of cessation time or treatment duration on DNAm. A 
Mendelian randomization (MR) approach based on genetic instrumental variables 
to explore a potential causal effect of statins on DNAm was not possible due to the 
lack of adequate genetic variants that may mimic the randomization of the hypoth-
esized adverse effect of statins on type 2 diabetes risk. The use of variants at the 
gene encoding 3hydroxy-3-methylglutaryl coenzyme-A reductase,39 statins’ target 
protein, would mimic the main effect of statins, rather than an alternative pathway 
leading to the hypothesized effect. Moreover, these variants were associated with 
LDL,39 reflecting cholesterol metabolism. This violates the MR assumption that the 
instrumental variable is associated with the outcome only through the exposure, 
since high cholesterol is a risk factor for type 2 diabetes.
All cohorts used Illumina 450K array to measure DNAm, except one using Illumina 
EPIC array (n=247). Despite differences, EPIC array covers approximately 90% of the 
same sites on the 450K chip, both use the same technology, and showed overall 
per-sample correlations of r>0.99,40 thus encouraging the application of combined 
data. Moreover, cohorts used different methods to diagnose type 2 diabetes, which 
might introduce error measurement. 
The heterogeneity observed in the meta-analysis for some of the CpGs might be 
consequence of differences in statin use prevalence (ranged from 9.2% to 18.1%), 
types and dose of statin used across cohorts. Additionally, differences in ethnicity 
could have influenced heterogeneity (the association statin use and cg06500161 
showed I2=52.30 in the overall meta-analysis, while I2=5.20 in Caucasians); as well as 
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different methods applied to collect data on medication and disease (pharmacy and 
general practitioner records or self-report). 
Finally, some analyses were performed using data from the replication panel only, 
which may introduce type-II error. 
COnCLUsiOn
We identified and replicated five DNAm sites associated with statin therapy, of 
which cg06500161 may be partially mediating the effect of statins on increasing 
insulin levels and HOMA-IR. This could be one potential mechanism linking statin 
therapy and type 2 diabetes onset observed in clinical trials and observational 
studies. Nevertheless, other biological pathways should not be discarded. From our 
study, it is not clear what might be the mechanism by which statins may induce 
DNAm changes; this shall be a challenge for future research.
Meanwhile, close monitoring of risk factors for type 2 diabetes in these patients is 
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eTable 3.  Pearson correlation among the replicated CpGs in two the sub-cohorts of the replica-
tion panel (Rs)
Rs-iii-1 cg06500161 cg27243685 cg17901584 cg10177197 cg05119988
cg06500161 1
cg27243685 0.244 1
cg17901584 0.176 0.289 1
cg10177197 0.065 0.353 0.174 1
cg05119988 -0.173 -0.092 -0.187 -0.107 1
Rs-BiOs cg06500161 cg27243685 cg17901584 cg10177197 cg05119988
cg06500161 1
cg27243685 0.477 1
cg17901584 -0.011 0.270 1
cg10177197 0.090 0.303 0.143 1
cg05119988 -0.201 -0.420 -0.222 -0.371 1
eTable 4 Replication of Dna methylation sites associated with current statin use in a subset of the 
replication sample, excluding former statin users
CpG Chr Position location Gene Effect SE P-value
cg17901584 1 55353706 TSS1500 DHCR24 -0.0179 0.0037 1.34E-06
cg06500161 21 43656587 gene body ABCG1 0.0123 0.0027 3.63E-06
cg05119988 4 166251189 5’UTR SC4MOL -0.0121 0.0039 1.94 E-03
cg27243685 21 43642366 gene body ABCG1 0.0072 0.0018 5.06E-05
cg10177197 1 55316481 gene body DHCR24 -0.0045 0.0010 1.35E-05
Model adjusted for leukocyte proportions, batch effects, sex, age, smoking status, body mass index, 
systolic blood pressure, anti-hypertensive medication, presence of coronary heart diseases, prevalent 
type 2 diabetes.
Bonferroni correction for significance for replication P < 7.14E-03.
Sample size n=1205 (RS)
Abbreviations: Chr, chromosome; SE, standard error. Bold text indicates statistically significant associa-
tions.
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Epigenetic Link Between Statin Therapy and Type 2 Diabetes
eTable 5: Causal mediation analysis on the significant associations between the statin-related 
CpG cg06500161 and glycemic traits and incident type 2 diabetes, with a model adjusted for sex, 
age, cohort and body mass index
Outcomes














































Models adjusted for sex, age, cohort and body mass index. Bold text indicates statistically significant 
results.
a Sample n=1,180 (RS) complete cases, of which 178 were current statin users. Non-fasting samples 
(n=25), prevalent type 2 diabetes cases (n=181) and former statin users (n=74) were excluded from the 
analysis. 
b Sample n=640 (RS) complete cases, of which 23 were cases of incident type 2 diabetes.
Abbreviations: CI, confidence interval; ACME, average causal mediator effect; ADE, average direct ef-
fect; HOMA-IR, homeostatic model assessment insulin resistance; T2D, type 2 diabetes.
eTable 6: Causal mediation analysis on the significant associations between the statin-related 
CpG cg06500161 and glycemic traits and incident type 2 diabetes, with a model adjusted for sex, 
age, cohort, body mass index and high density lipoprotein cholesterol
Outcomes














































Models adjusted for sex, age, cohort, body mass index and high density lipoprotein cholesterol. Bold 
text indicates statistically significant results.
a Sample n=1,180 (RS) complete cases, of which 178 were current statin users. Non-fasting samples 
(n=25), prevalent type 2 diabetes cases (n=181) and former statin users (n=74) were excluded from the 
analysis. 
b Sample n=640 (RS) complete cases, of which 23 were cases of incident type 2 diabetes.
Abbreviations: CI, confidence interval; ACME, average causal mediator effect; ADE, average direct ef-
fect; HOMA-IR, homeostatic model assessment insulin resistance; T2D, type 2 diabetes.
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eTable 7: Causal mediation analysis on the significant associations between the statin-related 
CpG (cg06500161) and glycemic traits and incident type 2 diabetes, with a comprehensive assess-
ment of confounder factors
Outcomes














































Models adjusted for sex, age, cohort, body mass index, smoking status, systolic blood pressure, anti-
hypertensive medication and presence of coronary heart disease. Bold text indicates statistically sig-
nificant results.
a Sample n=1,160 (RS) complete cases, of which 178 were current statin users. Non-fasting samples 
(n=25), prevalent type 2 diabetes cases (n=181) and former statin users (n=74) were excluded from the 
analysis.
b Sample n=622 (RS) complete cases, of which 23 were cases of incident type 2 diabetes.
Abbreviations: CI, confidence interval; ACME, average causal mediator effect; ADE, average direct ef-
fect; HOMA-IR, homeostatic model assessment insulin resistance; T2D, type 2 diabetes.
eTable 8: significant results of the gene expression-Dna methylation association analyses be-
tween the statin-related CpGs and expression probes









cg06500161 21 43656587 gene body ABCG1 iLMn_1794782 ABCG1 -13.000 8.85E-13
iLMn_2329927 ABCG1 -8.504 4.85E-12
cg27243685 1 43642366 gene body ABCG1 iLMn_1794782 ABCG1 -15.974 1.31E-07
cg17901584 1 55353706 TSS1500 DHCR24 iLMn_1794782 ABCG1 9.319 2.21E-10
ILMN_2329927 ABCG1 4.975 6.15E-07
Sample size n=731, from cohort RS (RSIII-1). Bonferroni correction p < 4.7E-07. Bold text indicates 
significant associations.
eTable 9: association between the CpGs-associated expression probes for ABCG1 and current 
statin use as exposure
ILMN_1794782 (ABCG1) ILMN_2329927 (ABCG1)
Effect SE P-value Effect SE P-value
-0.7999 0.1648 1.54E-06 -0.3750 0.1186 0.0016
Model: gene-expression ~ statin use, adjusted for age, sex, body mass index, coronary heart disease, 
systolic blood pressure, high-density lipoprotein cholesterol; n=631 (RS).
Cases of prevalent type 2 diabetes and former users of statins were excluded. Bold text indicates sig-
nificant associations.
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eTable 10: association between significant outcomes found in the causal mediation analyses (fast-
ing insulin and hOMa-iR) and the CpGs-associated expression probes for gene ABCG1 




Effect SE P-value Effect SE P-value
iLMn_1794782 ABCG1 -0.0290 0.0137 0.0355 -3.130E-02 1.5E-2 0.0354
ILMN_2329927 ABCG1 -0.0252 0.019774 0.2038 -2.921E-02 2.1E-2 0.1718
Model: glycemic trait (insulin or HOMA-IR) ~ statin use, adjusted for age, sex, body mass index, coro-
nary heart disease, systolic blood pressure, high-density lipoprotein cholesterol; n=616 (RS).
Cases of prevalent type 2 diabetes and former users of statins were excluded.
Bold text indicates significant associations.
eTable 11: association between Dna methylation at the identified statin-related CpGs and statin 
dose among current users of statins
CpG Chr Position location Gene Effect SE P-value
cg17901584 1 55353706 TSS1500 DHCR24 -0.0058 0.0019 2.104E-03
cg06500161 21 43656587 gene body ABCG1 0.0037 0.0014 9.579E-03
cg05119988 4 166251189 5’UTR SC4MOL -0.0068 0.0021 1.317E-03
cg27243685 21 43642366 gene body ABCG1 0.0025 0.0009 5.012E-03
cg10177197 1 55316481 gene body DHCR24 0.0025 0.0013 9.510E-03
Model adjusted for leukocyte proportions, batch effects, sex, age, smoking status, body mass index, sys-
tolic blood pressure, anti-hypertensive medication, presence of coronary heart diseases and prevalent 
type 2 diabetes.
Bonferroni correction for significance of P < 0.05/5 replicated CpGs = 0.01.
Sample size n=303 current statin users with dose data, from cohorts SHIP-Trend and RS.
Abbreviations: Chr, chromosome; SE, standard error.
eTable 12: association between gene expression and statin use
Statin use (exposure) Illumina Probe Gene at probe Effect SE P-value
Current use iLMn_1794782 ABCG1 -0.0490 0.0177 5.92 E-03
ILMN_2329927 ABCG1 -0.0496 0.0256 0.0529
Models adjusted for age, sex, body mass index, coronary heart disease, systolic blood pressure, high-
density lipoprotein cholesterol.
Cases of prevalent type 2 diabetes and former users of statins were excluded.
Sample size n=631 (RS)













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Dissecting the association between statin use and risk of type 2 diabetes
eTable 14: Replication of the identified statin-related CpGs in an independent sample excluding 
type 2 diabetes and pre-type 2 diabetes cases in the replication panel
CpG Chr Position location Gene Effect SE P-value
cg17901584 1 55353706 TSS1500 DHCR24 -0.0165 0.0041 5.21E-05
cg06500161 21 43656587 gene body ABCG1 0.0086 0.0028 2.08E-03
cg05119988 4 166251189 5’UTR SC4MOL -0.0136 0.0039 5.36E-04
cg27243685 21 43642366 gene body ABCG1 0.0068 0.0019 3.53E-04
cg10177197 1 55316481 gene body DHCR24 0.0081 0.0020 4.24E-05
Model adjusted for leukocyte proportions, batch effects, sex, age, smoking status, body mass index, 
systolic blood pressure, anti-hypertensive medication, presence of coronary heart diseases
Sample from RS  (n=1065). Bonferroni correction P < 7.14E-0








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Epigenetic Link Between Statin Therapy and Type 2 Diabetes
eFigure 1. Causal Mediation analysis
Schematic representation of the causal mediation analysis. βc’  represents the causal direct effect of 
statin use (exposure) on the glycemic traits and type 2 diabetes (outcome). βc  represents a non-causal 
pathway. βa represents the effect of statin use on DNA methylation. βb represents the effect of DNA 
methylation (mediator) on the outcome, which would be mediating an indirect effect of statins on the 
outcome. Covariates that may confound these associations are included in the model.
eFigure 2. Manhattan Plot of the epigenome-wide associations between current statin use and 
Dna methylation (compared to non-current use)
Using a model adjusted for batch effects, leukocyte proportions and cardiometabolic risk factors, 
we found genome-wide associations of seven methylation sites annotated to DHCR24 (cg17901584 
and cg10177197, chromosome 1), SC4MOL (cg05119988, chromosome 4), ABCG1 (cg06500161 and 
cg27243685, chromosome 21), AHRR (cg05575921, chromosome 5) and FAM50B (cg03467813, chromo-
some 6). Of these, five CpGs, annotated to DHCR24, ABCG and SC4MOL. From them, five could be repli-
cated in an independent cohort.
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1. inTEGRaTiOn OF ThE FinDinGs
The aims of this thesis were to investigate potential underlying mechanisms ex-
plaining associations of protective and adverse dietary and drug risk factors of type 
2 diabetes. I focused on the role of epigenetic changes and inflammation processes 
as potential pathways through the use of original studies and literature reviews 
approaches.
I studied epigenetic changes involved in promotion of type 2 diabetes development 
and the feasibility of their use in clinical practice for prediction, diagnosis and 
prognosis of this disease, as well as whether these epigenetic determinants for type 
2 diabetes and cardiometabolic health occur differently in women and men. Next, 
I explored DNA methylation and inflammatory processes as potential underlying 
mechanisms linking statin treatment and coffee consumption to type 2 diabetes 
development. Further, I explored uric acid levels as a risk for all-cause mortality and 
cardiovascular disease, and how this risk is affected by type 2 diabetes status and 
sex differences. Finally, in this section the main findings are summarized and some 
methodological considerations, as well as future perspectives are discussed.
1.1 Epigenetics and type 2 diabetes
In chapter 2 I extensively reviewed the chromatin landscape and epigenetic bio-
markers for clinical diagnosis and prognosis of type 2 diabetes and the sexually 
dimorphic DNA-methylation patterns in cardiometabolic health. Differential epi-
genetic patterns of around 77 genes and repetitive and transposable elements have 
been explored so far in association with glycemic traits and type 2 diabetes. These 
investigations have used diverse tissues such as whole blood, leukocytes, adipose tis-
sue, skeletal muscle, pancreas, liver, placenta and cord blood. Histone modifications 
and DNA methylation changes were explored, being the latter the most frequently 
epigenetic mechanisms studied. Notwithstanding the numerous efforts, evidence is 
still very limited and results are inconsistent, with some studies showing significant 
results while some others did not.
According to the reviewed literature, different approaches have been used for the 
study of DNA methylation signatures: global DNA methylation assessment, DNA 
methylation in candidate genes, or in a hypothesis free approach like in Epigenome-
Wide Association Studies (EWAS). In consequence, the different investigations 
explored different methylation sites in the genome using different techniques, 
making consistency in the replication of the findings challenging. Nevertheless, the 
reported differentially methylated genes seem to be involved in biological processes 
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that are relevant to type 2 diabetes development, such as insulin secretion, oxidative 
stress, energy expenditure, glucose transport and inflammation. Studies devoted to 
histone modifications and type 2 diabetes and glycemic traits are even more limited. 
The most repeatedly replicated methylation marks have been tested as potential 
biomarkers for risk prediction and disease prognosis. For this purpose, statistical 
prediction models have been used to examine the predictive value of methylation at 
LINE-1 in type 2 diabetes risk. This showed no significant improvement as compared 
to traditional type 2 diabetes risk assessment models. ABCG1 (CpG site cg06500161) 
and PHOSPHO1 (CpG site cg02650017) methylation have been suggested as biomark-
ers but their predictive value has not been tested to date.  Additionally, epigenetic 
modifications have been associated to cardiovascular disease, diabetic nephropathy, 
diabetic retinopathy and diabetic neuropathy, all of which are part of diabetic com-
plications. However, overall, little evidence is available.
Among the articles reviewed in this chapter, only a few reported sex-stratified as-
sociations between DNA methylation and glycemic traits and type 2 diabetes. On 
the one hand, men-specific hypomethylation was found in FTO and HOOK2, whereas 
men-specific hypermethylation was observed in BCL11A, GCK and IGFBP7 in associa-
tion with type 2 diabetes risk or in newly diagnosed patients versus healthy controls. 
On the other hand, women-specific differential hypermethylation was reported for 
HOOK2, PTPN1. Finally, X chromosome-wide global DNA methylation was higher 
in women pancreatic islets. Although there is some evidence linking differential 
DNA methylation modifications between sexes with risk of cardiometabolic disease 
including type 2 diabetes and glycemic traits, more studies and consistent results 
are lacking.
For the available evidence several limitations need to be addressed: the majority of 
the studies were carried out using a cross-sectional design, therefore causality or 
temporality cannot be claimed; the sample size of the reviewed studies were lim-
ited; most studies are in Caucasians, therefore generalization to other populations is 
not feasible; different studies used diverse levels of adjustment and apply different 
thresholds for statistical significance, thus making replication of the findings a very 
difficult endeavor. All the aforementioned and the high heterogeneity among the 
reports prevented us from pooling the existing data. Overall, I concluded that DNA 
methylation signatures associated to glycemic traits and type 2 diabetes may be 
promising tools to be used as biomarkers of early diagnosis, years before the clini-
cal diagnose, as well as for disease prognosis, however more robust and replicable 
results from carefully designed studies are required to validate their use in clinical 










1.2 Dissecting the association between environmental factors, 
epigenetics and risk of type 2 diabetes
Environmental exposures throughout life course have shown to modify epigenetic 
patterns which in turn may lead to disease development, such as type 2 diabetes. In 
this thesis I explored the association between statin drugs and type 2 diabetes, and 
the potential role of DNA methylation as a mediator in this association. 
Evidence from observational studies and randomized clinical trials have found a 
higher risk of type 2 diabetes among patients under statin class of drugs treatment 
as compared to non-statin users at baseline. However potential mechanisms un-
derlying such association were unknown. In chapter 3.1 I carried out a detailed 
population-based study investigating the effect of the different types of statins on 
type 2 diabetes risk.  I explored the relationship of incident type 2 diabetes with 
current, ever and past statin use as compared to never use in longitudinal analy-
ses; as well as the cross-sectional association of serum fasting glycemic traits with 
current, ever and past statin use as compared to never use. After comprehensive 
adjustment for confounders, I found that current statin treatment at baseline was 
associated with higher serum fasting insulin and HOMA-IR, while the relation with 
fasting glucose was mediated by BMI and hypertension. Moreover, current and ever 
statin users, but not former users, showed higher risk of developing type 2 diabetes. 
Duration of statin treatment but not statin subtype and dosage, was significantly 
related to higher risk of type 2 diabetes. Cumulative use of statins as well as higher 
statin dosage were associated with incident impaired fasting glucose. In stratified 
analyses, the increased risk of type 2 diabetes with statin therapy was significant 
only among statin users aged 65 years and above, males and overweight/obese.
In chapter 3.2 I further investigated a potential mechanism underlying the ob-
served associations of exposure to statin therapy with outcomes type 2 diabetes 
and glycemic traits. I hypothesized that statins may change DNA methylation pat-
ters consequently altering expression of relevant genes, thus leading to increased 
risk of type 2 diabetes. For this purpose, I performed a two-phase Epigenome-wide 
association analyses, using data from five prospective cohort studies. I identified 
and replicated five DNA methylation sites differentially methylated among cur-
rent statin users as compared to non-current users. The identified CpG sites were 
annotated to genes involved in lipids metabolism (genes DHCR24 and SC4MOL), as 
well as molecules transport and insulin secretion (ABCG1). Moreover, methylation 
at sites in DHCR24 and ABCG1 were associated with lower expression of gene ABCG1 
and with higher levels of serum fasting insulin and HOMA-R and incident type 2 
diabetes. Importantly, I provided evidence that methylation at CpG site cg06500161 
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(ABCG1) may have a role partially mediating the association between statins therapy 
and higher fasting insulin and HOMA-IR using causal mediation analysis. This latter 
result was independent of blood lipids, excluding type 2 diabetes participants and 
using a cross-sectional approach. Among statin users, I found that increasing dose of 
statins was associated with methylation at SC4MOL.
Based on our results and previous evidence from population and experimental stud-
ies, I hypothesize that statins promote DNA methylation changes that alter gene 
expression, suggesting an epigenetic regulation of ABCG1 expression. In turn, this 
may affect insulin secretion or other mechanisms leading to higher insulin and 
HOMA-IR. 
Previous studies have observed a protective association between coffee consumption 
and lower risk of type 2 diabetes. The hypothesized potential mechanisms explaining 
these observations are (i) the action of chlorogenic acid, a phenolic coffee compound 
which may reduce reducing glucose intestinal uptake through, thus reducing blood 
glucose levels; (ii) the antioxidant capacity of some coffee compounds that may 
reduce oxidative stress; (iii) the anti-inflammatory effects on inflammatory markers 
altered in T2D; (iv) the modulation of the microbiome content and diversity; and (v) 
the modulation of adenosine receptor signaling which in turn modulates insulin 
and glucagon signaling. Therefore, in chapter 4, I sought to investigate the associa-
tion between coffee consumption and risk of T2D as well as the potential role of 
type 2 diabetes related-proinflammatory cytokines and adipokines mediating this 
association. For this purpose, two large population studies were used, the Rotterdam 
Study and the UK Biobank. Overall, my work confirmed previous findings on the 
protective effect of coffee consumption lowering T2D risk, and I further observed 
beneficial associations between higher coffee consumption and lower insulin re-
sistance over time among non-diabetics, as well as with lower plasma C-reactive 
protein (CRP), lower complement 3 (C3) and higher adiponectin levels. In addition, I 
observed an adverse positive association of coffee intake with blood IL-18 levels. Fur-
thermore, I found evidence that CRP levels and adiponectin may mediate part of the 
observed protective effect of coffee intake. CRP, C3 and IL-18 are pro-inflammatory 
markers that are more often described to be increased in type 2 diabetes. Although 
my findings on IL-18 may seem contradictory, previous experimental studies have 
reported that deficiency of IL-18 may lead to metabolic syndrome due to hyper-
phagia, obesity and insulin resistance in mice. Thus, the study of the role of IL-18 
controlling energy expenditure may high interest for further research. Adiponectin 
is an adipokine with anti-inflammatory and insulin-sensitization effects, and it has 










those suggesting that the beneficial effect of coffee on lower risk of type 2 diabetes 
may occur through the modulation of the inflammatory response. To the best of my 
knowledge, this study is the first to suggest that CRP and adiponectin variations due 
to coffee consumption may be in the causal pathway. Further research should be 
conducted to determine to what extent coffee consumption should be promoted for 
T2D prevention in the population. 
Type 2 diabetes and high concentrations of serum uric acid have shown to be impor-
tant risk factors for all-cause mortality and cardiovascular events. Previous studies 
have also reported a higher risk of all-cause mortality and cardiovascular events 
among men. In chapter 5 I explored how diabetes and sex differences modified the 
effect of high serum uric acid (SUA) concentrations on fatal and nonfatal cardiovas-
cular disease-related events (cardiovascular disease, heart disease, ischemic coronary 
heart disease, heart failure, myocardial infarction and stroke), as well as all-cause 
mortality, in a prospective study. First, I observed that higher SUA concentrations 
were associated with a higher risk of all fatal and nonfatal outcomes, except for 
myocardial infarction fatal and nonfatal events. Further, I found that prevalent type 
2 diabetes status and female sex were factors that showed to increase, or to have a 
tendency to increase, SUA-related higher risks of the majority, but not all, the out-
comes under study. Further research should investigate the biological mechanisms 
underlying these associations. 
2. METhODOLOGiCaL COnsiDERaTiOns
2.1 study design in epigenetic studies
Epigenetic marks are prone to changes over time as the product of environmental 
exposures and the cumulative effect of an epigenetic maintenance system, and are 
closely related to biological age.1 These variations may contribute to the late onset 
of common human diseases as the result of (epi)genome-environment interaction. 
Such effects are better observed in studies with a prospective design where, by fol-
lowing up a sample of the population it is possible to identify risk factors before the 
occurrence of the event of interest.2 Although most of the cohort studies included 
in the original research described in this thesis (the Rotterdam Study,3 KORA-F4,4 
LOLIPOP,5 SHIP-Trend,6 ESTHER7) are prospective cohorts, the majority of these are 
limited to cross-sectional analyses of DNA methylation and risk factors or diseases 
status at one time-point, or the assessment of future risk of disease in association 
with single measurements of epigenetic marks before the event. Thus, among avail-
able evidence to date, research on diseases prevalence prevails over disease incidence 
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investigations. Due to the cross-sectional nature of the associations explored in such 
studies, conclusions on temporality cannot be derived; therefore, their results must 
be interpreted carefully.
Repeated measures of epigenetic marks overtime in longitudinal studies could cap-
ture the dynamic nature of epigenetic mechanisms, allowing us for the assessment 
of intra-individual time-dependent variations of the epigenome and their relation 
with disease development or treatment effect. For example, in the context of type 2 
diabetes risk, repeated measurements of DNA methylation at different time points 
would allow us to investigate to what extent insulin resistance progression towards 
type 2 diabetes is accompanied by a correlated progressive change in DNA methyla-
tion levels; or to determine temporality of the association, in other words, whether 
insulin resistant predicts DNA methylation variations or vice versa, and to identify 
the relevant genes; or to what extent some persistent exposure may affect a health 
outcome via DNA methylation changes over time; or how much time is needed to 
reverse the changes in some epigenetic mark after exposure cessation, in case it is 
reversible. To the best of our knowledge, there are only few articles reporting longi-
tudinal intra-individual DNA methylation variations, with a follow-up time ranging 
from 6 months up to 18 years and used limited sample sizes of specifically selected 
participants.2,8-10 Although this kind of evidence from large populations-based cohort 
studies is yet scarce, such approach have a series of benefits. While cross-sectional 
approaches cannot capture the dynamic nature of epigenetic patterns and causality 
cannot be inferred, multiple measurements of DNA methylation marks may con-
tribute providing insights on the involvement of the variations of DNA methylation 
marks in the progressions of diseases or the effect of a drug treatment or other kind 
of intervention by using each individual as their own control.11 Further, repeated 
measurements increase the statistical power as compared to cross-sectional designs. 
In addition, the longitudinal design allows the study of epigenetic heritability; 
monozygotic twins studies suggest there are no distinguishable epigenetic differ-
ences between twins in the early years of life, however in older ages twins show 
notable differences in the overall content and distribution of 5-methylcytosine DNA 
and histone acetylation, which in turn may affect their gene-expression pattern.12,13 
Therefore, in future epigenetic studies efforts should be put in the analysis of the 
longitudinal trajectories of DNA methylation patterns.14 Eventually, this evidence 
could be used as an additional tool for clinicians when designing strategies for the 
early identification of individuals at high risk of developing type 2 diabetes before 
the onset of the disease, as well as strategies to monitor the evolution of the health 










2.2 Tissue specificity and confounding in epigenetic studies
Gene regulations, including DNA methylation changes, seem to occur in a tissue-
specific manner.15,16 Thus, the trait or disease of interest should determine the selec-
tion of a suitable target tissue.17 For the study of diabetes, drugs, and biomarkers 
of inflammation and metabolism, samples from pancreas, liver and adipose tissue 
seem most appropriate. However, there is limited availability of such specific tissues 
from human studies. The majority of the published reports from large cohort stud-
ies, as well as the original studies included in this thesis, have used peripheral blood 
as tissue to measure biomarkers and DNA methylation signatures. Saliva samples 
are also often used. In the context of type 2 diabetes pathophysiology, measure-
ments in such non-specific tissues might not be representing the true effect of the 
exposure under investigation, leading to underestimation. Researchers are aware of 
such limitations, and in order to facilitate the study of gene regulation, expression, 
epigenomics and histology across specific less accessible tissues, large open access 
databases and web-based tools have been created based on data from studies in 
which these various tissues were available. Examples of these large scale efforts are 
genotype-tissue expression GTEx (https://gtexportal.org/home/), the Encyclopedia 
of DNA Elements ENCODE,18 Blood and Brain Correlation BECon,19 and the blood-
brain DNA methylation comparison tool (http://epigenetics.essex.ac.uk/bloodbrain/). 
Further joint efforts are needed in order to broad the range of tissues and enlarge 
the samples sizes available on these platforms.
As the epigenome can change in response to environmental factors, epigenetic 
studies are also prone to confounding. Confounding is a source of bias and arises 
when there are additional factors, other than the exposure under study, that are 
involved in either a risk or protective effect on the outcome, but do not take part in 
the pathway of the exposure of interest. If confounding is not properly addressed, it 
may lead to incorrect conclusions. Some confounders in observational studies, are 
often demographic and environmental factors. I have discussed in this thesis that 
changes in the epigenome are especially sensitive to various environmental stimuli 
and consequent disease development throughout the life course. Therefore, unlike 
genetic studies, epigenetic studies, are highly prone to confounding. An additional 
source of confounding commonly present in epigenetic studies comes from the fact 
that the epigenetic signatures, such as DNA methylation, are more often measured 
in leukocytes from peripheral whole blood and less frequently in specific target 
tissues, as discussed above. Leukocytes comprise an admixture of heterogeneous 
cell populations, with different functions and their own epigenetic profile, and 
whose presence in blood could vary during the occurrence of some disease. In this 
regard, to account for inter-individual cell heterogeneity, epigenetic epidemiologi-
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cal models adjust for measured or estimated white blood cells proportion. There has 
been a concern in EWAS research related to the potential confounding effect of this 
heterogeneity across leukocytes’ DNA methylation signatures. Under this scenario, 
the observed associations of DNA methylation in blood with some trait might reflect 
differences in leukocyte composition rather than true changes in the methylation 
sites. Nonetheless, one study concluded that this kind of confounding is not an 
issue in DNA methylation studies in blood.20 I my EWAS investigation, I addressed 
confounding through analysis, by performing a comprehensive adjustment for 
potential confounding variables, such as age, sex, lifestyle factors (smoking, diet, 
alcohol consumption, physical activity), comorbidities, medications and measured 
or estimated white blood cells proportion. However, despite adjustments, there is 
always a risk of residual confounding. An additional way to overcome confounding 
in epigenetic studies would be to carry out the measurements in specific tissues 
according to the disease or health condition of interest, to avoid the confounding 
due to blood leukocytes proportion; however, as discussed above, this is often not 
possible. Further, statistical tools could be implemented to deal with confounding, 
like the use of genetic instruments, like the case of Mendelian randomization analy-
ses. Nevertheless, I did not apply this approach in this thesis. 
2.3 Ethnic heterogeneity in epigenetic studies
The vast majority of the population studies have been performed in Caucasian 
ancestry and so are the majority of the repositories with publicly available data 
on genetics and epigenetics. Further, several studies have reported ethnic differ-
ences in cardiovascular disease, diabetes and other, but not all, cardiometabolic 
risk factors.21,22 Therefore, results obtained from studies in Caucasians cannot be 
extended to other ethnic groups. A study showed important differences in DNA 
methylation profile in naive CD4+ T in healthy African-Americans as compared to 
healthy European-American Caucasians.23 The authors of this study suggested that 
these differences would confer differential susceptibility to autoimmune diseases. 
Similarly, ethnic disparities in DNA methylation marks have been observed in can-
cer prognosis and survival, as well as in healthy controls from cancer studies, albeit 
the direction of the change is contradictory.24 For example, one study found higher 
levels of global DNA methylation among healthy non-Caucasians relative to healthy 
Caucasians;25 while other study observed higher global DNA methylation among 
non-Hispanic whites as compared Hispanics.26 In cancer, several studies have report-
ed ethnicity differences in methylation status of relevant genes for cancer or global 
DNA methylation in prostate tumors, breast, colorectal and lung cancer, among 
Americans, Hispanics, Caucasians, as well as European-,  American-, Asian-, African- 










symptoms in whole blood provided evidence that DNA methylation patterns may be 
similar across various ethnicities such as African Americans and European-American 
Caucasians.27 Possible factors contributing to the divergence in epigenetic patterns 
between ethnicities may be differences in allele frequencies, epigenetic heritability, 
or in gene-environment interactions.28 Nonetheless, in epigenetic studies the effect 
of different ethnicities might be diluted due to shared environmental exposures, 
such as diet and pollution,24 given that epigenetic patterns are influenced by the 
environment.
Thus, there is a need for more studies investigating epigenetic mechanisms in sub-
jects with ethnic backgrounds other than only Caucasians. These studies may con-
tribute not only to identify the potential underlying epigenetic mechanisms linking 
gene-environment differences among ethnicities, but also epigenetic mechanisms 
may constitute a potential tool for rapid adaptation to environmental exposures and 
thus for evolution.29 Nonetheless, this hypothesis requires further research.
2.4 nutrition assessment in population studies
A tool often used in populations studies to collect information on participants’ food 
consumption are food frequency questionnaires (FFQs). In FFQs subjects report the 
habitual intake of a given list of food and beverage items, specifying frequency 
and portion size consumed during a certain period of time, usually the past year. 
However, since FFQs are self-reports, they are prone to information bias and lead 
to measurement error, due to the retrospective nature of the dietary assessment. 
However, misclassification of the exposure is assumed to be non-differential, thus 
random and not related to the outcome of interest. However, misclassification of the 
exposure could also occur due to individuals either underreporting or over report-
ing their food consumption, depending on the type of food and specific participants’ 
characteristics, such as age, sex, ethnicity, socioeconomic status and body mass 
index (BMI). For example, healthy foods such as fruits and vegetables are often over 
reported,30 while individuals with higher BMI tend to underreport absolute energy, 
protein, sodium and potassium intake.31 Additionally, differences in the number 
and type of items included in the questionnaires may also be a source of measure-
ment error. More detailed FFQs including a higher number of items may be prone 
to overestimations of food consumption and total energy.30 This may constitute a 
limitation in studies where different populations using different questionnaires 
are compared. In our study in chapter 4 on coffee consumption, I included data 
on coffee intake as well as foods to build a diet quality score, that were collected 
through paper-based 170-item and 389-item FFQs, as well as in home interviews 
in the Rotterdam Study; while coffee consumption data in the UKBB was collected 
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through a web-based FFQ containing a total of 29 questions on dietary habits. The 
aforementioned sources of measurement error may affect the associations with the 
outcome of interest when foods constitute the main exposure of the study. In an 
effort to address the differences in the dietary assessment methods, the FFQs in both 
cohorts, the Rotterdam Study and the UK Biobank, were validated against 24-hours 
recall questionnaires32,33 and additional 9-days34 and 4-weeks35 dietary record in the 
Rotterdam Study. Overall, the aforesaid FFQs validation studies showed moderate to 
strong correlation and reliable reproducibility of the dietary assessments using the 
different questionnaires.
 An additional source of bias faced by nutrition studies is confounding, as also 
discussed in section 2.2. In an effort to diminish this issue, our study included ad-
justments for several potential confounding factors, such as sociodemographic and 
health-related factors, as well as other lifestyle factors, including physical activity, 
smoking status, and body mass index. Another way to deal with confounding is 
through stratification of the study population, in order to produce groups within 
which the confounding factor does not vary. Next, these subgroups are analyzed in-
dependently. Thus, the potential confounder cannot confound the association given 
that it does not differ across the exposure-outcome among those individuals. Dif-
ferent results between the non-stratified versus the stratified analyses indicate that 
confounding is likely. In chapter 4 of this thesis, additional to the comprehensive 
adjustment for potential confounders, I also addressed latent residual confounding 
by carrying out independent analyses among participants in each category of smok-
ing behavior (never, former and current smokers), normal weight and overweight/
obese participants and sex. For example, I found that higher coffee intake was sig-
nificantly associated with lower risk of T2D among never and former smokers. On 
the contrary, this was not observed among current smokers. Despite the adjustment 
for smoking in my primary analysis, this inconsistency observed across smoking 
categories suggested a residual confounding effect of smoking for the group of cur-
rent smokers, for whom higher coffee consumption did not show any significant 
effect on lower T2D risk. Notwithstanding all the efforts, in an observational study, 
residual confounding can never be ruled out.
3. FUTURE PERsPECTiVEs
3.1 Microarray technology for Dna methylation assessment
The development of new technology for the study of the epigenome has produced 










ment in biological processes not only in the field of type 2 diabetes, but also car-
diometabolic health, cancer, neuroscience, and many others. The more accessible 
arrays technology, have allowed cohort studies to perform massive profiling of the 
human epigenome among thousands of individuals. Regarding the assessment of 
DNA methylation signatures, arrays like Illumina Infinium HumanMethylation27 
BeadChip facilitated the interrogation of 27,578 CpG sites genome-wide; whereas In-
finium HumanMethylation450 BeadChip became the most popular, targeting more 
than 450,000 CpGs. The technology keeps evolving and currently studies are moving 
forward the use of Infinium MethylationEPIC BeadChip, interrogating more than 
850,000 CpG sites across the genome. Despite the differences between the Infinium 
450K BeadChip and the Infinium EPIC BeadChip, the latter covers approximately 
90% of the same sites on the 450K array. The design of future BeadChips shall aspire 
to further increase the amount of CpGs interrogated. However, scientists are still 
studying only a small part of the epigenome. There are approximately 28 million 
CpG dinucleotides across the genome. In this process an additional challenge should 
be considered: the new DNA methylation arrays shall include technology compatible 
with the existing BeadChips. Currently, both the Infinium 450K BeadChip and the 
Infinium EPIC BeadChip use the same technology and showed overall per-sample 
correlations of r > 0.99,36 which encourages the use of combined data. Future ar-
ray development should therefore keep aiming for the technologies compatibility, 
to make allow the comparability of the future studies with the already available 
evidence.
 3.2 Use of epigenetic marks in clinical practice
Notwithstanding the many mechanisms and pathways that still are to be unraveled, 
current evidence points out epigenetics as promising tools in clinical practice. Even-
tually, individuals’ methylation patterns may be used in precision medicine to guide 
clinicians to work out the most adequate prevention strategy or tailored treatment 
at the right time for that particular subject. For example, based on the methylation 
levels at relevant CpGs for type 2 diabetes development, a person at risk of develop-
ing the disease could be identified at a very early stage, before the clinical manifesta-
tion of the disease and the occurrence of the associated vascular damage. Since 
the robust replication of the current findings in this field is still limited, further 
research with comparable technology is needed to identify and validate epigenetic 
marks with potential use in clinical practice. Similarly, if suitable epi-biomarkers 
have been identified, they could serve as a tool to help monitoring the effect of 
medicine or other treatment intervention, as well as the disease progression.
240
General discussion and summary
Chapter 6.
Furthermore, the identification of epigenetic mechanisms involved in disease has al-
lowed the development of the pharmacoepigenomics field. This emerging discipline 
is being led by cancer research. Aberrant epigenetic changes are intimately associ-
ated to the genesis of cancer.37 Cancer cells suffer epimutations that modify the 
structure and stability of the genome, which it is suggested to contribute to propa-
gate carcinogenesis. Therefore, epigenetic reprogramming constitutes a promising 
approach for cancer treatment as well as fighting cancer drug resistance.37 With 
several ongoing trials, efforts are focused on the design of the so called epigenetic 
drugs, or epidrugs. Epidrugs are chemical compounds targeting epigenetic marks 
such as the enzymes DNA methyltransferases (DNMTs) and histone deacetylases 
(HDACs). These enzymes are responsible for the maintenance and establishment 
of epigenetic changes. Several epigenetic therapies have been proven to effectively 
inhibit DNMT to modulate DNA methylation levels, thus restoring the function of 
genes that had been aberrantly silenced in cancer; or to promote histone acetyla-
tion by blocking the catalytic sites of HDACs and causing growth arrest and death 
in a wide range of cancer transformed cells. Such therapies have therefore been 
approved by the United States Food and Drug Administration (FDA) for use in cancer 
treatment and also new ones are in evaluation in pre-clinical and clinical trials.37 In 
regard to type 2 diabetes research, clinical trials may also provide valuable evidence 
on epigenetic changes related to type 2 diabetes and cardiometabolic health. To 
the best of our knowledge, only a few clinical trials on epidrugs for the treatment 
of diabetes and its complications have been conducted or have recently started.38 
Some of those studies investigated antioxidant compounds such as resveratrol and 
curcumin, which may also have DNA methyltransferase and histone deacetylase in-
hibition or activation activities. However, the field of pharmacoepigenomics in the 
context of type 2 diabetes is still in its infancy and further efforts from clinical trials 
are required to gather enough evidence for the validation and safety and efficacy 
assessment of the compounds with potential epidrug use.
The inclusion of these novel preventive, treatment and monitoring strategies in the 
field of type 2 diabetes will positively impact the quality of life of the individuals 
at high risk of disease or newly diagnosed. However, further population research in 
the field of diabetes and cardiometabolic health is needed to robustly identify and 
replicate relevant epigenetic markers for their potential use as clinical biomark-
ers. These efforts may succeed based on collaborative work, for which the use of 
the similar technologies across the participating studies is key in order to allow 
replication and validation of the findings. Also, a stronger inclusion of trans-ethnic 
analyses and studies among populations with different environmental exposures, 










and the better understanding of the role of the epigenetic mechanisms underlying 
the observed associations and their translation into clinical practice.
4. COnCLUsiOn
The aims of this thesis were to study potential underlying mechanisms explaining 
associations of protective and adverse dietary and drug risk factors of type 2 diabe-
tes. Through the use of original studies and literature reviews, I emphasized the role 
of epigenetic changes, diet and inflammation processes.
Overall, from the work presented in this thesis, I can conclude that epigenetics may 
constitute a mechanism involved in type 2 diabetes onset, and that those epigenetic 
changes may occur in women and men differently. Further, among the environ-
mental factors promoting changes in the epigenome I could find statin medication, 
whose diabetogenic effect could be partially mediated by differential DNA methyla-
tion. On the side of protective factors against type 2 diabetes, I found that coffee 
consumption may contribute modulating the inflammatory response, consequently 
decreasing type 2 diabetes risk.
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Chapter 1 provides a general introduction on the role of epigenetics, medications 
and diet as protective or adverse determinants of type 2 diabetes, as well as a de-
scription of the studies on which this thesis is based.
In Chapter 2, I discuss the available evidence on epigenetics of type 2 diabetes 
and other cardiometabolic traits, including epigenetic differences between sexes. 
Specifically, Chapter 2.1 is a narrative review of the current literature on epigenetic 
alterations, such as DNA methylation and histone modifications, involved in glucose 
homeostasis, insulin metabolism and diabetes onset; as well as the potential use 
of the identified epigenetic patterns as biomarkers in diagnosis and prognosis in 
clinical practice. Studies on DNA methylation alterations in type 2 diabetes and 
glycemic traits have used global DNA methylation measurements, candidate gene 
approaches, and epigenome-wide studies (EWAS) to measure DNA methylation 
changes in peripheral whole blood, lymphocytes and target tissues such as skeletal 
muscle, adipose and pancreatic tissue, as well as placenta. Epigenetic signatures, 
especially on DNA methylation, have been found in association with glucose ho-
meostasis, insulin metabolism and prevalent type 2 diabetes, although they are 
often inconsistent across different tissues. Histone modifications in association with 
glycemic traits and type 2 diabetes is an understudied research topic. Evidence on 
the predictive value of epigenetic biomarkers in diabetes management is limited. 
However, some studies suggest that epigenetic marks, such as DNA methylation 
changes, may be a promising tool to complement the current practice on prediction, 
diagnosis and prognosis of type 2 diabetes. In Chapter 2.2, I systematically reviewed 
sex-specific associations of DNA methylation with intermediate cardiometabolic 
traits and incident cardiovascular disease. A total of 35 articles based on 30 unique 
studies and involving a total of 14,020 participants were identified. Overall, they 
reported sex differences in the associations of epigenome-wide and gene-candidate 
DNA methylation with blood lipids, stroke risk and cardiometabolic diseases. The 
identified genes were PLA2G7, BCL11A, KDM6A, LIPC, ABCG1, PLTP, CETP, ADD1, CNN1B, 
HOOK2, GFBP-7, PTPN1, GCK, PTX3, ABCG1, GALNT2, CDKN2B, APOE, CTH, GNASAS, INS, 
PON1, TCN2, CBS, AMT, KDMA6A, FTO, MAP3K13, CCDC8, MMP-2 and ER-α. Pathway analy-
sis showed that these genes are involved in vitamin B12 metabolism, statin pathway, 
plasma lipoprotein, plasma lipoprotein assembly, remodeling and clearance and 
cholesterol metabolism.
Chapter 3 aimed to dissect the association between statin therapy and the inci-
dence of the type 2 diabetes. Particularly, Chapter 3.1 shows the results of my 
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study investigating the association between statin treatment and glycemic traits 
and incident type 2 diabetes, in a prospective population-based cohort study, the 
Rotterdam Study. Baseline use of statins was associated with higher serum fasting 
insulin concentrations and insulin resistance, while ever use of statins increased the 
risk of developing type 2 diabetes by 38%, independent of statin type and dosage, 
and with higher risk of incident impaired fasting glucose by 9%. The statin-related 
increased risk of type 2 diabetes was higher among overweight/obese individuals, 
as compared with subjects with normal body mass index. Chapter 3.2 presents the 
findings of on my study aimed to identify DNA methylation signatures associated 
with statin therapy, and their potential role as mediators of the diabetogenic effect 
of statins use, using a two-phase epigenome-wide association study (EWAS). Using 
five cohort studies, I discovered and replicated five DNA methylation sites associated 
with statin use, annotated to genes DHCR24, ABCG1 and SC4MOL. Higher methylation 
at ABCG1 was associated with adverse plasma glycemic traits profile and prevalent 
type 2 diabetes, as well as with down-regulation of this gene. Evidence from media-
tion analysis suggested that higher ABCG1 methylation partially mediates the effect 
of statin use on insulin and insulin resistance.
Chapter 4 shows the results of the study of coffee dedicated to investigate the 
associations between coffee consumption, insulin resistance and biomarkers of 
inflammation, as well as adipokines, and to further explore whether subclinical 
inflammation response is implicated in the observed association between coffee 
and type 2 diabetes. Using data from two large population-based cohort studies, I 
observed that an increase in 1 cup per day in coffee consumption was associated 
with lower insulin resistance, lower C-reactive (CRP) plasma concentration, as well 
as with a 4 to 6% lower risk of type 2 diabetes incidence. Mediation analysis showed 
that coffee-related changes in concentrations of CRP and adiponectin may mediate 
part of the beneficial effect of higher coffee consumption and lower risk of type 2 
diabetes. Stronger associations were observed among women, never smokers, those 
with overweight and consumers of ground coffee as compared to instant coffee.
in chapter 5 presents the findings of the study on the association of serum uric 
acid (SUA) levels with all-cause and specific cardiovascular-related mortality, as well 
as with cardiovascular (CVD)-related nonfatal events, and the effect modification 
role of type 2 diabetes and sex. The CVD-related fatal and nonfatal events included 
mortality and incidence of CVD, heart failure (HF), myocardial infarction (MI) and 
stroke. Among the participants of the UK Biobank, higher SUA concentrations were 
associated with higher risk of all CVD-related fatal and nonfatal outcomes and all-










risk of most fatal outcomes tended to be stronger among women than men, and 
stronger among diabetics than non-diabetics; with the strongest association found 
among diabetic women. For nonfatal outcomes, SUA-related higher risk of CVD 
















hoofdstuk 1 geeft een algemene inleiding over de rol van epigenetica, medicatie en 
voeding als beschermende of ongunstige determinanten van diabetes type 2 evenals 
een beschrijving van de studies waarop dit proefschrift is gebaseerd.
In hoofdstuk 2 bespreek ik het beschikbare bewijs over de epigenetica van diabetes 
type 2 en andere cardiometabole kenmerken, inclusief epigenetische verschillen 
tussen geslacht. hoofdstuk 2.1 is een review van de huidige literatuur over epige-
netische veranderingen, zoals DNA-methylatie en histon modificaties, betrokken bij 
glucose-homeostase, insuline metabolisme en het ontstaan  van diabetes; evenals 
het mogelijke gebruik van de geïdentificeerde epigenetische sites als biomarkers 
voor diagnose en prognose in de klinische praktijk. Studies over DNA-methylatie 
veranderingen bij diabetes type 2 en glycemische eigenschappen hebben gebruik 
gemaakt van globaal DNA-methylatie, kandidaat-gen en epigenoom-brede studies 
(EWAS) om DNA-methylatie veranderingen te meten in perifeer volbloed, lymfo-
cyten en gerelateerd weefsel zoals skeletspieren, vet- en pancreasweefsel evenals 
de placenta. Epigenetische kenmerken, vooral DNA-methylatie, zijn gevonden in 
verband met glucose-homeostase, insuline metabolisme en prevalentie van diabetes 
type 2, echter vaak inconsistent in verschillende weefsels. Histon veranderingen in 
verband met glycemische eigenschappen en diabetes type 2 is een te weinig onder-
zocht onderzoeksonderwerp. Bewijs voor de voorspellende waarde van epigeneti-
sche biomarkers bij diabetes management is beperkt. Sommige studies suggereren 
echter dat epigenetische kenmerken, zoals veranderingen in DNA-methylatie, een 
veelbelovend hulpmiddel kunnen zijn als aanvulling van de huidige praktijk op het 
gebied van voorspelling, diagnose en prognose van diabetes type 2.
In hoofdstuk 2.2 heb ik systematisch de geslacht specifieke associaties van DNA-
methylatie met intermediaire cardiometabole kenmerken en incidentele cardiovas-
culaire aandoeningen bestudeerd. In totaal werden 35 artikelen geïdentificeerd op 
basis van 30 unieke studies met in totaal 14.020 deelnemers. Over het algemeen 
rapporteerden ze geslacht specifieke verschillen in de associaties van epigenoom-
brede en kandidaat-gen DNA-methylatie met bloedlipiden, het risico op beroerte en 
cardiometabole ziekten. De geïdentificeerde genen waren PLA2G7, BCL11A, KDM6A, 
LIPC, ABCG1, PLTP, CETP, ADD1, CNN1B, HOOK2, GFBP-7, PTPN1, GCK, PTX3, GALNT2, 
CDKN2B, APOE, CTH, GNASAS, INS, PON1, TCN2, CBS, AMT, KDMA6A, FTO, MAP3K13, 
CCDC8, MMP-2 en ER-α. Pathway-analyse toonde aan dat deze genen betrokken zijn 
bij vitamine B12-metabolisme, de statine-pathway, plasma lipoproteïnen, plasma 
lipoproteïne assemblage, her-modellering en klaring en cholesterol metabolisme.
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hoofdstuk 3 had als doel de associatie tussen statinetherapie en de incidentie van 
diabetes type 2 te ontleden. hoofdstuk 3.1 laat de resultaten zien van mijn onder-
zoek naar de associatie tussen statine behandeling en glycemische eigenschappen 
en diabetes type 2 incidenten, in een prospectieve op populatie-gebaseerde cohort-
studie, de Rotterdam Studie. Gebruik van statines bij baseline was geassocieerd 
met hogere nuchtere insuline concentraties in serum en met insulineresistentie. 
Daarnaast was ooit gebruik van statines geassocieerd met een 38% verhoogd risico 
op het ontwikkelen van diabetes type 2 onafhankelijk van het statine type en de 
dosering en met een 9% hoger risico op incidenteel verminderd nuchtere glucose. 
Het statine gerelateerde verhoogde risico op diabetes type 2 was hoger bij personen 
met overgewicht en obesitas, in vergelijking met personen met een normale body 
mass index.
hoofdstuk 3.2 presenteert de bevindingen van mijn studie gericht op het iden-
tificeren van DNA-methylatie patronen geassocieerd met statinetherapie en hun 
mogelijke rol als mediatoren van het diabetogene effect van statinegebruik met 
behulp van een twee-fase epigenoom-brede associatiestudie (EWAS). Met behulp 
van vijf cohortstudies identificeerde en repliceerde ik vijf DNA-methylatie sites die 
verband houden met het gebruik van statines en geannoteerd zijn aan de genen 
DHCR24, ABCG1 en SC4MOL. Hogere methylering van ABCG1 was geassocieerd met 
een ongunstig plasma glycemische profiel en prevalente diabetes type 2, evenals 
met downregulatie van dit gen. De resultaten van mediatie-analyse suggereerde dat 
hogere ABCG1-methylatie gedeeltelijk het effect van statine gebruik op insuline en 
insulineresistentie medieert.
hoofdstuk 4 toont de resultaten van de koffie studie die is gericht op het onderzoe-
ken van de associaties tussen koffieconsumptie, insulineresistentie en biomarkers 
van ontsteking, evenals adipokines. Daarnaast om verder te onderzoeken of sub-
klinische ontstekingsreacties betrokken zijn bij de waargenomen associatie tussen 
koffie en diabetes type 2. Met behulp van de gegevens van twee grote op populatie-
gebaseerde cohortstudies, observeerde ik dat een toename van 1 kopje koffie per 
dag was geassocieerd met een lagere insulineresistentie, een lager C-reactieve (CRP) 
plasmaconcentratie, evenals met een 4 tot 6% lager risico op de incidentie van dia-
betes type 2. Mediatie-analyse toonde aan dat koffie gerelateerde veranderingen in 
de concentraties van CRP en adiponectine een deel van het gunstige effect van een 
hogere koffieconsumptie en een lager risico op diabetes type 2 kunnen mediëren. 
Er werden sterkere associaties waargenomen bij vrouwen, niet-rokers, mensen met 










In hoofdstuk 5 worden de bevindingen gepresenteerd van de studie naar de as-
sociatie van serum urinezuur (SUA)-concentraties met alle oorzaken en specifieke 
cardiovasculaire gerelateerde sterfte, evenals met cardiovasculair gerelateerde niet-
fatale gebeurtenissen en de effect modificerende rol van diabetes type 2 en geslacht. 
De cardiovasculair gerelateerde fatale en niet-fatale voorvallen omvatten mortaliteit 
en incidentie van cardiovasculaire aandoeningen, hartfalen, myocardinfarct en 
beroerte. Onder de deelnemers van de UK Biobank waren hogere SUA-concentraties 
geassocieerd met een hoger risico op alle cardiovasculair gerelateerde fatale en niet-
fatale uitkomsten en met mortaliteit door alle oorzaken, behalve myocardinfarct. 
De meeste van deze associaties volgden een J-vorm. Een hoger risico op de meeste 
dodelijke aflopen waren over het algemeen sterker bij vrouwen dan bij mannen en 
sterker bij diabetici dan bij niet-diabetici; met de sterkste associatie bij vrouwen 
met diabetes. Voor niet-fatale uitkomsten was het SUA-gerelateerde hogere risico op 
cardiovasculaire-voorvallen ook sterker bij zowel diabetische vrouwen als mannen 
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1. Epigenetic signatures could serve as biomarkers for early diagnosis or disease 
progression in type 2 diabetes, and as novel targets for the design of new thera-
pies (this thesis). 
2. Sex-specific epigenetic changes may explain sex differences in cardiometabolic 
health (this thesis).
3. Statins treatment increase type 2 diabetes risk, which is partially mediated by 
methylation changes at gene ABCG1 (this thesis).
4. The protective effect of coffee consumption against development of type 2 dia-
betes is partially explained by modulation of the inflammatory response (this 
thesis).
5. High uric acid levels are a risk factor for premature mortality and cardiovascu-
lar disease, especially for women and type 2 diabetes patients (this thesis).
6. A person’s unique epigenome explains what genes alone cannot tell. Therefore, 
it should play a key role in precision medicine.
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